#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=MiR-137-derived polygenic risk: effects on cognitive performance in patients with schizophrenia and controls
#Text=Variants at microRNA-137 (MIR137), one of the most strongly associated schizophrenia risk loci identified to date, have been associated with poorer cognitive performance.
1-1	0-3	MiR	_
1-2	3-4	-	_
1-3	4-7	137	_
1-4	7-8	-	_
1-5	8-15	derived	_
1-6	16-25	polygenic	_
1-7	26-30	risk	_
1-8	30-31	:	_
1-9	32-39	effects	_
1-10	40-42	on	_
1-11	43-52	cognitive	_
1-12	53-64	performance	_
1-13	65-67	in	_
1-14	68-76	patients	_
1-15	77-81	with	_
1-16	82-95	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-17	96-99	and	_
1-18	100-108	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
1-19	109-117	Variants	_
1-20	118-120	at	_
1-21	121-129	microRNA	_
1-22	129-130	-	_
1-23	130-133	137	_
1-24	134-135	(	_
1-25	135-141	MIR137	_
1-26	141-142	)	_
1-27	142-143	,	_
1-28	144-147	one	_
1-29	148-150	of	_
1-30	151-154	the	_
1-31	155-159	most	_
1-32	160-168	strongly	_
1-33	169-179	associated	_
1-34	180-193	schizophrenia	_
1-35	194-198	risk	_
1-36	199-203	loci	_
1-37	204-214	identified	_
1-38	215-217	to	_
1-39	218-222	date	_
1-40	222-223	,	_
1-41	224-228	have	_
1-42	229-233	been	_
1-43	234-244	associated	_
1-44	245-249	with	_
1-45	250-256	poorer	_
1-46	257-266	cognitive	_
1-47	267-278	performance	_
1-48	278-279	.	_

#Text=As microRNA-137 is known to regulate the expression of ~1900 other genes, including several that are independently associated with schizophrenia, we tested whether this gene set was also associated with variation in cognitive performance.
2-1	280-282	As	_
2-2	283-291	microRNA	_
2-3	291-292	-	_
2-4	292-295	137	_
2-5	296-298	is	_
2-6	299-304	known	_
2-7	305-307	to	_
2-8	308-316	regulate	_
2-9	317-320	the	_
2-10	321-331	expression	_
2-11	332-334	of	_
2-12	335-336	~	_
2-13	336-340	1900	_
2-14	341-346	other	_
2-15	347-352	genes	_
2-16	352-353	,	_
2-17	354-363	including	_
2-18	364-371	several	_
2-19	372-376	that	_
2-20	377-380	are	_
2-21	381-394	independently	_
2-22	395-405	associated	_
2-23	406-410	with	_
2-24	411-424	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-25	424-425	,	_
2-26	426-428	we	_
2-27	429-435	tested	_
2-28	436-443	whether	_
2-29	444-448	this	_
2-30	449-453	gene	_
2-31	454-457	set	_
2-32	458-461	was	_
2-33	462-466	also	_
2-34	467-477	associated	_
2-35	478-482	with	_
2-36	483-492	variation	_
2-37	493-495	in	_
2-38	496-505	cognitive	_
2-39	506-517	performance	_
2-40	517-518	.	_

#Text=Our analysis was based on an empirically derived list of genes whose expression was altered by manipulation of MIR137 expression.
3-1	519-522	Our	_
3-2	523-531	analysis	_
3-3	532-535	was	_
3-4	536-541	based	_
3-5	542-544	on	_
3-6	545-547	an	_
3-7	548-559	empirically	_
3-8	560-567	derived	_
3-9	568-572	list	_
3-10	573-575	of	_
3-11	576-581	genes	_
3-12	582-587	whose	_
3-13	588-598	expression	_
3-14	599-602	was	_
3-15	603-610	altered	_
3-16	611-613	by	_
3-17	614-626	manipulation	_
3-18	627-629	of	_
3-19	630-636	MIR137	_
3-20	637-647	expression	_
3-21	647-648	.	_

#Text=This list was cross-referenced with genome-wide schizophrenia association data to construct individual polygenic scores.
4-1	649-653	This	_
4-2	654-658	list	_
4-3	659-662	was	_
4-4	663-679	cross-referenced	_
4-5	680-684	with	_
4-6	685-696	genome-wide	_
4-7	697-710	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-8	711-722	association	_
4-9	723-727	data	_
4-10	728-730	to	_
4-11	731-740	construct	_
4-12	741-751	individual	_
4-13	752-761	polygenic	_
4-14	762-768	scores	_
4-15	768-769	.	_

#Text=We then tested, in a sample of 808 patients and 192 controls, whether these risk scores were associated with altered performance on cognitive functions known to be affected in schizophrenia.
5-1	770-772	We	_
5-2	773-777	then	_
5-3	778-784	tested	_
5-4	784-785	,	_
5-5	786-788	in	_
5-6	789-790	a	_
5-7	791-797	sample	_
5-8	798-800	of	_
5-9	801-804	808	_
5-10	805-813	patients	_
5-11	814-817	and	_
5-12	818-821	192	_
5-13	822-830	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-14	830-831	,	_
5-15	832-839	whether	_
5-16	840-845	these	_
5-17	846-850	risk	_
5-18	851-857	scores	_
5-19	858-862	were	_
5-20	863-873	associated	_
5-21	874-878	with	_
5-22	879-886	altered	_
5-23	887-898	performance	_
5-24	899-901	on	_
5-25	902-911	cognitive	_
5-26	912-921	functions	_
5-27	922-927	known	_
5-28	928-930	to	_
5-29	931-933	be	_
5-30	934-942	affected	_
5-31	943-945	in	_
5-32	946-959	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-33	959-960	.	_

#Text=A subgroup of healthy participants also underwent functional imaging during memory (n=108) and face processing tasks (n=83).
6-1	961-962	A	_
6-2	963-971	subgroup	_
6-3	972-974	of	_
6-4	975-982	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]
6-5	983-995	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]
6-6	996-1000	also	_
6-7	1001-1010	underwent	_
6-8	1011-1021	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[2]
6-9	1022-1029	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[2]
6-10	1030-1036	during	_
6-11	1037-1043	memory	_
6-12	1044-1045	(	_
6-13	1045-1046	n	_
6-14	1046-1047	=	_
6-15	1047-1050	108	_
6-16	1050-1051	)	_
6-17	1052-1055	and	_
6-18	1056-1060	face	_
6-19	1061-1071	processing	_
6-20	1072-1077	tasks	_
6-21	1078-1079	(	_
6-22	1079-1080	n	_
6-23	1080-1081	=	_
6-24	1081-1083	83	_
6-25	1083-1084	)	_
6-26	1084-1085	.	_

#Text=Increased polygenic risk within the empirically derived miR-137 regulated gene score was associated with significantly lower performance on intelligence quotient, working memory and episodic memory.
7-1	1086-1095	Increased	_
7-2	1096-1105	polygenic	_
7-3	1106-1110	risk	_
7-4	1111-1117	within	_
7-5	1118-1121	the	_
7-6	1122-1133	empirically	_
7-7	1134-1141	derived	_
7-8	1142-1145	miR	_
7-9	1145-1146	-	_
7-10	1146-1149	137	_
7-11	1150-1159	regulated	_
7-12	1160-1164	gene	_
7-13	1165-1170	score	_
7-14	1171-1174	was	_
7-15	1175-1185	associated	_
7-16	1186-1190	with	_
7-17	1191-1204	significantly	_
7-18	1205-1210	lower	_
7-19	1211-1222	performance	_
7-20	1223-1225	on	_
7-21	1226-1238	intelligence	_
7-22	1239-1247	quotient	_
7-23	1247-1248	,	_
7-24	1249-1256	working	_
7-25	1257-1263	memory	_
7-26	1264-1267	and	_
7-27	1268-1276	episodic	_
7-28	1277-1283	memory	_
7-29	1283-1284	.	_

#Text=These effects were observed most clearly at a polygenic threshold of P=0.05, although significant results were observed at all three thresholds analyzed.
8-1	1285-1290	These	_
8-2	1291-1298	effects	_
8-3	1299-1303	were	_
8-4	1304-1312	observed	_
8-5	1313-1317	most	_
8-6	1318-1325	clearly	_
8-7	1326-1328	at	_
8-8	1329-1330	a	_
8-9	1331-1340	polygenic	_
8-10	1341-1350	threshold	_
8-11	1351-1353	of	_
8-12	1354-1355	P	_
8-13	1355-1356	=	_
8-14	1356-1360	0.05	_
8-15	1360-1361	,	_
8-16	1362-1370	although	_
8-17	1371-1382	significant	_
8-18	1383-1390	results	_
8-19	1391-1395	were	_
8-20	1396-1404	observed	_
8-21	1405-1407	at	_
8-22	1408-1411	all	_
8-23	1412-1417	three	_
8-24	1418-1428	thresholds	_
8-25	1429-1437	analyzed	_
8-26	1437-1438	.	_

#Text=This association was found independently for the gene set as a whole, excluding the schizophrenia-associated MIR137 SNP itself.
9-1	1439-1443	This	_
9-2	1444-1455	association	_
9-3	1456-1459	was	_
9-4	1460-1465	found	_
9-5	1466-1479	independently	_
9-6	1480-1483	for	_
9-7	1484-1487	the	_
9-8	1488-1492	gene	_
9-9	1493-1496	set	_
9-10	1497-1499	as	_
9-11	1500-1501	a	_
9-12	1502-1507	whole	_
9-13	1507-1508	,	_
9-14	1509-1518	excluding	_
9-15	1519-1522	the	_
9-16	1523-1547	schizophrenia-associated	_
9-17	1548-1554	MIR137	_
9-18	1555-1558	SNP	_
9-19	1559-1565	itself	_
9-20	1565-1566	.	_

#Text=Analysis of the spatial working memory fMRI task further suggested that increased risk score (thresholded at P=10−5) was significantly associated with increased activation of the right inferior occipital gyrus.
10-1	1567-1575	Analysis	_
10-2	1576-1578	of	_
10-3	1579-1582	the	_
10-4	1583-1590	spatial	_
10-5	1591-1598	working	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]
10-6	1599-1605	memory	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]
10-7	1606-1610	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]
10-8	1611-1615	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]
10-9	1616-1623	further	_
10-10	1624-1633	suggested	_
10-11	1634-1638	that	_
10-12	1639-1648	increased	_
10-13	1649-1653	risk	_
10-14	1654-1659	score	_
10-15	1660-1661	(	_
10-16	1661-1672	thresholded	_
10-17	1673-1675	at	_
10-18	1676-1677	P	_
10-19	1677-1678	=	_
10-20	1678-1680	10	_
10-21	1680-1681	−	_
10-22	1681-1682	5	_
10-23	1682-1683	)	_
10-24	1684-1687	was	_
10-25	1688-1701	significantly	_
10-26	1702-1712	associated	_
10-27	1713-1717	with	_
10-28	1718-1727	increased	_
10-29	1728-1738	activation	_
10-30	1739-1741	of	_
10-31	1742-1745	the	_
10-32	1746-1751	right	_
10-33	1752-1760	inferior	_
10-34	1761-1770	occipital	_
10-35	1771-1776	gyrus	_
10-36	1776-1777	.	_

#Text=In conclusion, these data are consistent with emerging evidence that MIR137 associated risk for schizophrenia may relate to its broader downstream genetic effects.
11-1	1778-1780	In	_
11-2	1781-1791	conclusion	_
11-3	1791-1792	,	_
11-4	1793-1798	these	_
11-5	1799-1803	data	_
11-6	1804-1807	are	_
11-7	1808-1818	consistent	_
11-8	1819-1823	with	_
11-9	1824-1832	emerging	_
11-10	1833-1841	evidence	_
11-11	1842-1846	that	_
11-12	1847-1853	MIR137	_
11-13	1854-1864	associated	_
11-14	1865-1869	risk	_
11-15	1870-1873	for	_
11-16	1874-1887	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-17	1888-1891	may	_
11-18	1892-1898	relate	_
11-19	1899-1901	to	_
11-20	1902-1905	its	_
11-21	1906-1913	broader	_
11-22	1914-1924	downstream	_
11-23	1925-1932	genetic	_
11-24	1933-1940	effects	_
11-25	1940-1941	.	_

#Text=Introduction
#Text=Genome-wide association studies (GWAS) have identified significant associations between schizophrenia (SZ) and multiple single nucleotide polymorphisms (SNPs) located within or near to the microRNA-137 (MIR137) host gene on chromosome 1.
12-1	1942-1954	Introduction	_
12-2	1955-1966	Genome-wide	_
12-3	1967-1978	association	_
12-4	1979-1986	studies	_
12-5	1987-1988	(	_
12-6	1988-1992	GWAS	_
12-7	1992-1993	)	_
12-8	1994-1998	have	_
12-9	1999-2009	identified	_
12-10	2010-2021	significant	_
12-11	2022-2034	associations	_
12-12	2035-2042	between	_
12-13	2043-2056	schizophrenia	_
12-14	2057-2058	(	_
12-15	2058-2060	SZ	_
12-16	2060-2061	)	_
12-17	2062-2065	and	_
12-18	2066-2074	multiple	_
12-19	2075-2081	single	_
12-20	2082-2092	nucleotide	_
12-21	2093-2106	polymorphisms	_
12-22	2107-2108	(	_
12-23	2108-2112	SNPs	_
12-24	2112-2113	)	_
12-25	2114-2121	located	_
12-26	2122-2128	within	_
12-27	2129-2131	or	_
12-28	2132-2136	near	_
12-29	2137-2139	to	_
12-30	2140-2143	the	_
12-31	2144-2152	microRNA	_
12-32	2152-2153	-	_
12-33	2153-2156	137	_
12-34	2157-2158	(	_
12-35	2158-2164	MIR137	_
12-36	2164-2165	)	_
12-37	2166-2170	host	_
12-38	2171-2175	gene	_
12-39	2176-2178	on	_
12-40	2179-2189	chromosome	_
12-41	2190-2191	1	_
12-42	2191-2192	.	_

#Text=In the most recent and largest SZ GWAS the SNP rs1702294, located intronically to MIR137, was identified as the second highest SZ-associated variant.
13-1	2193-2195	In	_
13-2	2196-2199	the	_
13-3	2200-2204	most	_
13-4	2205-2211	recent	_
13-5	2212-2215	and	_
13-6	2216-2223	largest	_
13-7	2224-2226	SZ	_
13-8	2227-2231	GWAS	_
13-9	2232-2235	the	_
13-10	2236-2239	SNP	_
13-11	2240-2249	rs1702294	_
13-12	2249-2250	,	_
13-13	2251-2258	located	_
13-14	2259-2271	intronically	_
13-15	2272-2274	to	_
13-16	2275-2281	MIR137	_
13-17	2281-2282	,	_
13-18	2283-2286	was	_
13-19	2287-2297	identified	_
13-20	2298-2300	as	_
13-21	2301-2304	the	_
13-22	2305-2311	second	_
13-23	2312-2319	highest	_
13-24	2320-2333	SZ-associated	_
13-25	2334-2341	variant	_
13-26	2341-2342	.	_

#Text=This SNP is in high linkage disequilibrium (LD) with MIR137 variants previously identified in smaller GWAS such as rs1622579 (r2=0.99) and rs1198588 (r2=0.8).
14-1	2343-2347	This	_
14-2	2348-2351	SNP	_
14-3	2352-2354	is	_
14-4	2355-2357	in	_
14-5	2358-2362	high	_
14-6	2363-2370	linkage	_
14-7	2371-2385	disequilibrium	_
14-8	2386-2387	(	_
14-9	2387-2389	LD	_
14-10	2389-2390	)	_
14-11	2391-2395	with	_
14-12	2396-2402	MIR137	_
14-13	2403-2411	variants	_
14-14	2412-2422	previously	_
14-15	2423-2433	identified	_
14-16	2434-2436	in	_
14-17	2437-2444	smaller	_
14-18	2445-2449	GWAS	_
14-19	2450-2454	such	_
14-20	2455-2457	as	_
14-21	2458-2467	rs1622579	_
14-22	2468-2469	(	_
14-23	2469-2471	r2	_
14-24	2471-2472	=	_
14-25	2472-2476	0.99	_
14-26	2476-2477	)	_
14-27	2478-2481	and	_
14-28	2482-2491	rs1198588	_
14-29	2492-2493	(	_
14-30	2493-2495	r2	_
14-31	2495-2496	=	_
14-32	2496-2499	0.8	_
14-33	2499-2500	)	_
14-34	2500-2501	.	_

#Text=In line with the proposed influence of microRNA-137 (miR-137) on proliferation, migration and maturation of neural cells, mechanisms important to the cognitive process, one of three intronic variants in high LD identified in this region (rs1625579) has been associated with a number of cognitively relevant phenotypes.
15-1	2502-2504	In	_
15-2	2505-2509	line	_
15-3	2510-2514	with	_
15-4	2515-2518	the	_
15-5	2519-2527	proposed	_
15-6	2528-2537	influence	_
15-7	2538-2540	of	_
15-8	2541-2549	microRNA	_
15-9	2549-2550	-	_
15-10	2550-2553	137	_
15-11	2554-2555	(	_
15-12	2555-2558	miR	_
15-13	2558-2559	-	_
15-14	2559-2562	137	_
15-15	2562-2563	)	_
15-16	2564-2566	on	_
15-17	2567-2580	proliferation	_
15-18	2580-2581	,	_
15-19	2582-2591	migration	_
15-20	2592-2595	and	_
15-21	2596-2606	maturation	_
15-22	2607-2609	of	_
15-23	2610-2616	neural	_
15-24	2617-2622	cells	_
15-25	2622-2623	,	_
15-26	2624-2634	mechanisms	_
15-27	2635-2644	important	_
15-28	2645-2647	to	_
15-29	2648-2651	the	_
15-30	2652-2661	cognitive	_
15-31	2662-2669	process	_
15-32	2669-2670	,	_
15-33	2671-2674	one	_
15-34	2675-2677	of	_
15-35	2678-2683	three	_
15-36	2684-2692	intronic	_
15-37	2693-2701	variants	_
15-38	2702-2704	in	_
15-39	2705-2709	high	_
15-40	2710-2712	LD	_
15-41	2713-2723	identified	_
15-42	2724-2726	in	_
15-43	2727-2731	this	_
15-44	2732-2738	region	_
15-45	2739-2740	(	_
15-46	2740-2749	rs1625579	_
15-47	2749-2750	)	_
15-48	2751-2754	has	_
15-49	2755-2759	been	_
15-50	2760-2770	associated	_
15-51	2771-2775	with	_
15-52	2776-2777	a	_
15-53	2778-2784	number	_
15-54	2785-2787	of	_
15-55	2788-2799	cognitively	_
15-56	2800-2808	relevant	_
15-57	2809-2819	phenotypes	_
15-58	2819-2820	.	_

#Text=These include lower performance in verbal episodic memory and vigilant attention, altered fronto-amygdala connectivity during a face processing task and decreased white matter integrity, although a number of other studies have reported conflicting findings, with no effects of the MIR137 risk allele on brain structure.
16-1	2821-2826	These	_
16-2	2827-2834	include	_
16-3	2835-2840	lower	_
16-4	2841-2852	performance	_
16-5	2853-2855	in	_
16-6	2856-2862	verbal	_
16-7	2863-2871	episodic	_
16-8	2872-2878	memory	_
16-9	2879-2882	and	_
16-10	2883-2891	vigilant	_
16-11	2892-2901	attention	_
16-12	2901-2902	,	_
16-13	2903-2910	altered	_
16-14	2911-2926	fronto-amygdala	_
16-15	2927-2939	connectivity	_
16-16	2940-2946	during	_
16-17	2947-2948	a	_
16-18	2949-2953	face	_
16-19	2954-2964	processing	_
16-20	2965-2969	task	_
16-21	2970-2973	and	_
16-22	2974-2983	decreased	_
16-23	2984-2989	white	_
16-24	2990-2996	matter	_
16-25	2997-3006	integrity	_
16-26	3006-3007	,	_
16-27	3008-3016	although	_
16-28	3017-3018	a	_
16-29	3019-3025	number	_
16-30	3026-3028	of	_
16-31	3029-3034	other	_
16-32	3035-3042	studies	_
16-33	3043-3047	have	_
16-34	3048-3056	reported	_
16-35	3057-3068	conflicting	_
16-36	3069-3077	findings	_
16-37	3077-3078	,	_
16-38	3079-3083	with	_
16-39	3084-3086	no	_
16-40	3087-3094	effects	_
16-41	3095-3097	of	_
16-42	3098-3101	the	_
16-43	3102-3108	MIR137	_
16-44	3109-3113	risk	_
16-45	3114-3120	allele	_
16-46	3121-3123	on	_
16-47	3124-3129	brain	_
16-48	3130-3139	structure	_
16-49	3139-3140	.	_

#Text=SZ GWAS to date suggest that the disorder is likely to be highly polygenic, involving a combination of both common risk variants of small effects, such as MIR137, and rare variants of larger effects.
17-1	3141-3143	SZ	_
17-2	3144-3148	GWAS	_
17-3	3149-3151	to	_
17-4	3152-3156	date	_
17-5	3157-3164	suggest	_
17-6	3165-3169	that	_
17-7	3170-3173	the	_
17-8	3174-3182	disorder	_
17-9	3183-3185	is	_
17-10	3186-3192	likely	_
17-11	3193-3195	to	_
17-12	3196-3198	be	_
17-13	3199-3205	highly	_
17-14	3206-3215	polygenic	_
17-15	3215-3216	,	_
17-16	3217-3226	involving	_
17-17	3227-3228	a	_
17-18	3229-3240	combination	_
17-19	3241-3243	of	_
17-20	3244-3248	both	_
17-21	3249-3255	common	_
17-22	3256-3260	risk	_
17-23	3261-3269	variants	_
17-24	3270-3272	of	_
17-25	3273-3278	small	_
17-26	3279-3286	effects	_
17-27	3286-3287	,	_
17-28	3288-3292	such	_
17-29	3293-3295	as	_
17-30	3296-3302	MIR137	_
17-31	3302-3303	,	_
17-32	3304-3307	and	_
17-33	3308-3312	rare	_
17-34	3313-3321	variants	_
17-35	3322-3324	of	_
17-36	3325-3331	larger	_
17-37	3332-3339	effects	_
17-38	3339-3340	.	_

#Text=Modeling or quantifying this polygenic risk is therefore important, both for the broader illness phenotypes, and for specific illness dimensions related to functional outcomes, such as cognitive deficits.
18-1	3341-3349	Modeling	_
18-2	3350-3352	or	_
18-3	3353-3364	quantifying	_
18-4	3365-3369	this	_
18-5	3370-3379	polygenic	_
18-6	3380-3384	risk	_
18-7	3385-3387	is	_
18-8	3388-3397	therefore	_
18-9	3398-3407	important	_
18-10	3407-3408	,	_
18-11	3409-3413	both	_
18-12	3414-3417	for	_
18-13	3418-3421	the	_
18-14	3422-3429	broader	_
18-15	3430-3437	illness	_
18-16	3438-3448	phenotypes	_
18-17	3448-3449	,	_
18-18	3450-3453	and	_
18-19	3454-3457	for	_
18-20	3458-3466	specific	_
18-21	3467-3474	illness	_
18-22	3475-3485	dimensions	_
18-23	3486-3493	related	_
18-24	3494-3496	to	_
18-25	3497-3507	functional	_
18-26	3508-3516	outcomes	_
18-27	3516-3517	,	_
18-28	3518-3522	such	_
18-29	3523-3525	as	_
18-30	3526-3535	cognitive	_
18-31	3536-3544	deficits	_
18-32	3544-3545	.	_

#Text=It is interesting to note that miR-137 is known or predicted to regulate hundreds of other genes, many of which are independently risk loci for SZ.
19-1	3546-3548	It	_
19-2	3549-3551	is	_
19-3	3552-3563	interesting	_
19-4	3564-3566	to	_
19-5	3567-3571	note	_
19-6	3572-3576	that	_
19-7	3577-3580	miR	_
19-8	3580-3581	-	_
19-9	3581-3584	137	_
19-10	3585-3587	is	_
19-11	3588-3593	known	_
19-12	3594-3596	or	_
19-13	3597-3606	predicted	_
19-14	3607-3609	to	_
19-15	3610-3618	regulate	_
19-16	3619-3627	hundreds	_
19-17	3628-3630	of	_
19-18	3631-3636	other	_
19-19	3637-3642	genes	_
19-20	3642-3643	,	_
19-21	3644-3648	many	_
19-22	3649-3651	of	_
19-23	3652-3657	which	_
19-24	3658-3661	are	_
19-25	3662-3675	independently	_
19-26	3676-3680	risk	_
19-27	3681-3685	loci	_
19-28	3686-3689	for	_
19-29	3690-3692	SZ	_
19-30	3692-3693	.	_

#Text=In vitro studies have suggested that miR-137 targets include BDNF, ZNF804A, TCF4, and CACNA1C, variants that have been shown to impact on both cognitive performance and cortical activity by our own group and others.
20-1	3694-3696	In	_
20-2	3697-3702	vitro	_
20-3	3703-3710	studies	_
20-4	3711-3715	have	_
20-5	3716-3725	suggested	_
20-6	3726-3730	that	_
20-7	3731-3734	miR	_
20-8	3734-3735	-	_
20-9	3735-3738	137	_
20-10	3739-3746	targets	_
20-11	3747-3754	include	_
20-12	3755-3759	BDNF	_
20-13	3759-3760	,	_
20-14	3761-3768	ZNF804A	_
20-15	3768-3769	,	_
20-16	3770-3774	TCF4	_
20-17	3774-3775	,	_
20-18	3776-3779	and	_
20-19	3780-3787	CACNA1C	_
20-20	3787-3788	,	_
20-21	3789-3797	variants	_
20-22	3798-3802	that	_
20-23	3803-3807	have	_
20-24	3808-3812	been	_
20-25	3813-3818	shown	_
20-26	3819-3821	to	_
20-27	3822-3828	impact	_
20-28	3829-3831	on	_
20-29	3832-3836	both	_
20-30	3837-3846	cognitive	_
20-31	3847-3858	performance	_
20-32	3859-3862	and	_
20-33	3863-3871	cortical	_
20-34	3872-3880	activity	_
20-35	3881-3883	by	_
20-36	3884-3887	our	_
20-37	3888-3891	own	_
20-38	3892-3897	group	_
20-39	3898-3901	and	_
20-40	3902-3908	others	_
20-41	3908-3909	.	_

#Text=Because miR-137’s downstream regulatory targets include loci that are independently associated with both SZ risk and with cognitive deficits, it is possible that miR-137’s regulation of these genes may also contribute to SZ-associated deficits in cognition, in addition to the MIR137 loci’s direct effects on cognition.
21-1	3910-3917	Because	_
21-2	3918-3921	miR	_
21-3	3921-3922	-	_
21-4	3922-3925	137	_
21-5	3925-3926	’	_
21-6	3926-3927	s	_
21-7	3928-3938	downstream	_
21-8	3939-3949	regulatory	_
21-9	3950-3957	targets	_
21-10	3958-3965	include	_
21-11	3966-3970	loci	_
21-12	3971-3975	that	_
21-13	3976-3979	are	_
21-14	3980-3993	independently	_
21-15	3994-4004	associated	_
21-16	4005-4009	with	_
21-17	4010-4014	both	_
21-18	4015-4017	SZ	_
21-19	4018-4022	risk	_
21-20	4023-4026	and	_
21-21	4027-4031	with	_
21-22	4032-4041	cognitive	_
21-23	4042-4050	deficits	_
21-24	4050-4051	,	_
21-25	4052-4054	it	_
21-26	4055-4057	is	_
21-27	4058-4066	possible	_
21-28	4067-4071	that	_
21-29	4072-4075	miR	_
21-30	4075-4076	-	_
21-31	4076-4079	137	_
21-32	4079-4080	’	_
21-33	4080-4081	s	_
21-34	4082-4092	regulation	_
21-35	4093-4095	of	_
21-36	4096-4101	these	_
21-37	4102-4107	genes	_
21-38	4108-4111	may	_
21-39	4112-4116	also	_
21-40	4117-4127	contribute	_
21-41	4128-4130	to	_
21-42	4131-4144	SZ-associated	_
21-43	4145-4153	deficits	_
21-44	4154-4156	in	_
21-45	4157-4166	cognition	_
21-46	4166-4167	,	_
21-47	4168-4170	in	_
21-48	4171-4179	addition	_
21-49	4180-4182	to	_
21-50	4183-4186	the	_
21-51	4187-4193	MIR137	_
21-52	4194-4198	loci	_
21-53	4198-4199	’	_
21-54	4199-4200	s	_
21-55	4201-4207	direct	_
21-56	4208-4215	effects	_
21-57	4216-4218	on	_
21-58	4219-4228	cognition	_
21-59	4228-4229	.	_

#Text=The purpose of the present study was to investigate the polygenic effects on cognition of variants within genes that are downstream targets of miR-137.
22-1	4230-4233	The	_
22-2	4234-4241	purpose	_
22-3	4242-4244	of	_
22-4	4245-4248	the	_
22-5	4249-4256	present	_
22-6	4257-4262	study	_
22-7	4263-4266	was	_
22-8	4267-4269	to	_
22-9	4270-4281	investigate	_
22-10	4282-4285	the	_
22-11	4286-4295	polygenic	_
22-12	4296-4303	effects	_
22-13	4304-4306	on	_
22-14	4307-4316	cognition	_
22-15	4317-4319	of	_
22-16	4320-4328	variants	_
22-17	4329-4335	within	_
22-18	4336-4341	genes	_
22-19	4342-4346	that	_
22-20	4347-4350	are	_
22-21	4351-4361	downstream	_
22-22	4362-4369	targets	_
22-23	4370-4372	of	_
22-24	4373-4376	miR	_
22-25	4376-4377	-	_
22-26	4377-4380	137	_
22-27	4380-4381	.	_

#Text=This was based on a previous study by Hill et al., which, through miR-137 manipulation (upregulation and inhibition), assessed genome-wide transcriptional changes in a human neural progenitor cell line.
23-1	4382-4386	This	_
23-2	4387-4390	was	_
23-3	4391-4396	based	_
23-4	4397-4399	on	_
23-5	4400-4401	a	_
23-6	4402-4410	previous	_
23-7	4411-4416	study	_
23-8	4417-4419	by	_
23-9	4420-4424	Hill	_
23-10	4425-4427	et	_
23-11	4428-4430	al	_
23-12	4430-4431	.	_
23-13	4431-4432	,	_
23-14	4433-4438	which	_
23-15	4438-4439	,	_
23-16	4440-4447	through	_
23-17	4448-4451	miR	_
23-18	4451-4452	-	_
23-19	4452-4455	137	_
23-20	4456-4468	manipulation	_
23-21	4469-4470	(	_
23-22	4470-4482	upregulation	_
23-23	4483-4486	and	_
23-24	4487-4497	inhibition	_
23-25	4497-4498	)	_
23-26	4498-4499	,	_
23-27	4500-4508	assessed	_
23-28	4509-4520	genome-wide	_
23-29	4521-4536	transcriptional	_
23-30	4537-4544	changes	_
23-31	4545-4547	in	_
23-32	4548-4549	a	_
23-33	4550-4555	human	_
23-34	4556-4562	neural	_
23-35	4563-4573	progenitor	_
23-36	4574-4578	cell	_
23-37	4579-4583	line	_
23-38	4583-4584	.	_

#Text=This was carried out in order to elucidate pathways through which genetic disruption of miR-137 may increase SZ susceptibility.
24-1	4585-4589	This	_
24-2	4590-4593	was	_
24-3	4594-4601	carried	_
24-4	4602-4605	out	_
24-5	4606-4608	in	_
24-6	4609-4614	order	_
24-7	4615-4617	to	_
24-8	4618-4627	elucidate	_
24-9	4628-4636	pathways	_
24-10	4637-4644	through	_
24-11	4645-4650	which	_
24-12	4651-4658	genetic	_
24-13	4659-4669	disruption	_
24-14	4670-4672	of	_
24-15	4673-4676	miR	_
24-16	4676-4677	-	_
24-17	4677-4680	137	_
24-18	4681-4684	may	_
24-19	4685-4693	increase	_
24-20	4694-4696	SZ	_
24-21	4697-4711	susceptibility	_
24-22	4711-4712	.	_

#Text=As disturbances in cognition are a cardinal feature of SZ, we investigated whether polygenic risk in this gene set explained variation in neuropsychological performance in patients and healthy participants.
25-1	4713-4715	As	_
25-2	4716-4728	disturbances	_
25-3	4729-4731	in	_
25-4	4732-4741	cognition	_
25-5	4742-4745	are	_
25-6	4746-4747	a	_
25-7	4748-4756	cardinal	_
25-8	4757-4764	feature	_
25-9	4765-4767	of	_
25-10	4768-4770	SZ	_
25-11	4770-4771	,	_
25-12	4772-4774	we	_
25-13	4775-4787	investigated	_
25-14	4788-4795	whether	_
25-15	4796-4805	polygenic	_
25-16	4806-4810	risk	_
25-17	4811-4813	in	_
25-18	4814-4818	this	_
25-19	4819-4823	gene	_
25-20	4824-4827	set	_
25-21	4828-4837	explained	_
25-22	4838-4847	variation	_
25-23	4848-4850	in	_
25-24	4851-4869	neuropsychological	_
25-25	4870-4881	performance	_
25-26	4882-4884	in	_
25-27	4885-4893	patients	_
25-28	4894-4897	and	_
25-29	4898-4905	healthy	_
25-30	4906-4918	participants	_
25-31	4918-4919	.	_

#Text=A key goal for this analysis was to estimate whether the variance explained by this downstream polygenic burden was independent to that explained by the single most robustly associated MIR137 SNP, rs1702294.
26-1	4920-4921	A	_
26-2	4922-4925	key	_
26-3	4926-4930	goal	_
26-4	4931-4934	for	_
26-5	4935-4939	this	_
26-6	4940-4948	analysis	_
26-7	4949-4952	was	_
26-8	4953-4955	to	_
26-9	4956-4964	estimate	_
26-10	4965-4972	whether	_
26-11	4973-4976	the	_
26-12	4977-4985	variance	_
26-13	4986-4995	explained	_
26-14	4996-4998	by	_
26-15	4999-5003	this	_
26-16	5004-5014	downstream	_
26-17	5015-5024	polygenic	_
26-18	5025-5031	burden	_
26-19	5032-5035	was	_
26-20	5036-5047	independent	_
26-21	5048-5050	to	_
26-22	5051-5055	that	_
26-23	5056-5065	explained	_
26-24	5066-5068	by	_
26-25	5069-5072	the	_
26-26	5073-5079	single	_
26-27	5080-5084	most	_
26-28	5085-5093	robustly	_
26-29	5094-5104	associated	_
26-30	5105-5111	MIR137	_
26-31	5112-5115	SNP	_
26-32	5115-5116	,	_
26-33	5117-5126	rs1702294	_
26-34	5126-5127	.	_

#Text=Our hypothesis was that a higher polygenic burden within the empirically derived miR-137 regulated gene score, excluding the rs1702294 SNP, would be associated with increased cognitive deficits in a sample of healthy participants and patients with psychosis.
27-1	5128-5131	Our	_
27-2	5132-5142	hypothesis	_
27-3	5143-5146	was	_
27-4	5147-5151	that	_
27-5	5152-5153	a	_
27-6	5154-5160	higher	_
27-7	5161-5170	polygenic	_
27-8	5171-5177	burden	_
27-9	5178-5184	within	_
27-10	5185-5188	the	_
27-11	5189-5200	empirically	_
27-12	5201-5208	derived	_
27-13	5209-5212	miR	_
27-14	5212-5213	-	_
27-15	5213-5216	137	_
27-16	5217-5226	regulated	_
27-17	5227-5231	gene	_
27-18	5232-5237	score	_
27-19	5237-5238	,	_
27-20	5239-5248	excluding	_
27-21	5249-5252	the	_
27-22	5253-5262	rs1702294	_
27-23	5263-5266	SNP	_
27-24	5266-5267	,	_
27-25	5268-5273	would	_
27-26	5274-5276	be	_
27-27	5277-5287	associated	_
27-28	5288-5292	with	_
27-29	5293-5302	increased	_
27-30	5303-5312	cognitive	_
27-31	5313-5321	deficits	_
27-32	5322-5324	in	_
27-33	5325-5326	a	_
27-34	5327-5333	sample	_
27-35	5334-5336	of	_
27-36	5337-5344	healthy	_
27-37	5345-5357	participants	_
27-38	5358-5361	and	_
27-39	5362-5370	patients	_
27-40	5371-5375	with	_
27-41	5376-5385	psychosis	_
27-42	5385-5386	.	_

#Text=Materials and methods
#Text=Participants
#Text=In total, 808 cases and 192 healthy participants completed a full neuropsychological assessment battery and had full genome-wide SNP data available.
28-1	5387-5396	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]
28-2	5397-5400	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]
28-3	5401-5408	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]
28-4	5409-5421	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-5	5422-5424	In	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-6	5425-5430	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-7	5430-5431	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-8	5432-5435	808	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-9	5436-5441	cases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-10	5442-5445	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-11	5446-5449	192	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-12	5450-5457	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]
28-13	5458-5470	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]
28-14	5471-5480	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-15	5481-5482	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-16	5483-5487	full	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-17	5488-5506	neuropsychological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-18	5507-5517	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-19	5518-5525	battery	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-20	5526-5529	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-21	5530-5533	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-22	5534-5538	full	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-23	5539-5550	genome-wide	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-24	5551-5554	SNP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-25	5555-5559	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-26	5560-5569	available	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
28-27	5569-5570	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]

#Text=Cases consisted of n=585 clinically stable patients with a diagnosis of SZ and schizoaffective disorder (SZA), which we refer to as ‘narrow-sense’ psychosis, and an additional n=223 patients diagnosed with bipolar disorder with psychotic features, major depressive disorder with psychotic features, delusional disorder, or psychosis not otherwise specified who combined with SZ/SZA patients to form a ‘broad-sense’ psychosis group.
29-1	5571-5576	Cases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-2	5577-5586	consisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-3	5587-5589	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-4	5590-5591	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-5	5591-5592	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-6	5592-5595	585	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-7	5596-5606	clinically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-8	5607-5613	stable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-9	5614-5622	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-10	5623-5627	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-11	5628-5629	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-12	5630-5639	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-13	5640-5642	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-14	5643-5645	SZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[8]
29-15	5646-5649	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-16	5650-5665	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[9]
29-17	5666-5674	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[9]
29-18	5675-5676	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[9]
29-19	5676-5679	SZA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[9]
29-20	5679-5680	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[9]
29-21	5680-5681	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-22	5682-5687	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-23	5688-5690	we	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-24	5691-5696	refer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-25	5697-5699	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-26	5700-5702	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-27	5703-5704	‘	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-28	5704-5716	narrow-sense	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-29	5716-5717	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-30	5718-5727	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-31	5727-5728	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-32	5729-5732	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-33	5733-5735	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-34	5736-5746	additional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-35	5747-5748	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-36	5748-5749	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-37	5749-5752	223	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-38	5753-5761	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-39	5762-5771	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-40	5772-5776	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-41	5777-5784	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder[10]
29-42	5785-5793	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder[10]
29-43	5794-5798	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder[10]
29-44	5799-5808	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder[10]
29-45	5809-5817	features	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder[10]
29-46	5817-5818	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-47	5819-5824	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[11]
29-48	5825-5835	depressive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[11]
29-49	5836-5844	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[11]
29-50	5845-5849	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[11]
29-51	5850-5859	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[11]
29-52	5860-5868	features	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[11]
29-53	5868-5869	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-54	5870-5880	delusional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-55	5881-5889	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-56	5889-5890	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-57	5891-5893	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-58	5894-5903	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[12]
29-59	5904-5907	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-60	5908-5917	otherwise	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-61	5918-5927	specified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-62	5928-5931	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-63	5932-5940	combined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-64	5941-5945	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-65	5946-5948	SZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]
29-66	5948-5949	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-67	5949-5952	SZA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder[14]
29-68	5953-5961	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-69	5962-5964	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-70	5965-5969	form	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-71	5970-5971	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-72	5972-5973	‘	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-73	5973-5984	broad-sense	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-74	5984-5985	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-75	5986-5995	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-76	5996-6001	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
29-77	6001-6002	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]

#Text=Patients were diagnosed by trained psychiatrists using the Structured Clinical Interview for DSM-IV Axis I Diagnosis.
30-1	6003-6011	Patients	_
30-2	6012-6016	were	_
30-3	6017-6026	diagnosed	_
30-4	6027-6029	by	_
30-5	6030-6037	trained	_
30-6	6038-6051	psychiatrists	_
30-7	6052-6057	using	_
30-8	6058-6061	the	_
30-9	6062-6072	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[15]
30-10	6073-6081	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[15]
30-11	6082-6091	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[15]
30-12	6092-6095	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[15]
30-13	6096-6102	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[15]
30-14	6103-6107	Axis	_
30-15	6108-6109	I	_
30-16	6110-6119	Diagnosis	_
30-17	6119-6120	.	_

#Text=Inclusion criteria required participants to be clinically stable at time of cognitive assessment, aged between 18 and 65 years, no history of co-morbid psychiatric disorder, no substance abuse in the preceding 6 months, no prior head injury with loss of consciousness, no history of seizures, and with Irish ancestry (all four grandparents born in Ireland).
31-1	6121-6130	Inclusion	_
31-2	6131-6139	criteria	_
31-3	6140-6148	required	_
31-4	6149-6161	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-5	6162-6164	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-6	6165-6167	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-7	6168-6178	clinically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-8	6179-6185	stable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-9	6186-6188	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-10	6189-6193	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-11	6194-6196	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-12	6197-6206	cognitive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-13	6207-6217	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-14	6217-6218	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-15	6219-6223	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-16	6224-6231	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-17	6232-6234	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-18	6235-6238	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-19	6239-6241	65	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-20	6242-6247	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-21	6247-6248	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-22	6249-6251	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-23	6252-6259	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-24	6260-6262	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-25	6263-6272	co-morbid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-26	6273-6284	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-27	6285-6293	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-28	6293-6294	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-29	6295-6297	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-30	6298-6307	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-31	6308-6313	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-32	6314-6316	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-33	6317-6320	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-34	6321-6330	preceding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-35	6331-6332	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-36	6333-6339	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-37	6339-6340	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-38	6341-6343	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-39	6344-6349	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-40	6350-6354	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-41	6355-6361	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-42	6362-6366	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-43	6367-6371	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-44	6372-6374	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-45	6375-6388	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-46	6388-6389	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-47	6390-6392	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-48	6393-6400	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-49	6401-6403	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-50	6404-6412	seizures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-51	6412-6413	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-52	6414-6417	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-53	6418-6422	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-54	6423-6428	Irish	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-55	6429-6437	ancestry	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
31-56	6438-6439	(	_
31-57	6439-6442	all	_
31-58	6443-6447	four	_
31-59	6448-6460	grandparents	_
31-60	6461-6465	born	_
31-61	6466-6468	in	_
31-62	6469-6476	Ireland	_
31-63	6476-6477	)	_
31-64	6477-6478	.	_

#Text=Healthy participants were recruited from the general population through local media advertisements.
32-1	6479-6486	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[18]
32-2	6487-6499	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[18]
32-3	6500-6504	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
32-4	6505-6514	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
32-5	6515-6519	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
32-6	6520-6523	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
32-7	6524-6531	general	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
32-8	6532-6542	population	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
32-9	6543-6550	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
32-10	6551-6556	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
32-11	6557-6562	media	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
32-12	6563-6577	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]
32-13	6577-6578	.	_

#Text=All were aged between 18 and 65 years and had Irish-born paternal and maternal grandparents, and satisfied, on the basis of clinical interview, the criteria of having no history of major mental health problems, intellectual disability or acquired brain injury, and no substance abuse in the preceding 6 months.
33-1	6579-6582	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-2	6583-6587	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-3	6588-6592	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-4	6593-6600	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-5	6601-6603	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-6	6604-6607	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-7	6608-6610	65	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-8	6611-6616	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-9	6617-6620	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-10	6621-6624	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-11	6625-6635	Irish-born	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-12	6636-6644	paternal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-13	6645-6648	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-14	6649-6657	maternal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-15	6658-6670	grandparents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-16	6670-6671	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-17	6672-6675	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-18	6676-6685	satisfied	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-19	6685-6686	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-20	6687-6689	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-21	6690-6693	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-22	6694-6699	basis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-23	6700-6702	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-24	6703-6711	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-25	6712-6721	interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-26	6721-6722	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-27	6723-6726	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-28	6727-6735	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-29	6736-6738	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-30	6739-6745	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-31	6746-6748	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-32	6749-6756	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-33	6757-6759	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-34	6760-6765	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-35	6766-6772	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-36	6773-6779	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-37	6780-6788	problems	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-38	6788-6789	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-39	6790-6802	intellectual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-40	6803-6813	disability	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-41	6814-6816	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-42	6817-6825	acquired	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-43	6826-6831	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-44	6832-6838	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-45	6838-6839	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-46	6840-6843	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-47	6844-6846	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-48	6847-6856	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-49	6857-6862	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-50	6863-6865	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-51	6866-6869	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-52	6870-6879	preceding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-53	6880-6881	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-54	6882-6888	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
33-55	6888-6889	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]

#Text=Exclusion criteria also included having a first-degree relative with a history of psychosis.
34-1	6890-6899	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
34-2	6900-6908	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
34-3	6909-6913	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
34-4	6914-6922	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
34-5	6923-6929	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
34-6	6930-6931	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
34-7	6932-6944	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
34-8	6945-6953	relative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
34-9	6954-6958	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
34-10	6959-6960	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
34-11	6961-6968	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
34-12	6969-6971	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
34-13	6972-6981	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
34-14	6981-6982	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]

#Text=All clinical and neuropsychological assessments were conducted in accordance with the relevant ethics committees’ approval for the six sites at which this data was collected, and all participants provided written informed consent.
35-1	6983-6986	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-2	6987-6995	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-3	6996-6999	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-4	7000-7018	neuropsychological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-5	7019-7030	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-6	7031-7035	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-7	7036-7045	conducted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-8	7046-7048	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-9	7049-7059	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-10	7060-7064	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-11	7065-7068	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-12	7069-7077	relevant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-13	7078-7084	ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-14	7085-7095	committees	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-15	7095-7096	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-16	7097-7105	approval	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-17	7106-7109	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-18	7110-7113	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-19	7114-7117	six	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-20	7118-7123	sites	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-21	7124-7126	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-22	7127-7132	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-23	7133-7137	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-24	7138-7142	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-25	7143-7146	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-26	7147-7156	collected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-27	7156-7157	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-28	7158-7161	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-29	7162-7165	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-30	7166-7178	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-31	7179-7187	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-32	7188-7195	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-33	7196-7204	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-34	7205-7212	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
35-35	7212-7213	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]

#Text=Cognitive assessment
#Text=A full neuropsychological assessment designed to evaluate the cognitive deficits typically reported in SZ (general cognitive ability, memory function, attention, and social cognition) was administered to each participant.
36-1	7214-7223	Cognitive	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[21]
36-2	7224-7234	assessment	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[21]
36-3	7235-7236	A	_
36-4	7237-7241	full	_
36-5	7242-7260	neuropsychological	_
36-6	7261-7271	assessment	_
36-7	7272-7280	designed	_
36-8	7281-7283	to	_
36-9	7284-7292	evaluate	_
36-10	7293-7296	the	_
36-11	7297-7306	cognitive	_
36-12	7307-7315	deficits	_
36-13	7316-7325	typically	_
36-14	7326-7334	reported	_
36-15	7335-7337	in	_
36-16	7338-7340	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
36-17	7341-7342	(	_
36-18	7342-7349	general	_
36-19	7350-7359	cognitive	_
36-20	7360-7367	ability	_
36-21	7367-7368	,	_
36-22	7369-7375	memory	_
36-23	7376-7384	function	_
36-24	7384-7385	,	_
36-25	7386-7395	attention	_
36-26	7395-7396	,	_
36-27	7397-7400	and	_
36-28	7401-7407	social	_
36-29	7408-7417	cognition	_
36-30	7417-7418	)	_
36-31	7419-7422	was	_
36-32	7423-7435	administered	_
36-33	7436-7438	to	_
36-34	7439-7443	each	_
36-35	7444-7455	participant	_
36-36	7455-7456	.	_

#Text=Selected subtests (Vocabulary, Similarities, Block Design, and Matrix Reasoning) of the Wechsler Adult Intelligence Scale, 3rd Edition (WAIS III) were used to measure general cognitive function.
37-1	7457-7465	Selected	_
37-2	7466-7474	subtests	_
37-3	7475-7476	(	_
37-4	7476-7486	Vocabulary	_
37-5	7486-7487	,	_
37-6	7488-7500	Similarities	_
37-7	7500-7501	,	_
37-8	7502-7507	Block	_
37-9	7508-7514	Design	_
37-10	7514-7515	,	_
37-11	7516-7519	and	_
37-12	7520-7526	Matrix	_
37-13	7527-7536	Reasoning	_
37-14	7536-7537	)	_
37-15	7538-7540	of	_
37-16	7541-7544	the	_
37-17	7545-7553	Wechsler	_
37-18	7554-7559	Adult	_
37-19	7560-7572	Intelligence	_
37-20	7573-7578	Scale	_
37-21	7578-7579	,	_
37-22	7580-7583	3rd	_
37-23	7584-7591	Edition	_
37-24	7592-7593	(	_
37-25	7593-7597	WAIS	_
37-26	7598-7601	III	_
37-27	7601-7602	)	_
37-28	7603-7607	were	_
37-29	7608-7612	used	_
37-30	7613-7615	to	_
37-31	7616-7623	measure	_
37-32	7624-7631	general	_
37-33	7632-7641	cognitive	_
37-34	7642-7650	function	_
37-35	7650-7651	.	_

#Text=The Logical Memory (LM) I and II and Faces I and II subtests from the Wechsler Memory Scale, 3rd Edition (WMS III) were used to assess episodic and visual memory.
38-1	7652-7655	The	_
38-2	7656-7663	Logical	_
38-3	7664-7670	Memory	_
38-4	7671-7672	(	_
38-5	7672-7674	LM	_
38-6	7674-7675	)	_
38-7	7676-7677	I	_
38-8	7678-7681	and	_
38-9	7682-7684	II	_
38-10	7685-7688	and	_
38-11	7689-7694	Faces	_
38-12	7695-7696	I	_
38-13	7697-7700	and	_
38-14	7701-7703	II	_
38-15	7704-7712	subtests	_
38-16	7713-7717	from	_
38-17	7718-7721	the	_
38-18	7722-7730	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[22]
38-19	7731-7737	Memory	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[22]
38-20	7738-7743	Scale	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[22]
38-21	7743-7744	,	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[22]
38-22	7745-7748	3rd	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[22]
38-23	7749-7756	Edition	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[22]
38-24	7757-7758	(	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[22]
38-25	7758-7761	WMS	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[22]
38-26	7762-7765	III	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[22]
38-27	7765-7766	)	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[22]
38-28	7767-7771	were	_
38-29	7772-7776	used	_
38-30	7777-7779	to	_
38-31	7780-7786	assess	_
38-32	7787-7795	episodic	_
38-33	7796-7799	and	_
38-34	7800-7806	visual	_
38-35	7807-7813	memory	_
38-36	7813-7814	.	_

#Text=Working memory was assessed using the Spatial Working Memory (SWM) subtest from the Cambridge Automated Neuropsychological Test Battery and Letter-Number Sequencing from the WMS III.
39-1	7815-7822	Working	_
39-2	7823-7829	memory	_
39-3	7830-7833	was	_
39-4	7834-7842	assessed	_
39-5	7843-7848	using	_
39-6	7849-7852	the	_
39-7	7853-7860	Spatial	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory[23]
39-8	7861-7868	Working	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory[23]
39-9	7869-7875	Memory	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory[23]
39-10	7876-7877	(	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory[23]
39-11	7877-7880	SWM	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory[23]
39-12	7880-7881	)	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory[23]
39-13	7882-7889	subtest	_
39-14	7890-7894	from	_
39-15	7895-7898	the	_
39-16	7899-7908	Cambridge	_
39-17	7909-7918	Automated	_
39-18	7919-7937	Neuropsychological	_
39-19	7938-7942	Test	_
39-20	7943-7950	Battery	_
39-21	7951-7954	and	_
39-22	7955-7968	Letter-Number	_
39-23	7969-7979	Sequencing	_
39-24	7980-7984	from	_
39-25	7985-7988	the	_
39-26	7989-7992	WMS	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[24]
39-27	7993-7996	III	http://maven.renci.org/NeuroBridge/neurobridge#WechslerMemoryScale-Revised[24]
39-28	7996-7997	.	_

#Text=Attentional control was assessed using the Continuous Performance Task (CPT) identical pairs version and the Sustained Attention to Response Task (SART).
40-1	7998-8009	Attentional	_
40-2	8010-8017	control	_
40-3	8018-8021	was	_
40-4	8022-8030	assessed	_
40-5	8031-8036	using	_
40-6	8037-8040	the	_
40-7	8041-8051	Continuous	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]
40-8	8052-8063	Performance	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]
40-9	8064-8068	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]
40-10	8069-8070	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]
40-11	8070-8073	CPT	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]
40-12	8073-8074	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[25]
40-13	8075-8084	identical	_
40-14	8085-8090	pairs	_
40-15	8091-8098	version	_
40-16	8099-8102	and	_
40-17	8103-8106	the	_
40-18	8107-8116	Sustained	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]
40-19	8117-8126	Attention	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]
40-20	8127-8129	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]
40-21	8130-8138	Response	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]
40-22	8139-8143	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]
40-23	8144-8145	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]
40-24	8145-8149	SART	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]
40-25	8149-8150	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]
40-26	8150-8151	.	_

#Text=In addition to neuropsychological assessment, this study included measures of two aspects of social cognition—theory of mind (ToM) (frequently altered among patients with SZ and previously associated with MIR137(ref.)) and attributional style.
41-1	8152-8154	In	_
41-2	8155-8163	addition	_
41-3	8164-8166	to	_
41-4	8167-8185	neuropsychological	_
41-5	8186-8196	assessment	_
41-6	8196-8197	,	_
41-7	8198-8202	this	_
41-8	8203-8208	study	_
41-9	8209-8217	included	_
41-10	8218-8226	measures	_
41-11	8227-8229	of	_
41-12	8230-8233	two	_
41-13	8234-8241	aspects	_
41-14	8242-8244	of	_
41-15	8245-8251	social	_
41-16	8252-8268	cognition—theory	_
41-17	8269-8271	of	_
41-18	8272-8276	mind	_
41-19	8277-8278	(	_
41-20	8278-8281	ToM	_
41-21	8281-8282	)	_
41-22	8283-8284	(	_
41-23	8284-8294	frequently	_
41-24	8295-8302	altered	_
41-25	8303-8308	among	_
41-26	8309-8317	patients	_
41-27	8318-8322	with	_
41-28	8323-8325	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
41-29	8326-8329	and	_
41-30	8330-8340	previously	_
41-31	8341-8351	associated	_
41-32	8352-8356	with	_
41-33	8357-8363	MIR137	_
41-34	8363-8364	(	_
41-35	8364-8367	ref	_
41-36	8367-8368	.	_
41-37	8368-8369	)	_
41-38	8369-8370	)	_
41-39	8371-8374	and	_
41-40	8375-8388	attributional	_
41-41	8389-8394	style	_
41-42	8394-8395	.	_

#Text=ToM is the ability to attribute mental states—beliefs, intents, desires, pretending, knowledge and so on—to oneself and others and to understand that others have beliefs, desires, intentions and perspectives that are different from one's own, and is estimated using the Reading the Mind in the Eyes Task and the Hinting Task.
42-1	8396-8399	ToM	_
42-2	8400-8402	is	_
42-3	8403-8406	the	_
42-4	8407-8414	ability	_
42-5	8415-8417	to	_
42-6	8418-8427	attribute	_
42-7	8428-8434	mental	_
42-8	8435-8449	states—beliefs	_
42-9	8449-8450	,	_
42-10	8451-8458	intents	_
42-11	8458-8459	,	_
42-12	8460-8467	desires	_
42-13	8467-8468	,	_
42-14	8469-8479	pretending	_
42-15	8479-8480	,	_
42-16	8481-8490	knowledge	_
42-17	8491-8494	and	_
42-18	8495-8497	so	_
42-19	8498-8503	on—to	_
42-20	8504-8511	oneself	_
42-21	8512-8515	and	_
42-22	8516-8522	others	_
42-23	8523-8526	and	_
42-24	8527-8529	to	_
42-25	8530-8540	understand	_
42-26	8541-8545	that	_
42-27	8546-8552	others	_
42-28	8553-8557	have	_
42-29	8558-8565	beliefs	_
42-30	8565-8566	,	_
42-31	8567-8574	desires	_
42-32	8574-8575	,	_
42-33	8576-8586	intentions	_
42-34	8587-8590	and	_
42-35	8591-8603	perspectives	_
42-36	8604-8608	that	_
42-37	8609-8612	are	_
42-38	8613-8622	different	_
42-39	8623-8627	from	_
42-40	8628-8633	one's	_
42-41	8634-8637	own	_
42-42	8637-8638	,	_
42-43	8639-8642	and	_
42-44	8643-8645	is	_
42-45	8646-8655	estimated	_
42-46	8656-8661	using	_
42-47	8662-8665	the	_
42-48	8666-8673	Reading	_
42-49	8674-8677	the	_
42-50	8678-8682	Mind	_
42-51	8683-8685	in	_
42-52	8686-8689	the	_
42-53	8690-8694	Eyes	_
42-54	8695-8699	Task	_
42-55	8700-8703	and	_
42-56	8704-8707	the	_
42-57	8708-8715	Hinting	_
42-58	8716-8720	Task	_
42-59	8720-8721	.	_

#Text=Attributional style refers to the pervasive tendency to explain personally significant events in a particular manner.
43-1	8722-8735	Attributional	_
43-2	8736-8741	style	_
43-3	8742-8748	refers	_
43-4	8749-8751	to	_
43-5	8752-8755	the	_
43-6	8756-8765	pervasive	_
43-7	8766-8774	tendency	_
43-8	8775-8777	to	_
43-9	8778-8785	explain	_
43-10	8786-8796	personally	_
43-11	8797-8808	significant	_
43-12	8809-8815	events	_
43-13	8816-8818	in	_
43-14	8819-8820	a	_
43-15	8821-8831	particular	_
43-16	8832-8838	manner	_
43-17	8838-8839	.	_

#Text=Consistency in cognitive assessment was assessed across sites by an independent researcher marking a number of patients assessed at each site.
44-1	8840-8851	Consistency	_
44-2	8852-8854	in	_
44-3	8855-8864	cognitive	_
44-4	8865-8875	assessment	_
44-5	8876-8879	was	_
44-6	8880-8888	assessed	_
44-7	8889-8895	across	_
44-8	8896-8901	sites	_
44-9	8902-8904	by	_
44-10	8905-8907	an	_
44-11	8908-8919	independent	_
44-12	8920-8930	researcher	_
44-13	8931-8938	marking	_
44-14	8939-8940	a	_
44-15	8941-8947	number	_
44-16	8948-8950	of	_
44-17	8951-8959	patients	_
44-18	8960-8968	assessed	_
44-19	8969-8971	at	_
44-20	8972-8976	each	_
44-21	8977-8981	site	_
44-22	8981-8982	.	_

#Text=Genotyping
#Text=Genotyping was conducted on DNA extracted from whole blood or saliva.
45-1	8983-8993	Genotyping	_
45-2	8994-9004	Genotyping	_
45-3	9005-9008	was	_
45-4	9009-9018	conducted	_
45-5	9019-9021	on	_
45-6	9022-9025	DNA	_
45-7	9026-9035	extracted	_
45-8	9036-9040	from	_
45-9	9041-9046	whole	_
45-10	9047-9052	blood	_
45-11	9053-9055	or	_
45-12	9056-9062	saliva	_
45-13	9062-9063	.	_

#Text=Full GWAS data were available for all samples.
46-1	9064-9068	Full	_
46-2	9069-9073	GWAS	_
46-3	9074-9078	data	_
46-4	9079-9083	were	_
46-5	9084-9093	available	_
46-6	9094-9097	for	_
46-7	9098-9101	all	_
46-8	9102-9109	samples	_
46-9	9109-9110	.	_

#Text=A proportion of samples were genotyped with an Affymetrix 6.0 chip (Santa Clara, CA, USA; as part of the WTCCC2, referred to as Sample A) and the remainder on the Illumina HumanCoreExome chip (San Diego, CA, USA; referred to as Sample B).
47-1	9111-9112	A	_
47-2	9113-9123	proportion	_
47-3	9124-9126	of	_
47-4	9127-9134	samples	_
47-5	9135-9139	were	_
47-6	9140-9149	genotyped	_
47-7	9150-9154	with	_
47-8	9155-9157	an	_
47-9	9158-9168	Affymetrix	_
47-10	9169-9172	6.0	_
47-11	9173-9177	chip	_
47-12	9178-9179	(	_
47-13	9179-9184	Santa	_
47-14	9185-9190	Clara	_
47-15	9190-9191	,	_
47-16	9192-9194	CA	_
47-17	9194-9195	,	_
47-18	9196-9199	USA	_
47-19	9199-9200	;	_
47-20	9201-9203	as	_
47-21	9204-9208	part	_
47-22	9209-9211	of	_
47-23	9212-9215	the	_
47-24	9216-9222	WTCCC2	_
47-25	9222-9223	,	_
47-26	9224-9232	referred	_
47-27	9233-9235	to	_
47-28	9236-9238	as	_
47-29	9239-9245	Sample	_
47-30	9246-9247	A	_
47-31	9247-9248	)	_
47-32	9249-9252	and	_
47-33	9253-9256	the	_
47-34	9257-9266	remainder	_
47-35	9267-9269	on	_
47-36	9270-9273	the	_
47-37	9274-9282	Illumina	_
47-38	9283-9297	HumanCoreExome	_
47-39	9298-9302	chip	_
47-40	9303-9304	(	_
47-41	9304-9307	San	_
47-42	9308-9313	Diego	_
47-43	9313-9314	,	_
47-44	9315-9317	CA	_
47-45	9317-9318	,	_
47-46	9319-9322	USA	_
47-47	9322-9323	;	_
47-48	9324-9332	referred	_
47-49	9333-9335	to	_
47-50	9336-9338	as	_
47-51	9339-9345	Sample	_
47-52	9346-9347	B	_
47-53	9347-9348	)	_
47-54	9348-9349	.	_

#Text=SNPs were excluded on the basis of MAF<0.1%, SNP missingness ⩽2%, and Hardy–Weinberg equilibrium P⩽10−6.
48-1	9350-9354	SNPs	_
48-2	9355-9359	were	_
48-3	9360-9368	excluded	_
48-4	9369-9371	on	_
48-5	9372-9375	the	_
48-6	9376-9381	basis	_
48-7	9382-9384	of	_
48-8	9385-9388	MAF	_
48-9	9388-9389	<	_
48-10	9389-9393	0.1%	_
48-11	9393-9394	,	_
48-12	9395-9398	SNP	_
48-13	9399-9410	missingness	_
48-14	9411-9412	⩽	_
48-15	9412-9414	2%	_
48-16	9414-9415	,	_
48-17	9416-9419	and	_
48-18	9420-9434	Hardy–Weinberg	_
48-19	9435-9446	equilibrium	_
48-20	9447-9448	P	_
48-21	9448-9449	⩽	_
48-22	9449-9451	10	_
48-23	9451-9452	−	_
48-24	9452-9453	6	_
48-25	9453-9454	.	_

#Text=Imputation was carried out on these data sets separately using 1000 Genomes Phase I integrated haplotypes (Dec 2013 release) and IMPUTE2 to give ~10 million SNPs genome-wide per sample.
49-1	9455-9465	Imputation	_
49-2	9466-9469	was	_
49-3	9470-9477	carried	_
49-4	9478-9481	out	_
49-5	9482-9484	on	_
49-6	9485-9490	these	_
49-7	9491-9495	data	_
49-8	9496-9500	sets	_
49-9	9501-9511	separately	_
49-10	9512-9517	using	_
49-11	9518-9522	1000	_
49-12	9523-9530	Genomes	_
49-13	9531-9536	Phase	_
49-14	9537-9538	I	_
49-15	9539-9549	integrated	_
49-16	9550-9560	haplotypes	_
49-17	9561-9562	(	_
49-18	9562-9565	Dec	_
49-19	9566-9570	2013	_
49-20	9571-9578	release	_
49-21	9578-9579	)	_
49-22	9580-9583	and	_
49-23	9584-9591	IMPUTE2	_
49-24	9592-9594	to	_
49-25	9595-9599	give	_
49-26	9600-9601	~	_
49-27	9601-9603	10	_
49-28	9604-9611	million	_
49-29	9612-9616	SNPs	_
49-30	9617-9628	genome-wide	_
49-31	9629-9632	per	_
49-32	9633-9639	sample	_
49-33	9639-9640	.	_

#Text=Polygene score
#Text=We began by constructing the miR-137 downstream pathway based on the set of 1016 genes whose expression was identified as being altered by miR-137 manipulation in the study by Hill et al., 831 of these genes could be unambiguously mapped to the autosomes and this gene set was used to generate polygene scores.
50-1	9641-9649	Polygene	_
50-2	9650-9655	score	_
50-3	9656-9658	We	_
50-4	9659-9664	began	_
50-5	9665-9667	by	_
50-6	9668-9680	constructing	_
50-7	9681-9684	the	_
50-8	9685-9688	miR	_
50-9	9688-9689	-	_
50-10	9689-9692	137	_
50-11	9693-9703	downstream	_
50-12	9704-9711	pathway	_
50-13	9712-9717	based	_
50-14	9718-9720	on	_
50-15	9721-9724	the	_
50-16	9725-9728	set	_
50-17	9729-9731	of	_
50-18	9732-9736	1016	_
50-19	9737-9742	genes	_
50-20	9743-9748	whose	_
50-21	9749-9759	expression	_
50-22	9760-9763	was	_
50-23	9764-9774	identified	_
50-24	9775-9777	as	_
50-25	9778-9783	being	_
50-26	9784-9791	altered	_
50-27	9792-9794	by	_
50-28	9795-9798	miR	_
50-29	9798-9799	-	_
50-30	9799-9802	137	_
50-31	9803-9815	manipulation	_
50-32	9816-9818	in	_
50-33	9819-9822	the	_
50-34	9823-9828	study	_
50-35	9829-9831	by	_
50-36	9832-9836	Hill	_
50-37	9837-9839	et	_
50-38	9840-9842	al	_
50-39	9842-9843	.	_
50-40	9843-9844	,	_
50-41	9845-9848	831	_
50-42	9849-9851	of	_
50-43	9852-9857	these	_
50-44	9858-9863	genes	_
50-45	9864-9869	could	_
50-46	9870-9872	be	_
50-47	9873-9886	unambiguously	_
50-48	9887-9893	mapped	_
50-49	9894-9896	to	_
50-50	9897-9900	the	_
50-51	9901-9910	autosomes	_
50-52	9911-9914	and	_
50-53	9915-9919	this	_
50-54	9920-9924	gene	_
50-55	9925-9928	set	_
50-56	9929-9932	was	_
50-57	9933-9937	used	_
50-58	9938-9940	to	_
50-59	9941-9949	generate	_
50-60	9950-9958	polygene	_
50-61	9959-9965	scores	_
50-62	9965-9966	.	_

#Text=We then cross-referenced with unweighted P-values from the PGC2 2014 GWAS for variants within 20 kb of each gene in this set without LD-pruning (scores with and without pruning were highly correlated).
51-1	9967-9969	We	_
51-2	9970-9974	then	_
51-3	9975-9991	cross-referenced	_
51-4	9992-9996	with	_
51-5	9997-10007	unweighted	_
51-6	10008-10016	P-values	_
51-7	10017-10021	from	_
51-8	10022-10025	the	_
51-9	10026-10030	PGC2	_
51-10	10031-10035	2014	_
51-11	10036-10040	GWAS	_
51-12	10041-10044	for	_
51-13	10045-10053	variants	_
51-14	10054-10060	within	_
51-15	10061-10063	20	_
51-16	10064-10066	kb	_
51-17	10067-10069	of	_
51-18	10070-10074	each	_
51-19	10075-10079	gene	_
51-20	10080-10082	in	_
51-21	10083-10087	this	_
51-22	10088-10091	set	_
51-23	10092-10099	without	_
51-24	10100-10110	LD-pruning	_
51-25	10111-10112	(	_
51-26	10112-10118	scores	_
51-27	10119-10123	with	_
51-28	10124-10127	and	_
51-29	10128-10135	without	_
51-30	10136-10143	pruning	_
51-31	10144-10148	were	_
51-32	10149-10155	highly	_
51-33	10156-10166	correlated	_
51-34	10166-10167	)	_
51-35	10167-10168	.	_

#Text=We next defined three arbitrary threshold values based on the PGC threshold values (P<10−5, P<0.05, and P<0.5) to generate three polygene risk score values for analysis.
52-1	10169-10171	We	_
52-2	10172-10176	next	_
52-3	10177-10184	defined	_
52-4	10185-10190	three	_
52-5	10191-10200	arbitrary	_
52-6	10201-10210	threshold	_
52-7	10211-10217	values	_
52-8	10218-10223	based	_
52-9	10224-10226	on	_
52-10	10227-10230	the	_
52-11	10231-10234	PGC	_
52-12	10235-10244	threshold	_
52-13	10245-10251	values	_
52-14	10252-10253	(	_
52-15	10253-10254	P	_
52-16	10254-10255	<	_
52-17	10255-10257	10	_
52-18	10257-10258	−	_
52-19	10258-10259	5	_
52-20	10259-10260	,	_
52-21	10261-10262	P	_
52-22	10262-10263	<	_
52-23	10263-10267	0.05	_
52-24	10267-10268	,	_
52-25	10269-10272	and	_
52-26	10273-10274	P	_
52-27	10274-10275	<	_
52-28	10275-10278	0.5	_
52-29	10278-10279	)	_
52-30	10280-10282	to	_
52-31	10283-10291	generate	_
52-32	10292-10297	three	_
52-33	10298-10306	polygene	_
52-34	10307-10311	risk	_
52-35	10312-10317	score	_
52-36	10318-10324	values	_
52-37	10325-10328	for	_
52-38	10329-10337	analysis	_
52-39	10337-10338	.	_

#Text=Using these thresholds, 1020, 20 920 and 89 102 SNPs were included in the analysis, respectively.
53-1	10339-10344	Using	_
53-2	10345-10350	these	_
53-3	10351-10361	thresholds	_
53-4	10361-10362	,	_
53-5	10363-10367	1020	_
53-6	10367-10368	,	_
53-7	10369-10371	20	_
53-8	10372-10375	920	_
53-9	10376-10379	and	_
53-10	10380-10382	89	_
53-11	10383-10386	102	_
53-12	10387-10391	SNPs	_
53-13	10392-10396	were	_
53-14	10397-10405	included	_
53-15	10406-10408	in	_
53-16	10409-10412	the	_
53-17	10413-10421	analysis	_
53-18	10421-10422	,	_
53-19	10423-10435	respectively	_
53-20	10435-10436	.	_

#Text=Finally, each participant was then given a weighted polygene score based on the number of risk alleles they carried within this gene list at the given gene threshold, weighted by the log of the SZ-association odds ratio from the PGC2.
54-1	10437-10444	Finally	_
54-2	10444-10445	,	_
54-3	10446-10450	each	_
54-4	10451-10462	participant	_
54-5	10463-10466	was	_
54-6	10467-10471	then	_
54-7	10472-10477	given	_
54-8	10478-10479	a	_
54-9	10480-10488	weighted	_
54-10	10489-10497	polygene	_
54-11	10498-10503	score	_
54-12	10504-10509	based	_
54-13	10510-10512	on	_
54-14	10513-10516	the	_
54-15	10517-10523	number	_
54-16	10524-10526	of	_
54-17	10527-10531	risk	_
54-18	10532-10539	alleles	_
54-19	10540-10544	they	_
54-20	10545-10552	carried	_
54-21	10553-10559	within	_
54-22	10560-10564	this	_
54-23	10565-10569	gene	_
54-24	10570-10574	list	_
54-25	10575-10577	at	_
54-26	10578-10581	the	_
54-27	10582-10587	given	_
54-28	10588-10592	gene	_
54-29	10593-10602	threshold	_
54-30	10602-10603	,	_
54-31	10604-10612	weighted	_
54-32	10613-10615	by	_
54-33	10616-10619	the	_
54-34	10620-10623	log	_
54-35	10624-10626	of	_
54-36	10627-10630	the	_
54-37	10631-10645	SZ-association	_
54-38	10646-10650	odds	_
54-39	10651-10656	ratio	_
54-40	10657-10661	from	_
54-41	10662-10665	the	_
54-42	10666-10670	PGC2	_
54-43	10670-10671	.	_

#Text=Genes used in this process are found in the Supplementary Information.
55-1	10672-10677	Genes	_
55-2	10678-10682	used	_
55-3	10683-10685	in	_
55-4	10686-10690	this	_
55-5	10691-10698	process	_
55-6	10699-10702	are	_
55-7	10703-10708	found	_
55-8	10709-10711	in	_
55-9	10712-10715	the	_
55-10	10716-10729	Supplementary	_
55-11	10730-10741	Information	_
55-12	10741-10742	.	_

#Text=Statistical analysis: neuropsychological tests and polygene scores
#Text=Data were inspected for heteroscedasticity, and outliers, which were excluded from analysis.
56-1	10743-10754	Statistical	_
56-2	10755-10763	analysis	_
56-3	10763-10764	:	_
56-4	10765-10783	neuropsychological	_
56-5	10784-10789	tests	_
56-6	10790-10793	and	_
56-7	10794-10802	polygene	_
56-8	10803-10809	scores	_
56-9	10810-10814	Data	_
56-10	10815-10819	were	_
56-11	10820-10829	inspected	_
56-12	10830-10833	for	_
56-13	10834-10852	heteroscedasticity	_
56-14	10852-10853	,	_
56-15	10854-10857	and	_
56-16	10858-10866	outliers	_
56-17	10866-10867	,	_
56-18	10868-10873	which	_
56-19	10874-10878	were	_
56-20	10879-10887	excluded	_
56-21	10888-10892	from	_
56-22	10893-10901	analysis	_
56-23	10901-10902	.	_

#Text=To estimate polygene effects on cognitive deficits associated with SZ (intelligence quotient (IQ), memory, attentional control and social cognition) linear regression analyses were performed using IBM SPSS Statistics, with age and gender entered as variables of no interest, and test score as the dependent variable.
57-1	10903-10905	To	_
57-2	10906-10914	estimate	_
57-3	10915-10923	polygene	_
57-4	10924-10931	effects	_
57-5	10932-10934	on	_
57-6	10935-10944	cognitive	_
57-7	10945-10953	deficits	_
57-8	10954-10964	associated	_
57-9	10965-10969	with	_
57-10	10970-10972	SZ	_
57-11	10973-10974	(	_
57-12	10974-10986	intelligence	_
57-13	10987-10995	quotient	_
57-14	10996-10997	(	_
57-15	10997-10999	IQ	_
57-16	10999-11000	)	_
57-17	11000-11001	,	_
57-18	11002-11008	memory	_
57-19	11008-11009	,	_
57-20	11010-11021	attentional	_
57-21	11022-11029	control	_
57-22	11030-11033	and	_
57-23	11034-11040	social	_
57-24	11041-11050	cognition	_
57-25	11050-11051	)	_
57-26	11052-11058	linear	_
57-27	11059-11069	regression	_
57-28	11070-11078	analyses	_
57-29	11079-11083	were	_
57-30	11084-11093	performed	_
57-31	11094-11099	using	_
57-32	11100-11103	IBM	_
57-33	11104-11108	SPSS	_
57-34	11109-11119	Statistics	_
57-35	11119-11120	,	_
57-36	11121-11125	with	_
57-37	11126-11129	age	_
57-38	11130-11133	and	_
57-39	11134-11140	gender	_
57-40	11141-11148	entered	_
57-41	11149-11151	as	_
57-42	11152-11161	variables	_
57-43	11162-11164	of	_
57-44	11165-11167	no	_
57-45	11168-11176	interest	_
57-46	11176-11177	,	_
57-47	11178-11181	and	_
57-48	11182-11186	test	_
57-49	11187-11192	score	_
57-50	11193-11195	as	_
57-51	11196-11199	the	_
57-52	11200-11209	dependent	_
57-53	11210-11218	variable	_
57-54	11218-11219	.	_

#Text=To take into account potential differences in results between Sample A and B due to the two differing genotyping platforms used, a linear regression was performed separately in each sample (those genotyped using Affymetrix and those with Illumina).
58-1	11220-11222	To	_
58-2	11223-11227	take	_
58-3	11228-11232	into	_
58-4	11233-11240	account	_
58-5	11241-11250	potential	_
58-6	11251-11262	differences	_
58-7	11263-11265	in	_
58-8	11266-11273	results	_
58-9	11274-11281	between	_
58-10	11282-11288	Sample	_
58-11	11289-11290	A	_
58-12	11291-11294	and	_
58-13	11295-11296	B	_
58-14	11297-11300	due	_
58-15	11301-11303	to	_
58-16	11304-11307	the	_
58-17	11308-11311	two	_
58-18	11312-11321	differing	_
58-19	11322-11332	genotyping	_
58-20	11333-11342	platforms	_
58-21	11343-11347	used	_
58-22	11347-11348	,	_
58-23	11349-11350	a	_
58-24	11351-11357	linear	_
58-25	11358-11368	regression	_
58-26	11369-11372	was	_
58-27	11373-11382	performed	_
58-28	11383-11393	separately	_
58-29	11394-11396	in	_
58-30	11397-11401	each	_
58-31	11402-11408	sample	_
58-32	11409-11410	(	_
58-33	11410-11415	those	_
58-34	11416-11425	genotyped	_
58-35	11426-11431	using	_
58-36	11432-11442	Affymetrix	_
58-37	11443-11446	and	_
58-38	11447-11452	those	_
58-39	11453-11457	with	_
58-40	11458-11466	Illumina	_
58-41	11466-11467	)	_
58-42	11467-11468	.	_

#Text=Results from these were then meta-analyzed using the inverse variance method.
59-1	11469-11476	Results	_
59-2	11477-11481	from	_
59-3	11482-11487	these	_
59-4	11488-11492	were	_
59-5	11493-11497	then	_
59-6	11498-11511	meta-analyzed	_
59-7	11512-11517	using	_
59-8	11518-11521	the	_
59-9	11522-11529	inverse	_
59-10	11530-11538	variance	_
59-11	11539-11545	method	_
59-12	11545-11546	.	_

#Text=In the inverse variance method, the weight given to each sample is chosen to be the inverse of the variance of the effect estimate (that is, one over the square of its standard error).
60-1	11547-11549	In	_
60-2	11550-11553	the	_
60-3	11554-11561	inverse	_
60-4	11562-11570	variance	_
60-5	11571-11577	method	_
60-6	11577-11578	,	_
60-7	11579-11582	the	_
60-8	11583-11589	weight	_
60-9	11590-11595	given	_
60-10	11596-11598	to	_
60-11	11599-11603	each	_
60-12	11604-11610	sample	_
60-13	11611-11613	is	_
60-14	11614-11620	chosen	_
60-15	11621-11623	to	_
60-16	11624-11626	be	_
60-17	11627-11630	the	_
60-18	11631-11638	inverse	_
60-19	11639-11641	of	_
60-20	11642-11645	the	_
60-21	11646-11654	variance	_
60-22	11655-11657	of	_
60-23	11658-11661	the	_
60-24	11662-11668	effect	_
60-25	11669-11677	estimate	_
60-26	11678-11679	(	_
60-27	11679-11683	that	_
60-28	11684-11686	is	_
60-29	11686-11687	,	_
60-30	11688-11691	one	_
60-31	11692-11696	over	_
60-32	11697-11700	the	_
60-33	11701-11707	square	_
60-34	11708-11710	of	_
60-35	11711-11714	its	_
60-36	11715-11723	standard	_
60-37	11724-11729	error	_
60-38	11729-11730	)	_
60-39	11730-11731	.	_

#Text=This minimizes the imprecision of the pooled effect estimate.
61-1	11732-11736	This	_
61-2	11737-11746	minimizes	_
61-3	11747-11750	the	_
61-4	11751-11762	imprecision	_
61-5	11763-11765	of	_
61-6	11766-11769	the	_
61-7	11770-11776	pooled	_
61-8	11777-11783	effect	_
61-9	11784-11792	estimate	_
61-10	11792-11793	.	_

#Text=An estimate of sample heterogeneity and significance of such is shown in Supplementary Table 1 (I2).
62-1	11794-11796	An	_
62-2	11797-11805	estimate	_
62-3	11806-11808	of	_
62-4	11809-11815	sample	_
62-5	11816-11829	heterogeneity	_
62-6	11830-11833	and	_
62-7	11834-11846	significance	_
62-8	11847-11849	of	_
62-9	11850-11854	such	_
62-10	11855-11857	is	_
62-11	11858-11863	shown	_
62-12	11864-11866	in	_
62-13	11867-11880	Supplementary	_
62-14	11881-11886	Table	_
62-15	11887-11888	1	_
62-16	11889-11890	(	_
62-17	11890-11892	I2	_
62-18	11892-11893	)	_
62-19	11893-11894	.	_

#Text=To maximize power to detect differences, we carried out our analysis on the full dataset of all cases and controls (n=1000).
63-1	11895-11897	To	_
63-2	11898-11906	maximize	_
63-3	11907-11912	power	_
63-4	11913-11915	to	_
63-5	11916-11922	detect	_
63-6	11923-11934	differences	_
63-7	11934-11935	,	_
63-8	11936-11938	we	_
63-9	11939-11946	carried	_
63-10	11947-11950	out	_
63-11	11951-11954	our	_
63-12	11955-11963	analysis	_
63-13	11964-11966	on	_
63-14	11967-11970	the	_
63-15	11971-11975	full	_
63-16	11976-11983	dataset	_
63-17	11984-11986	of	_
63-18	11987-11990	all	_
63-19	11991-11996	cases	_
63-20	11997-12000	and	_
63-21	12001-12009	controls	_
63-22	12010-12011	(	_
63-23	12011-12012	n	_
63-24	12012-12013	=	_
63-25	12013-12017	1000	_
63-26	12017-12018	)	_
63-27	12018-12019	.	_

#Text=We then followed any significant results in the patient only groups (both the broad psychosis group (n=808) and narrow psychosis group (patients with SZ and schizoaffective disorder only (n=585)) to confirm the direction of effects in these groups (Supplementary Tables 2 and 3).
64-1	12020-12022	We	_
64-2	12023-12027	then	_
64-3	12028-12036	followed	_
64-4	12037-12040	any	_
64-5	12041-12052	significant	_
64-6	12053-12060	results	_
64-7	12061-12063	in	_
64-8	12064-12067	the	_
64-9	12068-12075	patient	_
64-10	12076-12080	only	_
64-11	12081-12087	groups	_
64-12	12088-12089	(	_
64-13	12089-12093	both	_
64-14	12094-12097	the	_
64-15	12098-12103	broad	_
64-16	12104-12113	psychosis	_
64-17	12114-12119	group	_
64-18	12120-12121	(	_
64-19	12121-12122	n	_
64-20	12122-12123	=	_
64-21	12123-12126	808	_
64-22	12126-12127	)	_
64-23	12128-12131	and	_
64-24	12132-12138	narrow	_
64-25	12139-12148	psychosis	_
64-26	12149-12154	group	_
64-27	12155-12156	(	_
64-28	12156-12164	patients	_
64-29	12165-12169	with	_
64-30	12170-12172	SZ	_
64-31	12173-12176	and	_
64-32	12177-12192	schizoaffective	_
64-33	12193-12201	disorder	_
64-34	12202-12206	only	_
64-35	12207-12208	(	_
64-36	12208-12209	n	_
64-37	12209-12210	=	_
64-38	12210-12213	585	_
64-39	12213-12214	)	_
64-40	12214-12215	)	_
64-41	12216-12218	to	_
64-42	12219-12226	confirm	_
64-43	12227-12230	the	_
64-44	12231-12240	direction	_
64-45	12241-12243	of	_
64-46	12244-12251	effects	_
64-47	12252-12254	in	_
64-48	12255-12260	these	_
64-49	12261-12267	groups	_
64-50	12268-12269	(	_
64-51	12269-12282	Supplementary	_
64-52	12283-12289	Tables	_
64-53	12290-12291	2	_
64-54	12292-12295	and	_
64-55	12296-12297	3	_
64-56	12297-12298	)	_
64-57	12298-12299	.	_

#Text=As the meta-analyses showed little evidence of heterogeneity of results in Sample A and B despite the differing genotype platforms, the sample was analyzed as a whole to provide an estimate of effect size provide r2 and standardized β values (Supplementary Table 4).
65-1	12300-12302	As	_
65-2	12303-12306	the	_
65-3	12307-12320	meta-analyses	_
65-4	12321-12327	showed	_
65-5	12328-12334	little	_
65-6	12335-12343	evidence	_
65-7	12344-12346	of	_
65-8	12347-12360	heterogeneity	_
65-9	12361-12363	of	_
65-10	12364-12371	results	_
65-11	12372-12374	in	_
65-12	12375-12381	Sample	_
65-13	12382-12383	A	_
65-14	12384-12387	and	_
65-15	12388-12389	B	_
65-16	12390-12397	despite	_
65-17	12398-12401	the	_
65-18	12402-12411	differing	_
65-19	12412-12420	genotype	_
65-20	12421-12430	platforms	_
65-21	12430-12431	,	_
65-22	12432-12435	the	_
65-23	12436-12442	sample	_
65-24	12443-12446	was	_
65-25	12447-12455	analyzed	_
65-26	12456-12458	as	_
65-27	12459-12460	a	_
65-28	12461-12466	whole	_
65-29	12467-12469	to	_
65-30	12470-12477	provide	_
65-31	12478-12480	an	_
65-32	12481-12489	estimate	_
65-33	12490-12492	of	_
65-34	12493-12499	effect	_
65-35	12500-12504	size	_
65-36	12505-12512	provide	_
65-37	12513-12515	r2	_
65-38	12516-12519	and	_
65-39	12520-12532	standardized	_
65-40	12533-12534	β	_
65-41	12535-12541	values	_
65-42	12542-12543	(	_
65-43	12543-12556	Supplementary	_
65-44	12557-12562	Table	_
65-45	12563-12564	4	_
65-46	12564-12565	)	_
65-47	12565-12566	.	_

#Text=A post hoc power calculation estimated that n=988 has 0.88 power to detect a very conservative polygene score effect of r2=0.01, with α=0.05, although there are certain caveats to this type of calculation.
66-1	12567-12568	A	_
66-2	12569-12573	post	_
66-3	12574-12577	hoc	_
66-4	12578-12583	power	_
66-5	12584-12595	calculation	_
66-6	12596-12605	estimated	_
66-7	12606-12610	that	_
66-8	12611-12612	n	_
66-9	12612-12613	=	_
66-10	12613-12616	988	_
66-11	12617-12620	has	_
66-12	12621-12625	0.88	_
66-13	12626-12631	power	_
66-14	12632-12634	to	_
66-15	12635-12641	detect	_
66-16	12642-12643	a	_
66-17	12644-12648	very	_
66-18	12649-12661	conservative	_
66-19	12662-12670	polygene	_
66-20	12671-12676	score	_
66-21	12677-12683	effect	_
66-22	12684-12686	of	_
66-23	12687-12689	r2	_
66-24	12689-12690	=	_
66-25	12690-12694	0.01	_
66-26	12694-12695	,	_
66-27	12696-12700	with	_
66-28	12701-12702	α	_
66-29	12702-12703	=	_
66-30	12703-12707	0.05	_
66-31	12707-12708	,	_
66-32	12709-12717	although	_
66-33	12718-12723	there	_
66-34	12724-12727	are	_
66-35	12728-12735	certain	_
66-36	12736-12743	caveats	_
66-37	12744-12746	to	_
66-38	12747-12751	this	_
66-39	12752-12756	type	_
66-40	12757-12759	of	_
66-41	12760-12771	calculation	_
66-42	12771-12772	.	_

#Text=Functional MRI
#Text=A subgroup of the healthy participants in this study (all right handed) had also undergone functional imaging during two cognitive tasks.
67-1	12773-12783	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[27]
67-2	12784-12787	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[27]
67-3	12788-12789	A	_
67-4	12790-12798	subgroup	_
67-5	12799-12801	of	_
67-6	12802-12805	the	_
67-7	12806-12813	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[28]
67-8	12814-12826	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[28]
67-9	12827-12829	in	_
67-10	12830-12834	this	_
67-11	12835-12840	study	_
67-12	12841-12842	(	_
67-13	12842-12845	all	_
67-14	12846-12851	right	_
67-15	12852-12858	handed	_
67-16	12858-12859	)	_
67-17	12860-12863	had	_
67-18	12864-12868	also	_
67-19	12869-12878	undergone	_
67-20	12879-12889	functional	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[29]
67-21	12890-12897	imaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[29]
67-22	12898-12904	during	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[29]
67-23	12905-12908	two	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[29]
67-24	12909-12918	cognitive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[29]
67-25	12919-12924	tasks	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[29]
67-26	12924-12925	.	_

#Text=One hundred eight participants completed a spatial working memory task and 83 had completed a facial processing task, with tasks and acquisition parameters as described by us previously.
68-1	12926-12929	One	_
68-2	12930-12937	hundred	_
68-3	12938-12943	eight	_
68-4	12944-12956	participants	_
68-5	12957-12966	completed	_
68-6	12967-12968	a	_
68-7	12969-12976	spatial	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]
68-8	12977-12984	working	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]
68-9	12985-12991	memory	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]
68-10	12992-12996	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[30]
68-11	12997-13000	and	_
68-12	13001-13003	83	_
68-13	13004-13007	had	_
68-14	13008-13017	completed	_
68-15	13018-13019	a	_
68-16	13020-13026	facial	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]
68-17	13027-13037	processing	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]
68-18	13038-13042	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]
68-19	13042-13043	,	_
68-20	13044-13048	with	_
68-21	13049-13054	tasks	_
68-22	13055-13058	and	_
68-23	13059-13070	acquisition	_
68-24	13071-13081	parameters	_
68-25	13082-13084	as	_
68-26	13085-13094	described	_
68-27	13095-13097	by	_
68-28	13098-13100	us	_
68-29	13101-13111	previously	_
68-30	13111-13112	.	_

#Text=The task can be summarized as follows.
69-1	13113-13116	The	_
69-2	13117-13121	task	_
69-3	13122-13125	can	_
69-4	13126-13128	be	_
69-5	13129-13139	summarized	_
69-6	13140-13142	as	_
69-7	13143-13150	follows	_
69-8	13150-13151	.	_

#Text=Spatial working memory task
#Text=This block design task was presented using Presentation software (Neurobehavioral Systems, Albany, CA, USA).
70-1	13152-13159	Spatial	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory[32]
70-2	13160-13167	working	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory[32]
70-3	13168-13174	memory	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory[32]
70-4	13175-13179	task	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory[32]
70-5	13180-13184	This	_
70-6	13185-13190	block	_
70-7	13191-13197	design	_
70-8	13198-13202	task	_
70-9	13203-13206	was	_
70-10	13207-13216	presented	_
70-11	13217-13222	using	_
70-12	13223-13235	Presentation	_
70-13	13236-13244	software	_
70-14	13245-13246	(	_
70-15	13246-13261	Neurobehavioral	_
70-16	13262-13269	Systems	_
70-17	13269-13270	,	_
70-18	13271-13277	Albany	_
70-19	13277-13278	,	_
70-20	13279-13281	CA	_
70-21	13281-13282	,	_
70-22	13283-13286	USA	_
70-23	13286-13287	)	_
70-24	13287-13288	.	_

#Text=Participants were asked if a white dot was in the same spatial location as a red circle (Supplementary Figure 1) during three conditions.
71-1	13289-13301	Participants	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-2	13302-13306	were	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-3	13307-13312	asked	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-4	13313-13315	if	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-5	13316-13317	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-6	13318-13323	white	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-7	13324-13327	dot	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-8	13328-13331	was	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-9	13332-13334	in	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-10	13335-13338	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-11	13339-13343	same	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-12	13344-13351	spatial	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-13	13352-13360	location	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-14	13361-13363	as	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-15	13364-13365	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-16	13366-13369	red	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-17	13370-13376	circle	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-18	13377-13378	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-19	13378-13391	Supplementary	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-20	13392-13398	Figure	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-21	13399-13400	1	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-22	13400-13401	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-23	13402-13408	during	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-24	13409-13414	three	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-25	13415-13425	conditions	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
71-26	13425-13426	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]

#Text=In the baseline condition the white dot and red circle both appear at the same time.
72-1	13427-13429	In	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-2	13430-13433	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-3	13434-13442	baseline	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-4	13443-13452	condition	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-5	13453-13456	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-6	13457-13462	white	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-7	13463-13466	dot	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-8	13467-13470	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-9	13471-13474	red	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-10	13475-13481	circle	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-11	13482-13486	both	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-12	13487-13493	appear	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-13	13494-13496	at	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-14	13497-13500	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-15	13501-13505	same	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-16	13506-13510	time	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]
72-17	13510-13511	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[33]

#Text=In the 1-dot condition, the white dot and red circle are separated by a 3- s delay.
73-1	13512-13514	In	_
73-2	13515-13518	the	_
73-3	13519-13520	1	_
73-4	13520-13521	-	_
73-5	13521-13524	dot	_
73-6	13525-13534	condition	_
73-7	13534-13535	,	_
73-8	13536-13539	the	_
73-9	13540-13545	white	_
73-10	13546-13549	dot	_
73-11	13550-13553	and	_
73-12	13554-13557	red	_
73-13	13558-13564	circle	_
73-14	13565-13568	are	_
73-15	13569-13578	separated	_
73-16	13579-13581	by	_
73-17	13582-13583	a	_
73-18	13584-13585	3	_
73-19	13585-13586	-	_
73-20	13587-13588	s	_
73-21	13589-13594	delay	_
73-22	13594-13595	.	_

#Text=Finally, in the 3-dot condition, 3 white dots and a red circle are presented, separated by a 3- s delay.
74-1	13596-13603	Finally	_
74-2	13603-13604	,	_
74-3	13605-13607	in	_
74-4	13608-13611	the	_
74-5	13612-13613	3	_
74-6	13613-13614	-	_
74-7	13614-13617	dot	_
74-8	13618-13627	condition	_
74-9	13627-13628	,	_
74-10	13629-13630	3	_
74-11	13631-13636	white	_
74-12	13637-13641	dots	_
74-13	13642-13645	and	_
74-14	13646-13647	a	_
74-15	13648-13651	red	_
74-16	13652-13658	circle	_
74-17	13659-13662	are	_
74-18	13663-13672	presented	_
74-19	13672-13673	,	_
74-20	13674-13683	separated	_
74-21	13684-13686	by	_
74-22	13687-13688	a	_
74-23	13689-13690	3	_
74-24	13690-13691	-	_
74-25	13692-13693	s	_
74-26	13694-13699	delay	_
74-27	13699-13700	.	_

#Text=Task accuracy and reaction time were also measured.
75-1	13701-13705	Task	_
75-2	13706-13714	accuracy	_
75-3	13715-13718	and	_
75-4	13719-13727	reaction	_
75-5	13728-13732	time	_
75-6	13733-13737	were	_
75-7	13738-13742	also	_
75-8	13743-13751	measured	_
75-9	13751-13752	.	_

#Text=Out of 108 participants, there were 3 missing this behavioral data that were excluded from fMRI analysis, and one participant was excluded due to an error with the task that caused it to run for several seconds after the scan finished.
76-1	13753-13756	Out	_
76-2	13757-13759	of	_
76-3	13760-13763	108	_
76-4	13764-13776	participants	_
76-5	13776-13777	,	_
76-6	13778-13783	there	_
76-7	13784-13788	were	_
76-8	13789-13790	3	_
76-9	13791-13798	missing	_
76-10	13799-13803	this	_
76-11	13804-13814	behavioral	_
76-12	13815-13819	data	_
76-13	13820-13824	that	_
76-14	13825-13829	were	_
76-15	13830-13838	excluded	_
76-16	13839-13843	from	_
76-17	13844-13848	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
76-18	13849-13857	analysis	_
76-19	13857-13858	,	_
76-20	13859-13862	and	_
76-21	13863-13866	one	_
76-22	13867-13878	participant	_
76-23	13879-13882	was	_
76-24	13883-13891	excluded	_
76-25	13892-13895	due	_
76-26	13896-13898	to	_
76-27	13899-13901	an	_
76-28	13902-13907	error	_
76-29	13908-13912	with	_
76-30	13913-13916	the	_
76-31	13917-13921	task	_
76-32	13922-13926	that	_
76-33	13927-13933	caused	_
76-34	13934-13936	it	_
76-35	13937-13939	to	_
76-36	13940-13943	run	_
76-37	13944-13947	for	_
76-38	13948-13955	several	_
76-39	13956-13963	seconds	_
76-40	13964-13969	after	_
76-41	13970-13973	the	_
76-42	13974-13978	scan	_
76-43	13979-13987	finished	_
76-44	13987-13988	.	_

#Text=Two additional participants were excluded from analysis due to movement and 16 were excluded from all analysis due to low-quality MRI data.
77-1	13989-13992	Two	_
77-2	13993-14003	additional	_
77-3	14004-14016	participants	_
77-4	14017-14021	were	_
77-5	14022-14030	excluded	_
77-6	14031-14035	from	_
77-7	14036-14044	analysis	_
77-8	14045-14048	due	_
77-9	14049-14051	to	_
77-10	14052-14060	movement	_
77-11	14061-14064	and	_
77-12	14065-14067	16	_
77-13	14068-14072	were	_
77-14	14073-14081	excluded	_
77-15	14082-14086	from	_
77-16	14087-14090	all	_
77-17	14091-14099	analysis	_
77-18	14100-14103	due	_
77-19	14104-14106	to	_
77-20	14107-14118	low-quality	_
77-21	14119-14122	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
77-22	14123-14127	data	_
77-23	14127-14128	.	_

#Text=This left a final sample of 86 healthy participants.
78-1	14129-14133	This	_
78-2	14134-14138	left	_
78-3	14139-14140	a	_
78-4	14141-14146	final	_
78-5	14147-14153	sample	_
78-6	14154-14156	of	_
78-7	14157-14159	86	_
78-8	14160-14167	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[34]
78-9	14168-14180	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[34]
78-10	14180-14181	.	_

#Text=The beginning of the spatial working memory task was synchronized to the first transistor-transistor logic (TTL) pulse sent from the MRI scanner at the start of the sequence.
79-1	14182-14185	The	_
79-2	14186-14195	beginning	_
79-3	14196-14198	of	_
79-4	14199-14202	the	_
79-5	14203-14210	spatial	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[35]
79-6	14211-14218	working	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[35]
79-7	14219-14225	memory	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[35]
79-8	14226-14230	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[35]
79-9	14231-14234	was	_
79-10	14235-14247	synchronized	_
79-11	14248-14250	to	_
79-12	14251-14254	the	_
79-13	14255-14260	first	_
79-14	14261-14282	transistor-transistor	_
79-15	14283-14288	logic	_
79-16	14289-14290	(	_
79-17	14290-14293	TTL	_
79-18	14293-14294	)	_
79-19	14295-14300	pulse	_
79-20	14301-14305	sent	_
79-21	14306-14310	from	_
79-22	14311-14314	the	_
79-23	14315-14318	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[36]
79-24	14319-14326	scanner	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[36]
79-25	14327-14329	at	_
79-26	14330-14333	the	_
79-27	14334-14339	start	_
79-28	14340-14342	of	_
79-29	14343-14346	the	_
79-30	14347-14355	sequence	_
79-31	14355-14356	.	_

#Text=However, for a minority of participants the start of the task was not synchronized to the TTL pulse due to an experimental error; for these individuals the task was run manually at the start of the sequence.
80-1	14357-14364	However	_
80-2	14364-14365	,	_
80-3	14366-14369	for	_
80-4	14370-14371	a	_
80-5	14372-14380	minority	_
80-6	14381-14383	of	_
80-7	14384-14396	participants	_
80-8	14397-14400	the	_
80-9	14401-14406	start	_
80-10	14407-14409	of	_
80-11	14410-14413	the	_
80-12	14414-14418	task	_
80-13	14419-14422	was	_
80-14	14423-14426	not	_
80-15	14427-14439	synchronized	_
80-16	14440-14442	to	_
80-17	14443-14446	the	_
80-18	14447-14450	TTL	_
80-19	14451-14456	pulse	_
80-20	14457-14460	due	_
80-21	14461-14463	to	_
80-22	14464-14466	an	_
80-23	14467-14479	experimental	_
80-24	14480-14485	error	_
80-25	14485-14486	;	_
80-26	14487-14490	for	_
80-27	14491-14496	these	_
80-28	14497-14508	individuals	_
80-29	14509-14512	the	_
80-30	14513-14517	task	_
80-31	14518-14521	was	_
80-32	14522-14525	run	_
80-33	14526-14534	manually	_
80-34	14535-14537	at	_
80-35	14538-14541	the	_
80-36	14542-14547	start	_
80-37	14548-14550	of	_
80-38	14551-14554	the	_
80-39	14555-14563	sequence	_
80-40	14563-14564	.	_

#Text=Due to the block design nature of this task, any small discrepancies in timing resulting from this error are unlikely to affect results.
81-1	14565-14568	Due	_
81-2	14569-14571	to	_
81-3	14572-14575	the	_
81-4	14576-14581	block	_
81-5	14582-14588	design	_
81-6	14589-14595	nature	_
81-7	14596-14598	of	_
81-8	14599-14603	this	_
81-9	14604-14608	task	_
81-10	14608-14609	,	_
81-11	14610-14613	any	_
81-12	14614-14619	small	_
81-13	14620-14633	discrepancies	_
81-14	14634-14636	in	_
81-15	14637-14643	timing	_
81-16	14644-14653	resulting	_
81-17	14654-14658	from	_
81-18	14659-14663	this	_
81-19	14664-14669	error	_
81-20	14670-14673	are	_
81-21	14674-14682	unlikely	_
81-22	14683-14685	to	_
81-23	14686-14692	affect	_
81-24	14693-14700	results	_
81-25	14700-14701	.	_

#Text=Face processing task
#Text=Developed by Grosbras et al., participants (n=83) watched a series of 2-s to 5-s black and white videos of faces, which started from a neutral expression, and then turned into an angry expression or neutral expression, interspersed with a control condition consisting of video clips of black and white concentric circles expanding and contracting.
82-1	14702-14706	Face	_
82-2	14707-14717	processing	_
82-3	14718-14722	task	_
82-4	14723-14732	Developed	_
82-5	14733-14735	by	_
82-6	14736-14744	Grosbras	_
82-7	14745-14747	et	_
82-8	14748-14750	al	_
82-9	14750-14751	.	_
82-10	14751-14752	,	_
82-11	14753-14765	participants	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-12	14766-14767	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-13	14767-14768	n	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-14	14768-14769	=	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-15	14769-14771	83	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-16	14771-14772	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-17	14773-14780	watched	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-18	14781-14782	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-19	14783-14789	series	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-20	14790-14792	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-21	14793-14794	2	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-22	14794-14795	-	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-23	14795-14796	s	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-24	14797-14799	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-25	14800-14801	5	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-26	14801-14802	-	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-27	14802-14803	s	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-28	14804-14809	black	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-29	14810-14813	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-30	14814-14819	white	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-31	14820-14826	videos	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-32	14827-14829	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-33	14830-14835	faces	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-34	14835-14836	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-35	14837-14842	which	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-36	14843-14850	started	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-37	14851-14855	from	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-38	14856-14857	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-39	14858-14865	neutral	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-40	14866-14876	expression	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-41	14876-14877	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-42	14878-14881	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-43	14882-14886	then	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-44	14887-14893	turned	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-45	14894-14898	into	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-46	14899-14901	an	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-47	14902-14907	angry	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-48	14908-14918	expression	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-49	14919-14921	or	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-50	14922-14929	neutral	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-51	14930-14940	expression	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-52	14940-14941	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-53	14942-14954	interspersed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-54	14955-14959	with	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-55	14960-14961	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-56	14962-14969	control	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-57	14970-14979	condition	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-58	14980-14990	consisting	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-59	14991-14993	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-60	14994-14999	video	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-61	15000-15005	clips	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-62	15006-15008	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-63	15009-15014	black	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-64	15015-15018	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-65	15019-15024	white	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-66	15025-15035	concentric	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-67	15036-15043	circles	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-68	15044-15053	expanding	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-69	15054-15057	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-70	15058-15069	contracting	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[37]
82-71	15069-15070	.	_

#Text=Blocks of video clips lasted 18- s, with 4–7 video clips presented per block.
83-1	15071-15077	Blocks	_
83-2	15078-15080	of	_
83-3	15081-15086	video	_
83-4	15087-15092	clips	_
83-5	15093-15099	lasted	_
83-6	15100-15102	18	_
83-7	15102-15103	-	_
83-8	15104-15105	s	_
83-9	15105-15106	,	_
83-10	15107-15111	with	_
83-11	15112-15113	4	_
83-12	15113-15114	–	_
83-13	15114-15115	7	_
83-14	15116-15121	video	_
83-15	15122-15127	clips	_
83-16	15128-15137	presented	_
83-17	15138-15141	per	_
83-18	15142-15147	block	_
83-19	15147-15148	.	_

#Text=Overall, there were 19 blocks: 5 blocks of neutral face videos, 5 blocks of angry face videos and 9 control condition blocks (every second block was a control block).
84-1	15149-15156	Overall	_
84-2	15156-15157	,	_
84-3	15158-15163	there	_
84-4	15164-15168	were	_
84-5	15169-15171	19	_
84-6	15172-15178	blocks	_
84-7	15178-15179	:	_
84-8	15180-15181	5	_
84-9	15182-15188	blocks	_
84-10	15189-15191	of	_
84-11	15192-15199	neutral	_
84-12	15200-15204	face	_
84-13	15205-15211	videos	_
84-14	15211-15212	,	_
84-15	15213-15214	5	_
84-16	15215-15221	blocks	_
84-17	15222-15224	of	_
84-18	15225-15230	angry	_
84-19	15231-15235	face	_
84-20	15236-15242	videos	_
84-21	15243-15246	and	_
84-22	15247-15248	9	_
84-23	15249-15256	control	_
84-24	15257-15266	condition	_
84-25	15267-15273	blocks	_
84-26	15274-15275	(	_
84-27	15275-15280	every	_
84-28	15281-15287	second	_
84-29	15288-15293	block	_
84-30	15294-15297	was	_
84-31	15298-15299	a	_
84-32	15300-15307	control	_
84-33	15308-15313	block	_
84-34	15313-15314	)	_
84-35	15314-15315	.	_

#Text=To make sure that individuals had paid attention to the videos, they performed a face recognition test after scanning.
85-1	15316-15318	To	_
85-2	15319-15323	make	_
85-3	15324-15328	sure	_
85-4	15329-15333	that	_
85-5	15334-15345	individuals	_
85-6	15346-15349	had	_
85-7	15350-15354	paid	_
85-8	15355-15364	attention	_
85-9	15365-15367	to	_
85-10	15368-15371	the	_
85-11	15372-15378	videos	_
85-12	15378-15379	,	_
85-13	15380-15384	they	_
85-14	15385-15394	performed	_
85-15	15395-15396	a	_
85-16	15397-15401	face	_
85-17	15402-15413	recognition	_
85-18	15414-15418	test	_
85-19	15419-15424	after	_
85-20	15425-15433	scanning	_
85-21	15433-15434	.	_

#Text=In this test, 5 stil-color pictures of faces were presented and participants were asked to determine whether these matched faces seen during the task.
86-1	15435-15437	In	_
86-2	15438-15442	this	_
86-3	15443-15447	test	_
86-4	15447-15448	,	_
86-5	15449-15450	5	_
86-6	15451-15461	stil-color	_
86-7	15462-15470	pictures	_
86-8	15471-15473	of	_
86-9	15474-15479	faces	_
86-10	15480-15484	were	_
86-11	15485-15494	presented	_
86-12	15495-15498	and	_
86-13	15499-15511	participants	_
86-14	15512-15516	were	_
86-15	15517-15522	asked	_
86-16	15523-15525	to	_
86-17	15526-15535	determine	_
86-18	15536-15543	whether	_
86-19	15544-15549	these	_
86-20	15550-15557	matched	_
86-21	15558-15563	faces	_
86-22	15564-15568	seen	_
86-23	15569-15575	during	_
86-24	15576-15579	the	_
86-25	15580-15584	task	_
86-26	15584-15585	.	_

#Text=Six participants were excluded as they scored less than 4/5 correct answers or were missing data for the face recognition task.
87-1	15586-15589	Six	_
87-2	15590-15602	participants	_
87-3	15603-15607	were	_
87-4	15608-15616	excluded	_
87-5	15617-15619	as	_
87-6	15620-15624	they	_
87-7	15625-15631	scored	_
87-8	15632-15636	less	_
87-9	15637-15641	than	_
87-10	15642-15643	4	_
87-11	15643-15644	/	_
87-12	15644-15645	5	_
87-13	15646-15653	correct	_
87-14	15654-15661	answers	_
87-15	15662-15664	or	_
87-16	15665-15669	were	_
87-17	15670-15677	missing	_
87-18	15678-15682	data	_
87-19	15683-15686	for	_
87-20	15687-15690	the	_
87-21	15691-15695	face	_
87-22	15696-15707	recognition	_
87-23	15708-15712	task	_
87-24	15712-15713	.	_

#Text=One face processing participant was excluded from analysis due to excessive movement and 5 participants were excluded due to low-quality MRI data and/or significant artefacts, resulting in a final sample of 70 participants.
88-1	15714-15717	One	_
88-2	15718-15722	face	_
88-3	15723-15733	processing	_
88-4	15734-15745	participant	_
88-5	15746-15749	was	_
88-6	15750-15758	excluded	_
88-7	15759-15763	from	_
88-8	15764-15772	analysis	_
88-9	15773-15776	due	_
88-10	15777-15779	to	_
88-11	15780-15789	excessive	_
88-12	15790-15798	movement	_
88-13	15799-15802	and	_
88-14	15803-15804	5	_
88-15	15805-15817	participants	_
88-16	15818-15822	were	_
88-17	15823-15831	excluded	_
88-18	15832-15835	due	_
88-19	15836-15838	to	_
88-20	15839-15850	low-quality	_
88-21	15851-15854	MRI	_
88-22	15855-15859	data	_
88-23	15860-15863	and	_
88-24	15863-15864	/	_
88-25	15864-15866	or	_
88-26	15867-15878	significant	_
88-27	15879-15888	artefacts	_
88-28	15888-15889	,	_
88-29	15890-15899	resulting	_
88-30	15900-15902	in	_
88-31	15903-15904	a	_
88-32	15905-15910	final	_
88-33	15911-15917	sample	_
88-34	15918-15920	of	_
88-35	15921-15923	70	_
88-36	15924-15936	participants	_
88-37	15936-15937	.	_

#Text=Imaging pre-processing and statistical analysis
#Text=Spatial pre-processing and statistical analysis of MRI data was performed using Statistical Parametric Mapping (SPM8, revision 4290, http://www.fil.ion.ucl.ac.uk/spm/software/spm8/) and MATLAB R2011b (v7.13; http://www.mathworks.co.uk/).
89-1	15938-15945	Imaging	_
89-2	15946-15960	pre-processing	_
89-3	15961-15964	and	_
89-4	15965-15976	statistical	_
89-5	15977-15985	analysis	_
89-6	15986-15993	Spatial	_
89-7	15994-16008	pre-processing	_
89-8	16009-16012	and	_
89-9	16013-16024	statistical	_
89-10	16025-16033	analysis	_
89-11	16034-16036	of	_
89-12	16037-16040	MRI	_
89-13	16041-16045	data	_
89-14	16046-16049	was	_
89-15	16050-16059	performed	_
89-16	16060-16065	using	_
89-17	16066-16077	Statistical	_
89-18	16078-16088	Parametric	_
89-19	16089-16096	Mapping	_
89-20	16097-16098	(	_
89-21	16098-16102	SPM8	_
89-22	16102-16103	,	_
89-23	16104-16112	revision	_
89-24	16113-16117	4290	_
89-25	16117-16118	,	_
89-26	16119-16123	http	_
89-27	16123-16124	:	_
89-28	16124-16125	/	_
89-29	16125-16126	/	_
89-30	16126-16147	www.fil.ion.ucl.ac.uk	_
89-31	16147-16148	/	_
89-32	16148-16151	spm	_
89-33	16151-16152	/	_
89-34	16152-16160	software	_
89-35	16160-16161	/	_
89-36	16161-16165	spm8	_
89-37	16165-16166	/	_
89-38	16166-16167	)	_
89-39	16168-16171	and	_
89-40	16172-16178	MATLAB	_
89-41	16179-16185	R2011b	_
89-42	16186-16187	(	_
89-43	16187-16192	v7.13	_
89-44	16192-16193	;	_
89-45	16194-16198	http	_
89-46	16198-16199	:	_
89-47	16199-16200	/	_
89-48	16200-16201	/	_
89-49	16201-16220	www.mathworks.co.uk	_
89-50	16220-16221	/	_
89-51	16221-16222	)	_
89-52	16222-16223	.	_

#Text=Functional images were realigned to the mean functional image, normalized to MNI (Montreal Neurological Institute) space with a voxel size of 3 × 3 × 3 mm3 and smoothed using a 10 mm FWHM (full-width at half maximum) isotropic Gaussian filter.
90-1	16224-16234	Functional	_
90-2	16235-16241	images	_
90-3	16242-16246	were	_
90-4	16247-16256	realigned	_
90-5	16257-16259	to	_
90-6	16260-16263	the	_
90-7	16264-16268	mean	_
90-8	16269-16279	functional	_
90-9	16280-16285	image	_
90-10	16285-16286	,	_
90-11	16287-16297	normalized	_
90-12	16298-16300	to	_
90-13	16301-16304	MNI	_
90-14	16305-16306	(	_
90-15	16306-16314	Montreal	_
90-16	16315-16327	Neurological	_
90-17	16328-16337	Institute	_
90-18	16337-16338	)	_
90-19	16339-16344	space	_
90-20	16345-16349	with	_
90-21	16350-16351	a	_
90-22	16352-16357	voxel	_
90-23	16358-16362	size	_
90-24	16363-16365	of	_
90-25	16366-16367	3	_
90-26	16368-16369	×	_
90-27	16370-16371	3	_
90-28	16372-16373	×	_
90-29	16374-16375	3	_
90-30	16376-16379	mm3	_
90-31	16380-16383	and	_
90-32	16384-16392	smoothed	_
90-33	16393-16398	using	_
90-34	16399-16400	a	_
90-35	16401-16403	10	_
90-36	16404-16406	mm	_
90-37	16407-16411	FWHM	_
90-38	16412-16413	(	_
90-39	16413-16423	full-width	_
90-40	16424-16426	at	_
90-41	16427-16431	half	_
90-42	16432-16439	maximum	_
90-43	16439-16440	)	_
90-44	16441-16450	isotropic	_
90-45	16451-16459	Gaussian	_
90-46	16460-16466	filter	_
90-47	16466-16467	.	_

#Text=After spatial pre-processing, graphical plots of the estimated time series of translations and rotations were inspected for excessive motion, which we defined as more than 3 mm translation and/or 3° rotation.
91-1	16468-16473	After	_
91-2	16474-16481	spatial	_
91-3	16482-16496	pre-processing	_
91-4	16496-16497	,	_
91-5	16498-16507	graphical	_
91-6	16508-16513	plots	_
91-7	16514-16516	of	_
91-8	16517-16520	the	_
91-9	16521-16530	estimated	_
91-10	16531-16535	time	_
91-11	16536-16542	series	_
91-12	16543-16545	of	_
91-13	16546-16558	translations	_
91-14	16559-16562	and	_
91-15	16563-16572	rotations	_
91-16	16573-16577	were	_
91-17	16578-16587	inspected	_
91-18	16588-16591	for	_
91-19	16592-16601	excessive	_
91-20	16602-16608	motion	_
91-21	16608-16609	,	_
91-22	16610-16615	which	_
91-23	16616-16618	we	_
91-24	16619-16626	defined	_
91-25	16627-16629	as	_
91-26	16630-16634	more	_
91-27	16635-16639	than	_
91-28	16640-16641	3	_
91-29	16642-16644	mm	_
91-30	16645-16656	translation	_
91-31	16657-16660	and	_
91-32	16660-16661	/	_
91-33	16661-16663	or	_
91-34	16664-16665	3	_
91-35	16665-16666	°	_
91-36	16667-16675	rotation	_
91-37	16675-16676	.	_

#Text=For the spatial working memory task, statistical analysis was performed using a general linear model (GLM) with two contrasts: spatial working memory (1 dot and 3 dots versus baseline), and increased spatial working memory load (3 dots>1 dot).
92-1	16677-16680	For	_
92-2	16681-16684	the	_
92-3	16685-16692	spatial	_
92-4	16693-16700	working	_
92-5	16701-16707	memory	_
92-6	16708-16712	task	_
92-7	16712-16713	,	_
92-8	16714-16725	statistical	_
92-9	16726-16734	analysis	_
92-10	16735-16738	was	_
92-11	16739-16748	performed	_
92-12	16749-16754	using	_
92-13	16755-16756	a	_
92-14	16757-16764	general	_
92-15	16765-16771	linear	_
92-16	16772-16777	model	_
92-17	16778-16779	(	_
92-18	16779-16782	GLM	_
92-19	16782-16783	)	_
92-20	16784-16788	with	_
92-21	16789-16792	two	_
92-22	16793-16802	contrasts	_
92-23	16802-16803	:	_
92-24	16804-16811	spatial	_
92-25	16812-16819	working	_
92-26	16820-16826	memory	_
92-27	16827-16828	(	_
92-28	16828-16829	1	_
92-29	16830-16833	dot	_
92-30	16834-16837	and	_
92-31	16838-16839	3	_
92-32	16840-16844	dots	_
92-33	16845-16851	versus	_
92-34	16852-16860	baseline	_
92-35	16860-16861	)	_
92-36	16861-16862	,	_
92-37	16863-16866	and	_
92-38	16867-16876	increased	_
92-39	16877-16884	spatial	_
92-40	16885-16892	working	_
92-41	16893-16899	memory	_
92-42	16900-16904	load	_
92-43	16905-16906	(	_
92-44	16906-16907	3	_
92-45	16908-16912	dots	_
92-46	16912-16913	>	_
92-47	16913-16914	1	_
92-48	16915-16918	dot	_
92-49	16918-16919	)	_
92-50	16919-16920	.	_

#Text=For the face processing task, three task conditions (angry faces, neutral faces and baseline) and four contrasts consistent with our examination of neural activity associated with this task in SZ patients: Neutral faces versus baseline, angry faces versus baseline, all faces (angry and neutral) versus baseline, and angry faces versus neutral faces.
93-1	16921-16924	For	_
93-2	16925-16928	the	_
93-3	16929-16933	face	_
93-4	16934-16944	processing	_
93-5	16945-16949	task	_
93-6	16949-16950	,	_
93-7	16951-16956	three	_
93-8	16957-16961	task	_
93-9	16962-16972	conditions	_
93-10	16973-16974	(	_
93-11	16974-16979	angry	_
93-12	16980-16985	faces	_
93-13	16985-16986	,	_
93-14	16987-16994	neutral	_
93-15	16995-17000	faces	_
93-16	17001-17004	and	_
93-17	17005-17013	baseline	_
93-18	17013-17014	)	_
93-19	17015-17018	and	_
93-20	17019-17023	four	_
93-21	17024-17033	contrasts	_
93-22	17034-17044	consistent	_
93-23	17045-17049	with	_
93-24	17050-17053	our	_
93-25	17054-17065	examination	_
93-26	17066-17068	of	_
93-27	17069-17075	neural	_
93-28	17076-17084	activity	_
93-29	17085-17095	associated	_
93-30	17096-17100	with	_
93-31	17101-17105	this	_
93-32	17106-17110	task	_
93-33	17111-17113	in	_
93-34	17114-17116	SZ	_
93-35	17117-17125	patients	_
93-36	17125-17126	:	_
93-37	17127-17134	Neutral	_
93-38	17135-17140	faces	_
93-39	17141-17147	versus	_
93-40	17148-17156	baseline	_
93-41	17156-17157	,	_
93-42	17158-17163	angry	_
93-43	17164-17169	faces	_
93-44	17170-17176	versus	_
93-45	17177-17185	baseline	_
93-46	17185-17186	,	_
93-47	17187-17190	all	_
93-48	17191-17196	faces	_
93-49	17197-17198	(	_
93-50	17198-17203	angry	_
93-51	17204-17207	and	_
93-52	17208-17215	neutral	_
93-53	17215-17216	)	_
93-54	17217-17223	versus	_
93-55	17224-17232	baseline	_
93-56	17232-17233	,	_
93-57	17234-17237	and	_
93-58	17238-17243	angry	_
93-59	17244-17249	faces	_
93-60	17250-17256	versus	_
93-61	17257-17264	neutral	_
93-62	17265-17270	faces	_
93-63	17270-17271	.	_

#Text=Participants’ contrast maps were entered into a second-level analysis to investigate effects of MIR137 network on neural activity (multiple regression analysis with the empirically derived miR-137 regulated gene score as covariate of interest).
94-1	17272-17284	Participants	_
94-2	17284-17285	’	_
94-3	17286-17294	contrast	_
94-4	17295-17299	maps	_
94-5	17300-17304	were	_
94-6	17305-17312	entered	_
94-7	17313-17317	into	_
94-8	17318-17319	a	_
94-9	17320-17332	second-level	_
94-10	17333-17341	analysis	_
94-11	17342-17344	to	_
94-12	17345-17356	investigate	_
94-13	17357-17364	effects	_
94-14	17365-17367	of	_
94-15	17368-17374	MIR137	_
94-16	17375-17382	network	_
94-17	17383-17385	on	_
94-18	17386-17392	neural	_
94-19	17393-17401	activity	_
94-20	17402-17403	(	_
94-21	17403-17411	multiple	_
94-22	17412-17422	regression	_
94-23	17423-17431	analysis	_
94-24	17432-17436	with	_
94-25	17437-17440	the	_
94-26	17441-17452	empirically	_
94-27	17453-17460	derived	_
94-28	17461-17464	miR	_
94-29	17464-17465	-	_
94-30	17465-17468	137	_
94-31	17469-17478	regulated	_
94-32	17479-17483	gene	_
94-33	17484-17489	score	_
94-34	17490-17492	as	_
94-35	17493-17502	covariate	_
94-36	17503-17505	of	_
94-37	17506-17514	interest	_
94-38	17514-17515	)	_
94-39	17515-17516	.	_

#Text=This multiple regression analysis was performed for the empirically derived MIR137 gene score at the P=10−5, P=0.05 and P=0.5 levels.
95-1	17517-17521	This	_
95-2	17522-17530	multiple	_
95-3	17531-17541	regression	_
95-4	17542-17550	analysis	_
95-5	17551-17554	was	_
95-6	17555-17564	performed	_
95-7	17565-17568	for	_
95-8	17569-17572	the	_
95-9	17573-17584	empirically	_
95-10	17585-17592	derived	_
95-11	17593-17599	MIR137	_
95-12	17600-17604	gene	_
95-13	17605-17610	score	_
95-14	17611-17613	at	_
95-15	17614-17617	the	_
95-16	17618-17619	P	_
95-17	17619-17620	=	_
95-18	17620-17622	10	_
95-19	17622-17623	−	_
95-20	17623-17624	5	_
95-21	17624-17625	,	_
95-22	17626-17627	P	_
95-23	17627-17628	=	_
95-24	17628-17632	0.05	_
95-25	17633-17636	and	_
95-26	17637-17638	P	_
95-27	17638-17639	=	_
95-28	17639-17642	0.5	_
95-29	17643-17649	levels	_
95-30	17649-17650	.	_

#Text=Results were examined at a P<0.001 (uncorrected) level and clusters were considered statistically significant at a P<0.05 level, family-wise error (FWE) corrected for multiple comparisons across the whole brain at the cluster level.
96-1	17651-17658	Results	_
96-2	17659-17663	were	_
96-3	17664-17672	examined	_
96-4	17673-17675	at	_
96-5	17676-17677	a	_
96-6	17678-17679	P	_
96-7	17679-17680	<	_
96-8	17680-17685	0.001	_
96-9	17686-17687	(	_
96-10	17687-17698	uncorrected	_
96-11	17698-17699	)	_
96-12	17700-17705	level	_
96-13	17706-17709	and	_
96-14	17710-17718	clusters	_
96-15	17719-17723	were	_
96-16	17724-17734	considered	_
96-17	17735-17748	statistically	_
96-18	17749-17760	significant	_
96-19	17761-17763	at	_
96-20	17764-17765	a	_
96-21	17766-17767	P	_
96-22	17767-17768	<	_
96-23	17768-17772	0.05	_
96-24	17773-17778	level	_
96-25	17778-17779	,	_
96-26	17780-17791	family-wise	_
96-27	17792-17797	error	_
96-28	17798-17799	(	_
96-29	17799-17802	FWE	_
96-30	17802-17803	)	_
96-31	17804-17813	corrected	_
96-32	17814-17817	for	_
96-33	17818-17826	multiple	_
96-34	17827-17838	comparisons	_
96-35	17839-17845	across	_
96-36	17846-17849	the	_
96-37	17850-17855	whole	_
96-38	17856-17861	brain	_
96-39	17862-17864	at	_
96-40	17865-17868	the	_
96-41	17869-17876	cluster	_
96-42	17877-17882	level	_
96-43	17882-17883	.	_

#Text=For each of these clusters, MNI coordinates of significant maxima were entered into the Anatomy toolbox in SPM8 (refs) and probable anatomical regions were identified using the AllAreas_v18_MPM atlas.
97-1	17884-17887	For	_
97-2	17888-17892	each	_
97-3	17893-17895	of	_
97-4	17896-17901	these	_
97-5	17902-17910	clusters	_
97-6	17910-17911	,	_
97-7	17912-17915	MNI	_
97-8	17916-17927	coordinates	_
97-9	17928-17930	of	_
97-10	17931-17942	significant	_
97-11	17943-17949	maxima	_
97-12	17950-17954	were	_
97-13	17955-17962	entered	_
97-14	17963-17967	into	_
97-15	17968-17971	the	_
97-16	17972-17979	Anatomy	_
97-17	17980-17987	toolbox	_
97-18	17988-17990	in	_
97-19	17991-17995	SPM8	_
97-20	17996-17997	(	_
97-21	17997-18001	refs	_
97-22	18001-18002	)	_
97-23	18003-18006	and	_
97-24	18007-18015	probable	_
97-25	18016-18026	anatomical	_
97-26	18027-18034	regions	_
97-27	18035-18039	were	_
97-28	18040-18050	identified	_
97-29	18051-18056	using	_
97-30	18057-18060	the	_
97-31	18061-18073	AllAreas_v18	_
97-32	18073-18074	_	_
97-33	18074-18077	MPM	_
97-34	18078-18083	atlas	_
97-35	18083-18084	.	_

#Text=Results
#Text=Participant demographics: neuropsychological tests
#Text=Patient demographic information appears in Table 1.
98-1	18085-18092	Results	_
98-2	18093-18104	Participant	_
98-3	18105-18117	demographics	_
98-4	18117-18118	:	_
98-5	18119-18137	neuropsychological	_
98-6	18138-18143	tests	_
98-7	18144-18151	Patient	_
98-8	18152-18163	demographic	_
98-9	18164-18175	information	_
98-10	18176-18183	appears	_
98-11	18184-18186	in	_
98-12	18187-18192	Table	_
98-13	18193-18194	1	_
98-14	18194-18195	.	_

#Text=In all cognitive tests, healthy participants performed better than the patient groups.
99-1	18196-18198	In	_
99-2	18199-18202	all	_
99-3	18203-18212	cognitive	_
99-4	18213-18218	tests	_
99-5	18218-18219	,	_
99-6	18220-18227	healthy	_
99-7	18228-18240	participants	_
99-8	18241-18250	performed	_
99-9	18251-18257	better	_
99-10	18258-18262	than	_
99-11	18263-18266	the	_
99-12	18267-18274	patient	_
99-13	18275-18281	groups	_
99-14	18281-18282	.	_

#Text=An ANOVA found that the miR-137 polygene scores differed significantly between diagnosis groups at each threshold.
100-1	18283-18285	An	_
100-2	18286-18291	ANOVA	_
100-3	18292-18297	found	_
100-4	18298-18302	that	_
100-5	18303-18306	the	_
100-6	18307-18310	miR	_
100-7	18310-18311	-	_
100-8	18311-18314	137	_
100-9	18315-18323	polygene	_
100-10	18324-18330	scores	_
100-11	18331-18339	differed	_
100-12	18340-18353	significantly	_
100-13	18354-18361	between	_
100-14	18362-18371	diagnosis	_
100-15	18372-18378	groups	_
100-16	18379-18381	at	_
100-17	18382-18386	each	_
100-18	18387-18396	threshold	_
100-19	18396-18397	.	_

#Text=Predictably, patients showed higher polygene scores than healthy participants.
101-1	18398-18409	Predictably	_
101-2	18409-18410	,	_
101-3	18411-18419	patients	_
101-4	18420-18426	showed	_
101-5	18427-18433	higher	_
101-6	18434-18442	polygene	_
101-7	18443-18449	scores	_
101-8	18450-18454	than	_
101-9	18455-18462	healthy	_
101-10	18463-18475	participants	_
101-11	18475-18476	.	_

#Text=A post hoc Tukey test indicated that the polygene scores for each patient group (narrow and broad sense) was significantly different from the control group (P<0.001) but not from each other.
102-1	18477-18478	A	_
102-2	18479-18483	post	_
102-3	18484-18487	hoc	_
102-4	18488-18493	Tukey	_
102-5	18494-18498	test	_
102-6	18499-18508	indicated	_
102-7	18509-18513	that	_
102-8	18514-18517	the	_
102-9	18518-18526	polygene	_
102-10	18527-18533	scores	_
102-11	18534-18537	for	_
102-12	18538-18542	each	_
102-13	18543-18550	patient	_
102-14	18551-18556	group	_
102-15	18557-18558	(	_
102-16	18558-18564	narrow	_
102-17	18565-18568	and	_
102-18	18569-18574	broad	_
102-19	18575-18580	sense	_
102-20	18580-18581	)	_
102-21	18582-18585	was	_
102-22	18586-18599	significantly	_
102-23	18600-18609	different	_
102-24	18610-18614	from	_
102-25	18615-18618	the	_
102-26	18619-18626	control	_
102-27	18627-18632	group	_
102-28	18633-18634	(	_
102-29	18634-18635	P	_
102-30	18635-18636	<	_
102-31	18636-18641	0.001	_
102-32	18641-18642	)	_
102-33	18643-18646	but	_
102-34	18647-18650	not	_
102-35	18651-18655	from	_
102-36	18656-18660	each	_
102-37	18661-18666	other	_
102-38	18666-18667	.	_

#Text=Poorer performance on measures of IQ, memory, and attention were each found to be associated with higher miR-137 polygene scores at all P-value thresholds.
103-1	18668-18674	Poorer	_
103-2	18675-18686	performance	_
103-3	18687-18689	on	_
103-4	18690-18698	measures	_
103-5	18699-18701	of	_
103-6	18702-18704	IQ	_
103-7	18704-18705	,	_
103-8	18706-18712	memory	_
103-9	18712-18713	,	_
103-10	18714-18717	and	_
103-11	18718-18727	attention	_
103-12	18728-18732	were	_
103-13	18733-18737	each	_
103-14	18738-18743	found	_
103-15	18744-18746	to	_
103-16	18747-18749	be	_
103-17	18750-18760	associated	_
103-18	18761-18765	with	_
103-19	18766-18772	higher	_
103-20	18773-18776	miR	_
103-21	18776-18777	-	_
103-22	18777-18780	137	_
103-23	18781-18789	polygene	_
103-24	18790-18796	scores	_
103-25	18797-18799	at	_
103-26	18800-18803	all	_
103-27	18804-18811	P-value	_
103-28	18812-18822	thresholds	_
103-29	18822-18823	.	_

#Text=When participants were combined, significant findings were found across all three polygene thresholds in domains of IQ, episodic memory, visual memory and working memory (Table 2).
104-1	18824-18828	When	_
104-2	18829-18841	participants	_
104-3	18842-18846	were	_
104-4	18847-18855	combined	_
104-5	18855-18856	,	_
104-6	18857-18868	significant	_
104-7	18869-18877	findings	_
104-8	18878-18882	were	_
104-9	18883-18888	found	_
104-10	18889-18895	across	_
104-11	18896-18899	all	_
104-12	18900-18905	three	_
104-13	18906-18914	polygene	_
104-14	18915-18925	thresholds	_
104-15	18926-18928	in	_
104-16	18929-18936	domains	_
104-17	18937-18939	of	_
104-18	18940-18942	IQ	_
104-19	18942-18943	,	_
104-20	18944-18952	episodic	_
104-21	18953-18959	memory	_
104-22	18959-18960	,	_
104-23	18961-18967	visual	_
104-24	18968-18974	memory	_
104-25	18975-18978	and	_
104-26	18979-18986	working	_
104-27	18987-18993	memory	_
104-28	18994-18995	(	_
104-29	18995-19000	Table	_
104-30	19001-19002	2	_
104-31	19002-19003	)	_
104-32	19003-19004	.	_

#Text=As hypothesized, performance on these neuropsychological measures decreased as polygene score increased.
105-1	19005-19007	As	_
105-2	19008-19020	hypothesized	_
105-3	19020-19021	,	_
105-4	19022-19033	performance	_
105-5	19034-19036	on	_
105-6	19037-19042	these	_
105-7	19043-19061	neuropsychological	_
105-8	19062-19070	measures	_
105-9	19071-19080	decreased	_
105-10	19081-19083	as	_
105-11	19084-19092	polygene	_
105-12	19093-19098	score	_
105-13	19099-19108	increased	_
105-14	19108-19109	.	_

#Text=The most markedly significant domain was for declarative memory functioning.
106-1	19110-19113	The	_
106-2	19114-19118	most	_
106-3	19119-19127	markedly	_
106-4	19128-19139	significant	_
106-5	19140-19146	domain	_
106-6	19147-19150	was	_
106-7	19151-19154	for	_
106-8	19155-19166	declarative	_
106-9	19167-19173	memory	_
106-10	19174-19185	functioning	_
106-11	19185-19186	.	_

#Text=Multiple declarative memory subtests (the logical memory [immediate/delayed] and faces subtests [immediate/delayed] of the WMS III) were highly significant at each score threshold, surviving a stringent Bonferroni correction for the five cognitive domains analyzed.
107-1	19187-19195	Multiple	_
107-2	19196-19207	declarative	_
107-3	19208-19214	memory	_
107-4	19215-19223	subtests	_
107-5	19224-19225	(	_
107-6	19225-19228	the	_
107-7	19229-19236	logical	_
107-8	19237-19243	memory	_
107-9	19244-19245	[	_
107-10	19245-19254	immediate	_
107-11	19254-19255	/	_
107-12	19255-19262	delayed	_
107-13	19262-19263	]	_
107-14	19264-19267	and	_
107-15	19268-19273	faces	_
107-16	19274-19282	subtests	_
107-17	19283-19284	[	_
107-18	19284-19293	immediate	_
107-19	19293-19294	/	_
107-20	19294-19301	delayed	_
107-21	19301-19302	]	_
107-22	19303-19305	of	_
107-23	19306-19309	the	_
107-24	19310-19313	WMS	_
107-25	19314-19317	III	_
107-26	19317-19318	)	_
107-27	19319-19323	were	_
107-28	19324-19330	highly	_
107-29	19331-19342	significant	_
107-30	19343-19345	at	_
107-31	19346-19350	each	_
107-32	19351-19356	score	_
107-33	19357-19366	threshold	_
107-34	19366-19367	,	_
107-35	19368-19377	surviving	_
107-36	19378-19379	a	_
107-37	19380-19389	stringent	_
107-38	19390-19400	Bonferroni	_
107-39	19401-19411	correction	_
107-40	19412-19415	for	_
107-41	19416-19419	the	_
107-42	19420-19424	five	_
107-43	19425-19434	cognitive	_
107-44	19435-19442	domains	_
107-45	19443-19451	analyzed	_
107-46	19451-19452	.	_

#Text=In contrast, the analysis of the single miR-137 risk SNP rs1702294 only showed significant influence on three domains: IQ, attention, and a ToM measure (Table 3; P-values ranging from P=0.042 to P=0.007).
108-1	19453-19455	In	_
108-2	19456-19464	contrast	_
108-3	19464-19465	,	_
108-4	19466-19469	the	_
108-5	19470-19478	analysis	_
108-6	19479-19481	of	_
108-7	19482-19485	the	_
108-8	19486-19492	single	_
108-9	19493-19496	miR	_
108-10	19496-19497	-	_
108-11	19497-19500	137	_
108-12	19501-19505	risk	_
108-13	19506-19509	SNP	_
108-14	19510-19519	rs1702294	_
108-15	19520-19524	only	_
108-16	19525-19531	showed	_
108-17	19532-19543	significant	_
108-18	19544-19553	influence	_
108-19	19554-19556	on	_
108-20	19557-19562	three	_
108-21	19563-19570	domains	_
108-22	19570-19571	:	_
108-23	19572-19574	IQ	_
108-24	19574-19575	,	_
108-25	19576-19585	attention	_
108-26	19585-19586	,	_
108-27	19587-19590	and	_
108-28	19591-19592	a	_
108-29	19593-19596	ToM	_
108-30	19597-19604	measure	_
108-31	19605-19606	(	_
108-32	19606-19611	Table	_
108-33	19612-19613	3	_
108-34	19613-19614	;	_
108-35	19615-19623	P-values	_
108-36	19624-19631	ranging	_
108-37	19632-19636	from	_
108-38	19637-19638	P	_
108-39	19638-19639	=	_
108-40	19639-19644	0.042	_
108-41	19645-19647	to	_
108-42	19648-19649	P	_
108-43	19649-19650	=	_
108-44	19650-19655	0.007	_
108-45	19655-19656	)	_
108-46	19656-19657	.	_

#Text=As a post hoc analysis, when only patients were considered (and not controls), the same general pattern of results were observed as for the full group, with the relationship between higher polygene scores and lower test accuracy remaining significant at the P=10−5 threshold, and nominally significant at the P=0.05 threshold.
109-1	19658-19660	As	_
109-2	19661-19662	a	_
109-3	19663-19667	post	_
109-4	19668-19671	hoc	_
109-5	19672-19680	analysis	_
109-6	19680-19681	,	_
109-7	19682-19686	when	_
109-8	19687-19691	only	_
109-9	19692-19700	patients	_
109-10	19701-19705	were	_
109-11	19706-19716	considered	_
109-12	19717-19718	(	_
109-13	19718-19721	and	_
109-14	19722-19725	not	_
109-15	19726-19734	controls	_
109-16	19734-19735	)	_
109-17	19735-19736	,	_
109-18	19737-19740	the	_
109-19	19741-19745	same	_
109-20	19746-19753	general	_
109-21	19754-19761	pattern	_
109-22	19762-19764	of	_
109-23	19765-19772	results	_
109-24	19773-19777	were	_
109-25	19778-19786	observed	_
109-26	19787-19789	as	_
109-27	19790-19793	for	_
109-28	19794-19797	the	_
109-29	19798-19802	full	_
109-30	19803-19808	group	_
109-31	19808-19809	,	_
109-32	19810-19814	with	_
109-33	19815-19818	the	_
109-34	19819-19831	relationship	_
109-35	19832-19839	between	_
109-36	19840-19846	higher	_
109-37	19847-19855	polygene	_
109-38	19856-19862	scores	_
109-39	19863-19866	and	_
109-40	19867-19872	lower	_
109-41	19873-19877	test	_
109-42	19878-19886	accuracy	_
109-43	19887-19896	remaining	_
109-44	19897-19908	significant	_
109-45	19909-19911	at	_
109-46	19912-19915	the	_
109-47	19916-19917	P	_
109-48	19917-19918	=	_
109-49	19918-19920	10	_
109-50	19920-19921	−	_
109-51	19921-19922	5	_
109-52	19923-19932	threshold	_
109-53	19932-19933	,	_
109-54	19934-19937	and	_
109-55	19938-19947	nominally	_
109-56	19948-19959	significant	_
109-57	19960-19962	at	_
109-58	19963-19966	the	_
109-59	19967-19968	P	_
109-60	19968-19969	=	_
109-61	19969-19973	0.05	_
109-62	19974-19983	threshold	_
109-63	19983-19984	.	_

#Text=Similarly, when the effects of rs1702294 were considered in patients only, nominal effects of the risk allele on poorer general cognitive ability and memory ability remained.
110-1	19985-19994	Similarly	_
110-2	19994-19995	,	_
110-3	19996-20000	when	_
110-4	20001-20004	the	_
110-5	20005-20012	effects	_
110-6	20013-20015	of	_
110-7	20016-20025	rs1702294	_
110-8	20026-20030	were	_
110-9	20031-20041	considered	_
110-10	20042-20044	in	_
110-11	20045-20053	patients	_
110-12	20054-20058	only	_
110-13	20058-20059	,	_
110-14	20060-20067	nominal	_
110-15	20068-20075	effects	_
110-16	20076-20078	of	_
110-17	20079-20082	the	_
110-18	20083-20087	risk	_
110-19	20088-20094	allele	_
110-20	20095-20097	on	_
110-21	20098-20104	poorer	_
110-22	20105-20112	general	_
110-23	20113-20122	cognitive	_
110-24	20123-20130	ability	_
110-25	20131-20134	and	_
110-26	20135-20141	memory	_
110-27	20142-20149	ability	_
110-28	20150-20158	remained	_
110-29	20158-20159	.	_

#Text=Finally, when only SZ/SZA patients (‘narrow sense psychosis’) were analyzed, the same direction of results was also observed for both the polygene (Supplementary Tables 2 and 3) and single SNP analysis (Table 3).
111-1	20160-20167	Finally	_
111-2	20167-20168	,	_
111-3	20169-20173	when	_
111-4	20174-20178	only	_
111-5	20179-20181	SZ	_
111-6	20181-20182	/	_
111-7	20182-20185	SZA	_
111-8	20186-20194	patients	_
111-9	20195-20196	(	_
111-10	20196-20197	‘	_
111-11	20197-20203	narrow	_
111-12	20204-20209	sense	_
111-13	20210-20219	psychosis	_
111-14	20219-20220	’	_
111-15	20220-20221	)	_
111-16	20222-20226	were	_
111-17	20227-20235	analyzed	_
111-18	20235-20236	,	_
111-19	20237-20240	the	_
111-20	20241-20245	same	_
111-21	20246-20255	direction	_
111-22	20256-20258	of	_
111-23	20259-20266	results	_
111-24	20267-20270	was	_
111-25	20271-20275	also	_
111-26	20276-20284	observed	_
111-27	20285-20288	for	_
111-28	20289-20293	both	_
111-29	20294-20297	the	_
111-30	20298-20306	polygene	_
111-31	20307-20308	(	_
111-32	20308-20321	Supplementary	_
111-33	20322-20328	Tables	_
111-34	20329-20330	2	_
111-35	20331-20334	and	_
111-36	20335-20336	3	_
111-37	20336-20337	)	_
111-38	20338-20341	and	_
111-39	20342-20348	single	_
111-40	20349-20352	SNP	_
111-41	20353-20361	analysis	_
111-42	20362-20363	(	_
111-43	20363-20368	Table	_
111-44	20369-20370	3	_
111-45	20370-20371	)	_
111-46	20371-20372	.	_

#Text=The effects of polygene risk on cognitive test performance were broader than that seen for the rs1702294 SNP alone (Supplementary Table 4).
112-1	20373-20376	The	_
112-2	20377-20384	effects	_
112-3	20385-20387	of	_
112-4	20388-20396	polygene	_
112-5	20397-20401	risk	_
112-6	20402-20404	on	_
112-7	20405-20414	cognitive	_
112-8	20415-20419	test	_
112-9	20420-20431	performance	_
112-10	20432-20436	were	_
112-11	20437-20444	broader	_
112-12	20445-20449	than	_
112-13	20450-20454	that	_
112-14	20455-20459	seen	_
112-15	20460-20463	for	_
112-16	20464-20467	the	_
112-17	20468-20477	rs1702294	_
112-18	20478-20481	SNP	_
112-19	20482-20487	alone	_
112-20	20488-20489	(	_
112-21	20489-20502	Supplementary	_
112-22	20503-20508	Table	_
112-23	20509-20510	4	_
112-24	20510-20511	)	_
112-25	20511-20512	.	_

#Text=This was the case across each of the whole, broad psychosis and narrow psychosis samples.
113-1	20513-20517	This	_
113-2	20518-20521	was	_
113-3	20522-20525	the	_
113-4	20526-20530	case	_
113-5	20531-20537	across	_
113-6	20538-20542	each	_
113-7	20543-20545	of	_
113-8	20546-20549	the	_
113-9	20550-20555	whole	_
113-10	20555-20556	,	_
113-11	20557-20562	broad	_
113-12	20563-20572	psychosis	_
113-13	20573-20576	and	_
113-14	20577-20583	narrow	_
113-15	20584-20593	psychosis	_
113-16	20594-20601	samples	_
113-17	20601-20602	.	_

#Text=Whereas the risk ‘C’ allele of rs1702294 was associated with variance on only three cognitive tests, the polygenic risk was associated with multiple test scores in both the memory and general cognitive domains.
114-1	20603-20610	Whereas	_
114-2	20611-20614	the	_
114-3	20615-20619	risk	_
114-4	20620-20621	‘	_
114-5	20621-20622	C	_
114-6	20622-20623	’	_
114-7	20624-20630	allele	_
114-8	20631-20633	of	_
114-9	20634-20643	rs1702294	_
114-10	20644-20647	was	_
114-11	20648-20658	associated	_
114-12	20659-20663	with	_
114-13	20664-20672	variance	_
114-14	20673-20675	on	_
114-15	20676-20680	only	_
114-16	20681-20686	three	_
114-17	20687-20696	cognitive	_
114-18	20697-20702	tests	_
114-19	20702-20703	,	_
114-20	20704-20707	the	_
114-21	20708-20717	polygenic	_
114-22	20718-20722	risk	_
114-23	20723-20726	was	_
114-24	20727-20737	associated	_
114-25	20738-20742	with	_
114-26	20743-20751	multiple	_
114-27	20752-20756	test	_
114-28	20757-20763	scores	_
114-29	20764-20766	in	_
114-30	20767-20771	both	_
114-31	20772-20775	the	_
114-32	20776-20782	memory	_
114-33	20783-20786	and	_
114-34	20787-20794	general	_
114-35	20795-20804	cognitive	_
114-36	20805-20812	domains	_
114-37	20812-20813	.	_

#Text=Participant demographics: fMRI
#Text=Participant demographics for the fMRI spatial working memory sample are presented in Table 4.
115-1	20814-20825	Participant	_
115-2	20826-20838	demographics	_
115-3	20838-20839	:	_
115-4	20840-20844	fMRI	_
115-5	20845-20856	Participant	_
115-6	20857-20869	demographics	_
115-7	20870-20873	for	_
115-8	20874-20877	the	_
115-9	20878-20882	fMRI	_
115-10	20883-20890	spatial	_
115-11	20891-20898	working	_
115-12	20899-20905	memory	_
115-13	20906-20912	sample	_
115-14	20913-20916	are	_
115-15	20917-20926	presented	_
115-16	20927-20929	in	_
115-17	20930-20935	Table	_
115-18	20936-20937	4	_
115-19	20937-20938	.	_

#Text=A regression analysis was performed in SPSS (22.0.0) to examine any significant effects of MIR137 pathway risk (at P=10−5, P=0.05 and P=0.5 levels) on age, gender, years of education, SWM accuracy or SWM reaction time in our sample.
116-1	20939-20940	A	_
116-2	20941-20951	regression	_
116-3	20952-20960	analysis	_
116-4	20961-20964	was	_
116-5	20965-20974	performed	_
116-6	20975-20977	in	_
116-7	20978-20982	SPSS	_
116-8	20983-20984	(	_
116-9	20984-20990	22.0.0	_
116-10	20990-20991	)	_
116-11	20992-20994	to	_
116-12	20995-21002	examine	_
116-13	21003-21006	any	_
116-14	21007-21018	significant	_
116-15	21019-21026	effects	_
116-16	21027-21029	of	_
116-17	21030-21036	MIR137	_
116-18	21037-21044	pathway	_
116-19	21045-21049	risk	_
116-20	21050-21051	(	_
116-21	21051-21053	at	_
116-22	21054-21055	P	_
116-23	21055-21056	=	_
116-24	21056-21058	10	_
116-25	21058-21059	−	_
116-26	21059-21060	5	_
116-27	21060-21061	,	_
116-28	21062-21063	P	_
116-29	21063-21064	=	_
116-30	21064-21068	0.05	_
116-31	21069-21072	and	_
116-32	21073-21074	P	_
116-33	21074-21075	=	_
116-34	21075-21078	0.5	_
116-35	21079-21085	levels	_
116-36	21085-21086	)	_
116-37	21087-21089	on	_
116-38	21090-21093	age	_
116-39	21093-21094	,	_
116-40	21095-21101	gender	_
116-41	21101-21102	,	_
116-42	21103-21108	years	_
116-43	21109-21111	of	_
116-44	21112-21121	education	_
116-45	21121-21122	,	_
116-46	21123-21126	SWM	_
116-47	21127-21135	accuracy	_
116-48	21136-21138	or	_
116-49	21139-21142	SWM	_
116-50	21143-21151	reaction	_
116-51	21152-21156	time	_
116-52	21157-21159	in	_
116-53	21160-21163	our	_
116-54	21164-21170	sample	_
116-55	21170-21171	.	_

#Text=Overall, there were no significant effects of MIR137 pathway risk on any of these variables (P>0.05).
117-1	21172-21179	Overall	_
117-2	21179-21180	,	_
117-3	21181-21186	there	_
117-4	21187-21191	were	_
117-5	21192-21194	no	_
117-6	21195-21206	significant	_
117-7	21207-21214	effects	_
117-8	21215-21217	of	_
117-9	21218-21224	MIR137	_
117-10	21225-21232	pathway	_
117-11	21233-21237	risk	_
117-12	21238-21240	on	_
117-13	21241-21244	any	_
117-14	21245-21247	of	_
117-15	21248-21253	these	_
117-16	21254-21263	variables	_
117-17	21264-21265	(	_
117-18	21265-21266	P	_
117-19	21266-21267	>	_
117-20	21267-21271	0.05	_
117-21	21271-21272	)	_
117-22	21272-21273	.	_

#Text=Participant demographics for the overlapping fMRI face processing sample are presented in Supplementary Table 5.
118-1	21274-21285	Participant	_
118-2	21286-21298	demographics	_
118-3	21299-21302	for	_
118-4	21303-21306	the	_
118-5	21307-21318	overlapping	_
118-6	21319-21323	fMRI	_
118-7	21324-21328	face	_
118-8	21329-21339	processing	_
118-9	21340-21346	sample	_
118-10	21347-21350	are	_
118-11	21351-21360	presented	_
118-12	21361-21363	in	_
118-13	21364-21377	Supplementary	_
118-14	21378-21383	Table	_
118-15	21384-21385	5	_
118-16	21385-21386	.	_

#Text=A regression analysis was performed in SPSS (22.0.0) to examine any significant effects of MIR137 pathway risk (at P=10−5, P=0.05 and P=0.5 levels) on age, gender, or years of education, and once again there were no significant effects of MIR137 pathway risk on any of these variables (P>0.05).
119-1	21387-21388	A	_
119-2	21389-21399	regression	_
119-3	21400-21408	analysis	_
119-4	21409-21412	was	_
119-5	21413-21422	performed	_
119-6	21423-21425	in	_
119-7	21426-21430	SPSS	_
119-8	21431-21432	(	_
119-9	21432-21438	22.0.0	_
119-10	21438-21439	)	_
119-11	21440-21442	to	_
119-12	21443-21450	examine	_
119-13	21451-21454	any	_
119-14	21455-21466	significant	_
119-15	21467-21474	effects	_
119-16	21475-21477	of	_
119-17	21478-21484	MIR137	_
119-18	21485-21492	pathway	_
119-19	21493-21497	risk	_
119-20	21498-21499	(	_
119-21	21499-21501	at	_
119-22	21502-21503	P	_
119-23	21503-21504	=	_
119-24	21504-21506	10	_
119-25	21506-21507	−	_
119-26	21507-21508	5	_
119-27	21508-21509	,	_
119-28	21510-21511	P	_
119-29	21511-21512	=	_
119-30	21512-21516	0.05	_
119-31	21517-21520	and	_
119-32	21521-21522	P	_
119-33	21522-21523	=	_
119-34	21523-21526	0.5	_
119-35	21527-21533	levels	_
119-36	21533-21534	)	_
119-37	21535-21537	on	_
119-38	21538-21541	age	_
119-39	21541-21542	,	_
119-40	21543-21549	gender	_
119-41	21549-21550	,	_
119-42	21551-21553	or	_
119-43	21554-21559	years	_
119-44	21560-21562	of	_
119-45	21563-21572	education	_
119-46	21572-21573	,	_
119-47	21574-21577	and	_
119-48	21578-21582	once	_
119-49	21583-21588	again	_
119-50	21589-21594	there	_
119-51	21595-21599	were	_
119-52	21600-21602	no	_
119-53	21603-21614	significant	_
119-54	21615-21622	effects	_
119-55	21623-21625	of	_
119-56	21626-21632	MIR137	_
119-57	21633-21640	pathway	_
119-58	21641-21645	risk	_
119-59	21646-21648	on	_
119-60	21649-21652	any	_
119-61	21653-21655	of	_
119-62	21656-21661	these	_
119-63	21662-21671	variables	_
119-64	21672-21673	(	_
119-65	21673-21674	P	_
119-66	21674-21675	>	_
119-67	21675-21679	0.05	_
119-68	21679-21680	)	_
119-69	21680-21681	.	_

#Text=Effects of MIR137 pathway risk score on neural activity
#Text=Increasing MIR137 pathway risk score (P=10−5 level) was associated with significantly increased neural activation in clusters incorporating the right middle temporal gyrus, left posterior cingulate and left thalamus with increasing spatial working memory load (3 dots versus 1 dot contrast, Supplementary Table 6).
120-1	21682-21689	Effects	_
120-2	21690-21692	of	_
120-3	21693-21699	MIR137	_
120-4	21700-21707	pathway	_
120-5	21708-21712	risk	_
120-6	21713-21718	score	_
120-7	21719-21721	on	_
120-8	21722-21728	neural	_
120-9	21729-21737	activity	_
120-10	21738-21748	Increasing	_
120-11	21749-21755	MIR137	_
120-12	21756-21763	pathway	_
120-13	21764-21768	risk	_
120-14	21769-21774	score	_
120-15	21775-21776	(	_
120-16	21776-21777	P	_
120-17	21777-21778	=	_
120-18	21778-21780	10	_
120-19	21780-21781	−	_
120-20	21781-21782	5	_
120-21	21783-21788	level	_
120-22	21788-21789	)	_
120-23	21790-21793	was	_
120-24	21794-21804	associated	_
120-25	21805-21809	with	_
120-26	21810-21823	significantly	_
120-27	21824-21833	increased	_
120-28	21834-21840	neural	_
120-29	21841-21851	activation	_
120-30	21852-21854	in	_
120-31	21855-21863	clusters	_
120-32	21864-21877	incorporating	_
120-33	21878-21881	the	_
120-34	21882-21887	right	_
120-35	21888-21894	middle	_
120-36	21895-21903	temporal	_
120-37	21904-21909	gyrus	_
120-38	21909-21910	,	_
120-39	21911-21915	left	_
120-40	21916-21925	posterior	_
120-41	21926-21935	cingulate	_
120-42	21936-21939	and	_
120-43	21940-21944	left	_
120-44	21945-21953	thalamus	_
120-45	21954-21958	with	_
120-46	21959-21969	increasing	_
120-47	21970-21977	spatial	_
120-48	21978-21985	working	_
120-49	21986-21992	memory	_
120-50	21993-21997	load	_
120-51	21998-21999	(	_
120-52	21999-22000	3	_
120-53	22001-22005	dots	_
120-54	22006-22012	versus	_
120-55	22013-22014	1	_
120-56	22015-22018	dot	_
120-57	22019-22027	contrast	_
120-58	22027-22028	,	_
120-59	22029-22042	Supplementary	_
120-60	22043-22048	Table	_
120-61	22049-22050	6	_
120-62	22050-22051	)	_
120-63	22051-22052	.	_

#Text=In each individual the mean parameters estimates of all voxels was calculated for each cluster showing a significant effect.
121-1	22053-22055	In	_
121-2	22056-22060	each	_
121-3	22061-22071	individual	_
121-4	22072-22075	the	_
121-5	22076-22080	mean	_
121-6	22081-22091	parameters	_
121-7	22092-22101	estimates	_
121-8	22102-22104	of	_
121-9	22105-22108	all	_
121-10	22109-22115	voxels	_
121-11	22116-22119	was	_
121-12	22120-22130	calculated	_
121-13	22131-22134	for	_
121-14	22135-22139	each	_
121-15	22140-22147	cluster	_
121-16	22148-22155	showing	_
121-17	22156-22157	a	_
121-18	22158-22169	significant	_
121-19	22170-22176	effect	_
121-20	22176-22177	.	_

#Text=These values were then entered into SPSS to check for outliers.
122-1	22178-22183	These	_
122-2	22184-22190	values	_
122-3	22191-22195	were	_
122-4	22196-22200	then	_
122-5	22201-22208	entered	_
122-6	22209-22213	into	_
122-7	22214-22218	SPSS	_
122-8	22219-22221	to	_
122-9	22222-22227	check	_
122-10	22228-22231	for	_
122-11	22232-22240	outliers	_
122-12	22240-22241	.	_

#Text=Overall, three outliers were detected.
123-1	22242-22249	Overall	_
123-2	22249-22250	,	_
123-3	22251-22256	three	_
123-4	22257-22265	outliers	_
123-5	22266-22270	were	_
123-6	22271-22279	detected	_
123-7	22279-22280	.	_

#Text=As such, the analysis was run again, excluding these individuals.
124-1	22281-22283	As	_
124-2	22284-22288	such	_
124-3	22288-22289	,	_
124-4	22290-22293	the	_
124-5	22294-22302	analysis	_
124-6	22303-22306	was	_
124-7	22307-22310	run	_
124-8	22311-22316	again	_
124-9	22316-22317	,	_
124-10	22318-22327	excluding	_
124-11	22328-22333	these	_
124-12	22334-22345	individuals	_
124-13	22345-22346	.	_

#Text=When this analysis was re-run, two clusters showed a significant effect of increasing MIR137 pathway risk score, one incorporating the right inferior occipital gyrus and right middle temporal gyrus, and another in the medial parietal region (individual cluster peaks not found on any probability maps using Anatomy toolbox).
125-1	22347-22351	When	_
125-2	22352-22356	this	_
125-3	22357-22365	analysis	_
125-4	22366-22369	was	_
125-5	22370-22376	re-run	_
125-6	22376-22377	,	_
125-7	22378-22381	two	_
125-8	22382-22390	clusters	_
125-9	22391-22397	showed	_
125-10	22398-22399	a	_
125-11	22400-22411	significant	_
125-12	22412-22418	effect	_
125-13	22419-22421	of	_
125-14	22422-22432	increasing	_
125-15	22433-22439	MIR137	_
125-16	22440-22447	pathway	_
125-17	22448-22452	risk	_
125-18	22453-22458	score	_
125-19	22458-22459	,	_
125-20	22460-22463	one	_
125-21	22464-22477	incorporating	_
125-22	22478-22481	the	_
125-23	22482-22487	right	_
125-24	22488-22496	inferior	_
125-25	22497-22506	occipital	_
125-26	22507-22512	gyrus	_
125-27	22513-22516	and	_
125-28	22517-22522	right	_
125-29	22523-22529	middle	_
125-30	22530-22538	temporal	_
125-31	22539-22544	gyrus	_
125-32	22544-22545	,	_
125-33	22546-22549	and	_
125-34	22550-22557	another	_
125-35	22558-22560	in	_
125-36	22561-22564	the	_
125-37	22565-22571	medial	_
125-38	22572-22580	parietal	_
125-39	22581-22587	region	_
125-40	22588-22589	(	_
125-41	22589-22599	individual	_
125-42	22600-22607	cluster	_
125-43	22608-22613	peaks	_
125-44	22614-22617	not	_
125-45	22618-22623	found	_
125-46	22624-22626	on	_
125-47	22627-22630	any	_
125-48	22631-22642	probability	_
125-49	22643-22647	maps	_
125-50	22648-22653	using	_
125-51	22654-22661	Anatomy	_
125-52	22662-22669	toolbox	_
125-53	22669-22670	)	_
125-54	22670-22671	.	_

#Text=We observed that, in the high working memory load condition (3-dot versus 1-dot) increasing MIR137 polygenic risk score (P=10−5 level) was associated with increased activation across two clusters (Supplementary Table 6).
126-1	22672-22674	We	_
126-2	22675-22683	observed	_
126-3	22684-22688	that	_
126-4	22688-22689	,	_
126-5	22690-22692	in	_
126-6	22693-22696	the	_
126-7	22697-22701	high	_
126-8	22702-22709	working	_
126-9	22710-22716	memory	_
126-10	22717-22721	load	_
126-11	22722-22731	condition	_
126-12	22732-22733	(	_
126-13	22733-22734	3	_
126-14	22734-22735	-	_
126-15	22735-22738	dot	_
126-16	22739-22745	versus	_
126-17	22746-22747	1	_
126-18	22747-22748	-	_
126-19	22748-22751	dot	_
126-20	22751-22752	)	_
126-21	22753-22763	increasing	_
126-22	22764-22770	MIR137	_
126-23	22771-22780	polygenic	_
126-24	22781-22785	risk	_
126-25	22786-22791	score	_
126-26	22792-22793	(	_
126-27	22793-22794	P	_
126-28	22794-22795	=	_
126-29	22795-22797	10	_
126-30	22797-22798	−	_
126-31	22798-22799	5	_
126-32	22800-22805	level	_
126-33	22805-22806	)	_
126-34	22807-22810	was	_
126-35	22811-22821	associated	_
126-36	22822-22826	with	_
126-37	22827-22836	increased	_
126-38	22837-22847	activation	_
126-39	22848-22854	across	_
126-40	22855-22858	two	_
126-41	22859-22867	clusters	_
126-42	22868-22869	(	_
126-43	22869-22882	Supplementary	_
126-44	22883-22888	Table	_
126-45	22889-22890	6	_
126-46	22890-22891	)	_
126-47	22891-22892	.	_

#Text=The first incorporated the right inferior occipital gyrus and right middle temporal gyrus and showed peak coordinates in the right inferior occipital gyrus (MNI peak coordinates 48, −76, −2; tmax=4.80; P-value=0.011; cluster extent (voxels)=175; Figure 1).
127-1	22893-22896	The	_
127-2	22897-22902	first	_
127-3	22903-22915	incorporated	_
127-4	22916-22919	the	_
127-5	22920-22925	right	_
127-6	22926-22934	inferior	_
127-7	22935-22944	occipital	_
127-8	22945-22950	gyrus	_
127-9	22951-22954	and	_
127-10	22955-22960	right	_
127-11	22961-22967	middle	_
127-12	22968-22976	temporal	_
127-13	22977-22982	gyrus	_
127-14	22983-22986	and	_
127-15	22987-22993	showed	_
127-16	22994-22998	peak	_
127-17	22999-23010	coordinates	_
127-18	23011-23013	in	_
127-19	23014-23017	the	_
127-20	23018-23023	right	_
127-21	23024-23032	inferior	_
127-22	23033-23042	occipital	_
127-23	23043-23048	gyrus	_
127-24	23049-23050	(	_
127-25	23050-23053	MNI	_
127-26	23054-23058	peak	_
127-27	23059-23070	coordinates	_
127-28	23071-23073	48	_
127-29	23073-23074	,	_
127-30	23075-23076	−	_
127-31	23076-23078	76	_
127-32	23078-23079	,	_
127-33	23080-23081	−	_
127-34	23081-23082	2	_
127-35	23082-23083	;	_
127-36	23084-23088	tmax	_
127-37	23088-23089	=	_
127-38	23089-23093	4.80	_
127-39	23093-23094	;	_
127-40	23095-23102	P-value	_
127-41	23102-23103	=	_
127-42	23103-23108	0.011	_
127-43	23108-23109	;	_
127-44	23110-23117	cluster	_
127-45	23118-23124	extent	_
127-46	23125-23126	(	_
127-47	23126-23132	voxels	_
127-48	23132-23133	)	_
127-49	23133-23134	=	_
127-50	23134-23137	175	_
127-51	23137-23138	;	_
127-52	23139-23145	Figure	_
127-53	23146-23147	1	_
127-54	23147-23148	)	_
127-55	23148-23149	.	_

#Text=A second cluster, located in the medial parietal region, did not localize to any known probability maps using Anatomy toolbox (Cluster extent [voxel]=121, P=0.038, tmax=4.19; MNI peak coordinates 3, −34, 16), possibly because these coordinates represent a region of overlap between gray and white matter (Figure 1).
128-1	23150-23151	A	_
128-2	23152-23158	second	_
128-3	23159-23166	cluster	_
128-4	23166-23167	,	_
128-5	23168-23175	located	_
128-6	23176-23178	in	_
128-7	23179-23182	the	_
128-8	23183-23189	medial	_
128-9	23190-23198	parietal	_
128-10	23199-23205	region	_
128-11	23205-23206	,	_
128-12	23207-23210	did	_
128-13	23211-23214	not	_
128-14	23215-23223	localize	_
128-15	23224-23226	to	_
128-16	23227-23230	any	_
128-17	23231-23236	known	_
128-18	23237-23248	probability	_
128-19	23249-23253	maps	_
128-20	23254-23259	using	_
128-21	23260-23267	Anatomy	_
128-22	23268-23275	toolbox	_
128-23	23276-23277	(	_
128-24	23277-23284	Cluster	_
128-25	23285-23291	extent	_
128-26	23292-23293	[	_
128-27	23293-23298	voxel	_
128-28	23298-23299	]	_
128-29	23299-23300	=	_
128-30	23300-23303	121	_
128-31	23303-23304	,	_
128-32	23305-23306	P	_
128-33	23306-23307	=	_
128-34	23307-23312	0.038	_
128-35	23312-23313	,	_
128-36	23314-23318	tmax	_
128-37	23318-23319	=	_
128-38	23319-23323	4.19	_
128-39	23323-23324	;	_
128-40	23325-23328	MNI	_
128-41	23329-23333	peak	_
128-42	23334-23345	coordinates	_
128-43	23346-23347	3	_
128-44	23347-23348	,	_
128-45	23349-23350	−	_
128-46	23350-23352	34	_
128-47	23352-23353	,	_
128-48	23354-23356	16	_
128-49	23356-23357	)	_
128-50	23357-23358	,	_
128-51	23359-23367	possibly	_
128-52	23368-23375	because	_
128-53	23376-23381	these	_
128-54	23382-23393	coordinates	_
128-55	23394-23403	represent	_
128-56	23404-23405	a	_
128-57	23406-23412	region	_
128-58	23413-23415	of	_
128-59	23416-23423	overlap	_
128-60	23424-23431	between	_
128-61	23432-23436	gray	_
128-62	23437-23440	and	_
128-63	23441-23446	white	_
128-64	23447-23453	matter	_
128-65	23454-23455	(	_
128-66	23455-23461	Figure	_
128-67	23462-23463	1	_
128-68	23463-23464	)	_
128-69	23464-23465	.	_

#Text=No other effects were observed either for other MIR137 polygenic thresholds or other contrasts.
129-1	23466-23468	No	_
129-2	23469-23474	other	_
129-3	23475-23482	effects	_
129-4	23483-23487	were	_
129-5	23488-23496	observed	_
129-6	23497-23503	either	_
129-7	23504-23507	for	_
129-8	23508-23513	other	_
129-9	23514-23520	MIR137	_
129-10	23521-23530	polygenic	_
129-11	23531-23541	thresholds	_
129-12	23542-23544	or	_
129-13	23545-23550	other	_
129-14	23551-23560	contrasts	_
129-15	23560-23561	.	_

#Text=Note that neural activity associated with the 3-dot versus 1-dot condition across all participants is presented in Supplementary Table 7 and Figure 1, showing overlap with the right inferior occipital cluster in which a MIR137 effect was observed.
130-1	23562-23566	Note	_
130-2	23567-23571	that	_
130-3	23572-23578	neural	_
130-4	23579-23587	activity	_
130-5	23588-23598	associated	_
130-6	23599-23603	with	_
130-7	23604-23607	the	_
130-8	23608-23609	3	_
130-9	23609-23610	-	_
130-10	23610-23613	dot	_
130-11	23614-23620	versus	_
130-12	23621-23622	1	_
130-13	23622-23623	-	_
130-14	23623-23626	dot	_
130-15	23627-23636	condition	_
130-16	23637-23643	across	_
130-17	23644-23647	all	_
130-18	23648-23660	participants	_
130-19	23661-23663	is	_
130-20	23664-23673	presented	_
130-21	23674-23676	in	_
130-22	23677-23690	Supplementary	_
130-23	23691-23696	Table	_
130-24	23697-23698	7	_
130-25	23699-23702	and	_
130-26	23703-23709	Figure	_
130-27	23710-23711	1	_
130-28	23711-23712	,	_
130-29	23713-23720	showing	_
130-30	23721-23728	overlap	_
130-31	23729-23733	with	_
130-32	23734-23737	the	_
130-33	23738-23743	right	_
130-34	23744-23752	inferior	_
130-35	23753-23762	occipital	_
130-36	23763-23770	cluster	_
130-37	23771-23773	in	_
130-38	23774-23779	which	_
130-39	23780-23781	a	_
130-40	23782-23788	MIR137	_
130-41	23789-23795	effect	_
130-42	23796-23799	was	_
130-43	23800-23808	observed	_
130-44	23808-23809	.	_

#Text=Finally, for the face processing task, after correcting for outliers (n=1 using the same outlier detection method as for the spatial working memory data) no significant effects of the empirically derived miR-137 regulated gene score (at P=10−5, P=0.05, or P=0.5 levels) were observed for any other contrast.
131-1	23810-23817	Finally	_
131-2	23817-23818	,	_
131-3	23819-23822	for	_
131-4	23823-23826	the	_
131-5	23827-23831	face	_
131-6	23832-23842	processing	_
131-7	23843-23847	task	_
131-8	23847-23848	,	_
131-9	23849-23854	after	_
131-10	23855-23865	correcting	_
131-11	23866-23869	for	_
131-12	23870-23878	outliers	_
131-13	23879-23880	(	_
131-14	23880-23881	n	_
131-15	23881-23882	=	_
131-16	23882-23883	1	_
131-17	23884-23889	using	_
131-18	23890-23893	the	_
131-19	23894-23898	same	_
131-20	23899-23906	outlier	_
131-21	23907-23916	detection	_
131-22	23917-23923	method	_
131-23	23924-23926	as	_
131-24	23927-23930	for	_
131-25	23931-23934	the	_
131-26	23935-23942	spatial	_
131-27	23943-23950	working	_
131-28	23951-23957	memory	_
131-29	23958-23962	data	_
131-30	23962-23963	)	_
131-31	23964-23966	no	_
131-32	23967-23978	significant	_
131-33	23979-23986	effects	_
131-34	23987-23989	of	_
131-35	23990-23993	the	_
131-36	23994-24005	empirically	_
131-37	24006-24013	derived	_
131-38	24014-24017	miR	_
131-39	24017-24018	-	_
131-40	24018-24021	137	_
131-41	24022-24031	regulated	_
131-42	24032-24036	gene	_
131-43	24037-24042	score	_
131-44	24043-24044	(	_
131-45	24044-24046	at	_
131-46	24047-24048	P	_
131-47	24048-24049	=	_
131-48	24049-24051	10	_
131-49	24051-24052	−	_
131-50	24052-24053	5	_
131-51	24053-24054	,	_
131-52	24055-24056	P	_
131-53	24056-24057	=	_
131-54	24057-24061	0.05	_
131-55	24061-24062	,	_
131-56	24063-24065	or	_
131-57	24066-24067	P	_
131-58	24067-24068	=	_
131-59	24068-24071	0.5	_
131-60	24072-24078	levels	_
131-61	24078-24079	)	_
131-62	24080-24084	were	_
131-63	24085-24093	observed	_
131-64	24094-24097	for	_
131-65	24098-24101	any	_
131-66	24102-24107	other	_
131-67	24108-24116	contrast	_
131-68	24116-24117	.	_

#Text=Discussion
#Text=This study assessed the effects of higher polygenic risk burden in a network of genes whose expression was altered by manipulation of miR-137 expression, the gene product of a SZ risk gene.
132-1	24118-24128	Discussion	_
132-2	24129-24133	This	_
132-3	24134-24139	study	_
132-4	24140-24148	assessed	_
132-5	24149-24152	the	_
132-6	24153-24160	effects	_
132-7	24161-24163	of	_
132-8	24164-24170	higher	_
132-9	24171-24180	polygenic	_
132-10	24181-24185	risk	_
132-11	24186-24192	burden	_
132-12	24193-24195	in	_
132-13	24196-24197	a	_
132-14	24198-24205	network	_
132-15	24206-24208	of	_
132-16	24209-24214	genes	_
132-17	24215-24220	whose	_
132-18	24221-24231	expression	_
132-19	24232-24235	was	_
132-20	24236-24243	altered	_
132-21	24244-24246	by	_
132-22	24247-24259	manipulation	_
132-23	24260-24262	of	_
132-24	24263-24266	miR	_
132-25	24266-24267	-	_
132-26	24267-24270	137	_
132-27	24271-24281	expression	_
132-28	24281-24282	,	_
132-29	24283-24286	the	_
132-30	24287-24291	gene	_
132-31	24292-24299	product	_
132-32	24300-24302	of	_
132-33	24303-24304	a	_
132-34	24305-24307	SZ	_
132-35	24308-24312	risk	_
132-36	24313-24317	gene	_
132-37	24317-24318	.	_

#Text=On the basis of previous studies from our group and others, we sought to establish whether this gene network would convey the same cognitive and cortical effects as have been associated with individual risk variants at this locus and, if so, whether the amount of variance explained was the same or greater.
133-1	24319-24321	On	_
133-2	24322-24325	the	_
133-3	24326-24331	basis	_
133-4	24332-24334	of	_
133-5	24335-24343	previous	_
133-6	24344-24351	studies	_
133-7	24352-24356	from	_
133-8	24357-24360	our	_
133-9	24361-24366	group	_
133-10	24367-24370	and	_
133-11	24371-24377	others	_
133-12	24377-24378	,	_
133-13	24379-24381	we	_
133-14	24382-24388	sought	_
133-15	24389-24391	to	_
133-16	24392-24401	establish	_
133-17	24402-24409	whether	_
133-18	24410-24414	this	_
133-19	24415-24419	gene	_
133-20	24420-24427	network	_
133-21	24428-24433	would	_
133-22	24434-24440	convey	_
133-23	24441-24444	the	_
133-24	24445-24449	same	_
133-25	24450-24459	cognitive	_
133-26	24460-24463	and	_
133-27	24464-24472	cortical	_
133-28	24473-24480	effects	_
133-29	24481-24483	as	_
133-30	24484-24488	have	_
133-31	24489-24493	been	_
133-32	24494-24504	associated	_
133-33	24505-24509	with	_
133-34	24510-24520	individual	_
133-35	24521-24525	risk	_
133-36	24526-24534	variants	_
133-37	24535-24537	at	_
133-38	24538-24542	this	_
133-39	24543-24548	locus	_
133-40	24549-24552	and	_
133-41	24552-24553	,	_
133-42	24554-24556	if	_
133-43	24557-24559	so	_
133-44	24559-24560	,	_
133-45	24561-24568	whether	_
133-46	24569-24572	the	_
133-47	24573-24579	amount	_
133-48	24580-24582	of	_
133-49	24583-24591	variance	_
133-50	24592-24601	explained	_
133-51	24602-24605	was	_
133-52	24606-24609	the	_
133-53	24610-24614	same	_
133-54	24615-24617	or	_
133-55	24618-24625	greater	_
133-56	24625-24626	.	_

#Text=We did this based on polygene scores derived from all risk variants within this network (not including MIR137 risk SNPs themselves), calculated from three risk thresholds using the PGC-SCZ data (P=10−5, P=0.05 and P=0.5).
134-1	24627-24629	We	_
134-2	24630-24633	did	_
134-3	24634-24638	this	_
134-4	24639-24644	based	_
134-5	24645-24647	on	_
134-6	24648-24656	polygene	_
134-7	24657-24663	scores	_
134-8	24664-24671	derived	_
134-9	24672-24676	from	_
134-10	24677-24680	all	_
134-11	24681-24685	risk	_
134-12	24686-24694	variants	_
134-13	24695-24701	within	_
134-14	24702-24706	this	_
134-15	24707-24714	network	_
134-16	24715-24716	(	_
134-17	24716-24719	not	_
134-18	24720-24729	including	_
134-19	24730-24736	MIR137	_
134-20	24737-24741	risk	_
134-21	24742-24746	SNPs	_
134-22	24747-24757	themselves	_
134-23	24757-24758	)	_
134-24	24758-24759	,	_
134-25	24760-24770	calculated	_
134-26	24771-24775	from	_
134-27	24776-24781	three	_
134-28	24782-24786	risk	_
134-29	24787-24797	thresholds	_
134-30	24798-24803	using	_
134-31	24804-24807	the	_
134-32	24808-24815	PGC-SCZ	_
134-33	24816-24820	data	_
134-34	24821-24822	(	_
134-35	24822-24823	P	_
134-36	24823-24824	=	_
134-37	24824-24826	10	_
134-38	24826-24827	−	_
134-39	24827-24828	5	_
134-40	24828-24829	,	_
134-41	24830-24831	P	_
134-42	24831-24832	=	_
134-43	24832-24836	0.05	_
134-44	24837-24840	and	_
134-45	24841-24842	P	_
134-46	24842-24843	=	_
134-47	24843-24846	0.5	_
134-48	24846-24847	)	_
134-49	24847-24848	.	_

#Text=Following correction for multiple testing we found that, irrespective of the threshold used, genetic variants within the defined MIR137 score were associated with lower declarative memory performance.
135-1	24849-24858	Following	_
135-2	24859-24869	correction	_
135-3	24870-24873	for	_
135-4	24874-24882	multiple	_
135-5	24883-24890	testing	_
135-6	24891-24893	we	_
135-7	24894-24899	found	_
135-8	24900-24904	that	_
135-9	24904-24905	,	_
135-10	24906-24918	irrespective	_
135-11	24919-24921	of	_
135-12	24922-24925	the	_
135-13	24926-24935	threshold	_
135-14	24936-24940	used	_
135-15	24940-24941	,	_
135-16	24942-24949	genetic	_
135-17	24950-24958	variants	_
135-18	24959-24965	within	_
135-19	24966-24969	the	_
135-20	24970-24977	defined	_
135-21	24978-24984	MIR137	_
135-22	24985-24990	score	_
135-23	24991-24995	were	_
135-24	24996-25006	associated	_
135-25	25007-25011	with	_
135-26	25012-25017	lower	_
135-27	25018-25029	declarative	_
135-28	25030-25036	memory	_
135-29	25037-25048	performance	_
135-30	25048-25049	.	_

#Text=We also found that the MIR137 pathway was nominally associated with poorer working memory and general cognitive ability.
136-1	25050-25052	We	_
136-2	25053-25057	also	_
136-3	25058-25063	found	_
136-4	25064-25068	that	_
136-5	25069-25072	the	_
136-6	25073-25079	MIR137	_
136-7	25080-25087	pathway	_
136-8	25088-25091	was	_
136-9	25092-25101	nominally	_
136-10	25102-25112	associated	_
136-11	25113-25117	with	_
136-12	25118-25124	poorer	_
136-13	25125-25132	working	_
136-14	25133-25139	memory	_
136-15	25140-25143	and	_
136-16	25144-25151	general	_
136-17	25152-25161	cognitive	_
136-18	25162-25169	ability	_
136-19	25169-25170	.	_

#Text=Finally, functional imaging revealed that participants showed increased cortical activation in right inferior occipital gyrus during a spatial working memory task.
137-1	25171-25178	Finally	_
137-2	25178-25179	,	_
137-3	25180-25190	functional	_
137-4	25191-25198	imaging	_
137-5	25199-25207	revealed	_
137-6	25208-25212	that	_
137-7	25213-25225	participants	_
137-8	25226-25232	showed	_
137-9	25233-25242	increased	_
137-10	25243-25251	cortical	_
137-11	25252-25262	activation	_
137-12	25263-25265	in	_
137-13	25266-25271	right	_
137-14	25272-25280	inferior	_
137-15	25281-25290	occipital	_
137-16	25291-25296	gyrus	_
137-17	25297-25303	during	_
137-18	25304-25305	a	_
137-19	25306-25313	spatial	_
137-20	25314-25321	working	_
137-21	25322-25328	memory	_
137-22	25329-25333	task	_
137-23	25333-25334	.	_

#Text=This was found in the absence of any association with cortical activity during a face processing task and polygenic risk.
138-1	25335-25339	This	_
138-2	25340-25343	was	_
138-3	25344-25349	found	_
138-4	25350-25352	in	_
138-5	25353-25356	the	_
138-6	25357-25364	absence	_
138-7	25365-25367	of	_
138-8	25368-25371	any	_
138-9	25372-25383	association	_
138-10	25384-25388	with	_
138-11	25389-25397	cortical	_
138-12	25398-25406	activity	_
138-13	25407-25413	during	_
138-14	25414-25415	a	_
138-15	25416-25420	face	_
138-16	25421-25431	processing	_
138-17	25432-25436	task	_
138-18	25437-25440	and	_
138-19	25441-25450	polygenic	_
138-20	25451-25455	risk	_
138-21	25455-25456	.	_

#Text=Collectively, these data indicate deleterious effects of risk variants within the empirically derived miR-137 regulated gene score was on cognitive function in patients and controls.
139-1	25457-25469	Collectively	_
139-2	25469-25470	,	_
139-3	25471-25476	these	_
139-4	25477-25481	data	_
139-5	25482-25490	indicate	_
139-6	25491-25502	deleterious	_
139-7	25503-25510	effects	_
139-8	25511-25513	of	_
139-9	25514-25518	risk	_
139-10	25519-25527	variants	_
139-11	25528-25534	within	_
139-12	25535-25538	the	_
139-13	25539-25550	empirically	_
139-14	25551-25558	derived	_
139-15	25559-25562	miR	_
139-16	25562-25563	-	_
139-17	25563-25566	137	_
139-18	25567-25576	regulated	_
139-19	25577-25581	gene	_
139-20	25582-25587	score	_
139-21	25588-25591	was	_
139-22	25592-25594	on	_
139-23	25595-25604	cognitive	_
139-24	25605-25613	function	_
139-25	25614-25616	in	_
139-26	25617-25625	patients	_
139-27	25626-25629	and	_
139-28	25630-25638	controls	_
139-29	25638-25639	.	_

#Text=Studies seeking to characterize the cognitive effects of individual risk variants have been criticized previously for low power, making their findings difficult to replicate.
140-1	25640-25647	Studies	_
140-2	25648-25655	seeking	_
140-3	25656-25658	to	_
140-4	25659-25671	characterize	_
140-5	25672-25675	the	_
140-6	25676-25685	cognitive	_
140-7	25686-25693	effects	_
140-8	25694-25696	of	_
140-9	25697-25707	individual	_
140-10	25708-25712	risk	_
140-11	25713-25721	variants	_
140-12	25722-25726	have	_
140-13	25727-25731	been	_
140-14	25732-25742	criticized	_
140-15	25743-25753	previously	_
140-16	25754-25757	for	_
140-17	25758-25761	low	_
140-18	25762-25767	power	_
140-19	25767-25768	,	_
140-20	25769-25775	making	_
140-21	25776-25781	their	_
140-22	25782-25790	findings	_
140-23	25791-25800	difficult	_
140-24	25801-25803	to	_
140-25	25804-25813	replicate	_
140-26	25813-25814	.	_

#Text=This study, based on one of the largest single data sets available (n=1000 individuals with adequate genetic information available from a total of 1269 participants collected) attempted to overcome this difficulty through the use of a relatively large sample size and a novel approach to risk—that is, calculated on the basis of a risk gene molecular pathway.
141-1	25815-25819	This	_
141-2	25820-25825	study	_
141-3	25825-25826	,	_
141-4	25827-25832	based	_
141-5	25833-25835	on	_
141-6	25836-25839	one	_
141-7	25840-25842	of	_
141-8	25843-25846	the	_
141-9	25847-25854	largest	_
141-10	25855-25861	single	_
141-11	25862-25866	data	_
141-12	25867-25871	sets	_
141-13	25872-25881	available	_
141-14	25882-25883	(	_
141-15	25883-25884	n	_
141-16	25884-25885	=	_
141-17	25885-25889	1000	_
141-18	25890-25901	individuals	_
141-19	25902-25906	with	_
141-20	25907-25915	adequate	_
141-21	25916-25923	genetic	_
141-22	25924-25935	information	_
141-23	25936-25945	available	_
141-24	25946-25950	from	_
141-25	25951-25952	a	_
141-26	25953-25958	total	_
141-27	25959-25961	of	_
141-28	25962-25966	1269	_
141-29	25967-25979	participants	_
141-30	25980-25989	collected	_
141-31	25989-25990	)	_
141-32	25991-26000	attempted	_
141-33	26001-26003	to	_
141-34	26004-26012	overcome	_
141-35	26013-26017	this	_
141-36	26018-26028	difficulty	_
141-37	26029-26036	through	_
141-38	26037-26040	the	_
141-39	26041-26044	use	_
141-40	26045-26047	of	_
141-41	26048-26049	a	_
141-42	26050-26060	relatively	_
141-43	26061-26066	large	_
141-44	26067-26073	sample	_
141-45	26074-26078	size	_
141-46	26079-26082	and	_
141-47	26083-26084	a	_
141-48	26085-26090	novel	_
141-49	26091-26099	approach	_
141-50	26100-26102	to	_
141-51	26103-26112	risk—that	_
141-52	26113-26115	is	_
141-53	26115-26116	,	_
141-54	26117-26127	calculated	_
141-55	26128-26130	on	_
141-56	26131-26134	the	_
141-57	26135-26140	basis	_
141-58	26141-26143	of	_
141-59	26144-26145	a	_
141-60	26146-26150	risk	_
141-61	26151-26155	gene	_
141-62	26156-26165	molecular	_
141-63	26166-26173	pathway	_
141-64	26173-26174	.	_

#Text=The robustness of our results are supported by the following: (1) the direction of all significant results were the same both for the full dataset and when both the narrow and broad patients groups were analyzed alone; (2) the findings were consistent across all genetic risk thresholds, even after correction for the number of cognitive functions assessed (general cognitive ability, declarative memory, working memory, attentional control, and social cognition) was made; (3) in the case of the memory subtests used, findings replicated across modalities, that is, increased polygenic risk was associated with both poorer verbal performance and poorer non-verbal performance; finally, (4) the amount of variation in cognitive performance explained by the empirically derived miR-137 regulated gene score was larger than that explained by the single MIR137 variant, rs1702294, with the polygenic pathway score explaining in the region of ~2% (Supplementary Table 1) of variance on declarative memory measures.
142-1	26175-26178	The	_
142-2	26179-26189	robustness	_
142-3	26190-26192	of	_
142-4	26193-26196	our	_
142-5	26197-26204	results	_
142-6	26205-26208	are	_
142-7	26209-26218	supported	_
142-8	26219-26221	by	_
142-9	26222-26225	the	_
142-10	26226-26235	following	_
142-11	26235-26236	:	_
142-12	26237-26238	(	_
142-13	26238-26239	1	_
142-14	26239-26240	)	_
142-15	26241-26244	the	_
142-16	26245-26254	direction	_
142-17	26255-26257	of	_
142-18	26258-26261	all	_
142-19	26262-26273	significant	_
142-20	26274-26281	results	_
142-21	26282-26286	were	_
142-22	26287-26290	the	_
142-23	26291-26295	same	_
142-24	26296-26300	both	_
142-25	26301-26304	for	_
142-26	26305-26308	the	_
142-27	26309-26313	full	_
142-28	26314-26321	dataset	_
142-29	26322-26325	and	_
142-30	26326-26330	when	_
142-31	26331-26335	both	_
142-32	26336-26339	the	_
142-33	26340-26346	narrow	_
142-34	26347-26350	and	_
142-35	26351-26356	broad	_
142-36	26357-26365	patients	_
142-37	26366-26372	groups	_
142-38	26373-26377	were	_
142-39	26378-26386	analyzed	_
142-40	26387-26392	alone	_
142-41	26392-26393	;	_
142-42	26394-26395	(	_
142-43	26395-26396	2	_
142-44	26396-26397	)	_
142-45	26398-26401	the	_
142-46	26402-26410	findings	_
142-47	26411-26415	were	_
142-48	26416-26426	consistent	_
142-49	26427-26433	across	_
142-50	26434-26437	all	_
142-51	26438-26445	genetic	_
142-52	26446-26450	risk	_
142-53	26451-26461	thresholds	_
142-54	26461-26462	,	_
142-55	26463-26467	even	_
142-56	26468-26473	after	_
142-57	26474-26484	correction	_
142-58	26485-26488	for	_
142-59	26489-26492	the	_
142-60	26493-26499	number	_
142-61	26500-26502	of	_
142-62	26503-26512	cognitive	_
142-63	26513-26522	functions	_
142-64	26523-26531	assessed	_
142-65	26532-26533	(	_
142-66	26533-26540	general	_
142-67	26541-26550	cognitive	_
142-68	26551-26558	ability	_
142-69	26558-26559	,	_
142-70	26560-26571	declarative	_
142-71	26572-26578	memory	_
142-72	26578-26579	,	_
142-73	26580-26587	working	_
142-74	26588-26594	memory	_
142-75	26594-26595	,	_
142-76	26596-26607	attentional	_
142-77	26608-26615	control	_
142-78	26615-26616	,	_
142-79	26617-26620	and	_
142-80	26621-26627	social	_
142-81	26628-26637	cognition	_
142-82	26637-26638	)	_
142-83	26639-26642	was	_
142-84	26643-26647	made	_
142-85	26647-26648	;	_
142-86	26649-26650	(	_
142-87	26650-26651	3	_
142-88	26651-26652	)	_
142-89	26653-26655	in	_
142-90	26656-26659	the	_
142-91	26660-26664	case	_
142-92	26665-26667	of	_
142-93	26668-26671	the	_
142-94	26672-26678	memory	_
142-95	26679-26687	subtests	_
142-96	26688-26692	used	_
142-97	26692-26693	,	_
142-98	26694-26702	findings	_
142-99	26703-26713	replicated	_
142-100	26714-26720	across	_
142-101	26721-26731	modalities	_
142-102	26731-26732	,	_
142-103	26733-26737	that	_
142-104	26738-26740	is	_
142-105	26740-26741	,	_
142-106	26742-26751	increased	_
142-107	26752-26761	polygenic	_
142-108	26762-26766	risk	_
142-109	26767-26770	was	_
142-110	26771-26781	associated	_
142-111	26782-26786	with	_
142-112	26787-26791	both	_
142-113	26792-26798	poorer	_
142-114	26799-26805	verbal	_
142-115	26806-26817	performance	_
142-116	26818-26821	and	_
142-117	26822-26828	poorer	_
142-118	26829-26839	non-verbal	_
142-119	26840-26851	performance	_
142-120	26851-26852	;	_
142-121	26853-26860	finally	_
142-122	26860-26861	,	_
142-123	26862-26863	(	_
142-124	26863-26864	4	_
142-125	26864-26865	)	_
142-126	26866-26869	the	_
142-127	26870-26876	amount	_
142-128	26877-26879	of	_
142-129	26880-26889	variation	_
142-130	26890-26892	in	_
142-131	26893-26902	cognitive	_
142-132	26903-26914	performance	_
142-133	26915-26924	explained	_
142-134	26925-26927	by	_
142-135	26928-26931	the	_
142-136	26932-26943	empirically	_
142-137	26944-26951	derived	_
142-138	26952-26955	miR	_
142-139	26955-26956	-	_
142-140	26956-26959	137	_
142-141	26960-26969	regulated	_
142-142	26970-26974	gene	_
142-143	26975-26980	score	_
142-144	26981-26984	was	_
142-145	26985-26991	larger	_
142-146	26992-26996	than	_
142-147	26997-27001	that	_
142-148	27002-27011	explained	_
142-149	27012-27014	by	_
142-150	27015-27018	the	_
142-151	27019-27025	single	_
142-152	27026-27032	MIR137	_
142-153	27033-27040	variant	_
142-154	27040-27041	,	_
142-155	27042-27051	rs1702294	_
142-156	27051-27052	,	_
142-157	27053-27057	with	_
142-158	27058-27061	the	_
142-159	27062-27071	polygenic	_
142-160	27072-27079	pathway	_
142-161	27080-27085	score	_
142-162	27086-27096	explaining	_
142-163	27097-27099	in	_
142-164	27100-27103	the	_
142-165	27104-27110	region	_
142-166	27111-27113	of	_
142-167	27114-27115	~	_
142-168	27115-27117	2%	_
142-169	27118-27119	(	_
142-170	27119-27132	Supplementary	_
142-171	27133-27138	Table	_
142-172	27139-27140	1	_
142-173	27140-27141	)	_
142-174	27142-27144	of	_
142-175	27145-27153	variance	_
142-176	27154-27156	on	_
142-177	27157-27168	declarative	_
142-178	27169-27175	memory	_
142-179	27176-27184	measures	_
142-180	27184-27185	.	_

#Text=Although still modest, this is approximately two to three times the variance explained by the individual rs1702294 SNP.
143-1	27186-27194	Although	_
143-2	27195-27200	still	_
143-3	27201-27207	modest	_
143-4	27207-27208	,	_
143-5	27209-27213	this	_
143-6	27214-27216	is	_
143-7	27217-27230	approximately	_
143-8	27231-27234	two	_
143-9	27235-27237	to	_
143-10	27238-27243	three	_
143-11	27244-27249	times	_
143-12	27250-27253	the	_
143-13	27254-27262	variance	_
143-14	27263-27272	explained	_
143-15	27273-27275	by	_
143-16	27276-27279	the	_
143-17	27280-27290	individual	_
143-18	27291-27300	rs1702294	_
143-19	27301-27304	SNP	_
143-20	27304-27305	.	_

#Text=Although correction for multiple testing was carried out for the cognitive component of the study (a Bonferroni correction for five domains: IQ, working memory, visual declarative memory, attention and social cognition) we did not correct for the fact that three polygenic risk significance thresholds were used.
144-1	27306-27314	Although	_
144-2	27315-27325	correction	_
144-3	27326-27329	for	_
144-4	27330-27338	multiple	_
144-5	27339-27346	testing	_
144-6	27347-27350	was	_
144-7	27351-27358	carried	_
144-8	27359-27362	out	_
144-9	27363-27366	for	_
144-10	27367-27370	the	_
144-11	27371-27380	cognitive	_
144-12	27381-27390	component	_
144-13	27391-27393	of	_
144-14	27394-27397	the	_
144-15	27398-27403	study	_
144-16	27404-27405	(	_
144-17	27405-27406	a	_
144-18	27407-27417	Bonferroni	_
144-19	27418-27428	correction	_
144-20	27429-27432	for	_
144-21	27433-27437	five	_
144-22	27438-27445	domains	_
144-23	27445-27446	:	_
144-24	27447-27449	IQ	_
144-25	27449-27450	,	_
144-26	27451-27458	working	_
144-27	27459-27465	memory	_
144-28	27465-27466	,	_
144-29	27467-27473	visual	_
144-30	27474-27485	declarative	_
144-31	27486-27492	memory	_
144-32	27492-27493	,	_
144-33	27494-27503	attention	_
144-34	27504-27507	and	_
144-35	27508-27514	social	_
144-36	27515-27524	cognition	_
144-37	27524-27525	)	_
144-38	27526-27528	we	_
144-39	27529-27532	did	_
144-40	27533-27536	not	_
144-41	27537-27544	correct	_
144-42	27545-27548	for	_
144-43	27549-27552	the	_
144-44	27553-27557	fact	_
144-45	27558-27562	that	_
144-46	27563-27568	three	_
144-47	27569-27578	polygenic	_
144-48	27579-27583	risk	_
144-49	27584-27596	significance	_
144-50	27597-27607	thresholds	_
144-51	27608-27612	were	_
144-52	27613-27617	used	_
144-53	27617-27618	.	_

#Text=It is still unclear what the best approach to selecting thresholds is.
145-1	27619-27621	It	_
145-2	27622-27624	is	_
145-3	27625-27630	still	_
145-4	27631-27638	unclear	_
145-5	27639-27643	what	_
145-6	27644-27647	the	_
145-7	27648-27652	best	_
145-8	27653-27661	approach	_
145-9	27662-27664	to	_
145-10	27665-27674	selecting	_
145-11	27675-27685	thresholds	_
145-12	27686-27688	is	_
145-13	27688-27689	.	_

#Text=The original PGC analysis reported 10 risk thresholds.
146-1	27690-27693	The	_
146-2	27694-27702	original	_
146-3	27703-27706	PGC	_
146-4	27707-27715	analysis	_
146-5	27716-27724	reported	_
146-6	27725-27727	10	_
146-7	27728-27732	risk	_
146-8	27733-27743	thresholds	_
146-9	27743-27744	.	_

#Text=We have included three to reduce the multiple testing burden, while others have reduced this burden even further by including only one, for example, a threshold of P=0.5.
147-1	27745-27747	We	_
147-2	27748-27752	have	_
147-3	27753-27761	included	_
147-4	27762-27767	three	_
147-5	27768-27770	to	_
147-6	27771-27777	reduce	_
147-7	27778-27781	the	_
147-8	27782-27790	multiple	_
147-9	27791-27798	testing	_
147-10	27799-27805	burden	_
147-11	27805-27806	,	_
147-12	27807-27812	while	_
147-13	27813-27819	others	_
147-14	27820-27824	have	_
147-15	27825-27832	reduced	_
147-16	27833-27837	this	_
147-17	27838-27844	burden	_
147-18	27845-27849	even	_
147-19	27850-27857	further	_
147-20	27858-27860	by	_
147-21	27861-27870	including	_
147-22	27871-27875	only	_
147-23	27876-27879	one	_
147-24	27879-27880	,	_
147-25	27881-27884	for	_
147-26	27885-27892	example	_
147-27	27892-27893	,	_
147-28	27894-27895	a	_
147-29	27896-27905	threshold	_
147-30	27906-27908	of	_
147-31	27909-27910	P	_
147-32	27910-27911	=	_
147-33	27911-27914	0.5	_
147-34	27914-27915	.	_

#Text=However, for our cognitive analysis the threshold considered would appear to have been unimportant: broadly the same cognitive associations were observed for each of the three thresholds considered.
148-1	27916-27923	However	_
148-2	27923-27924	,	_
148-3	27925-27928	for	_
148-4	27929-27932	our	_
148-5	27933-27942	cognitive	_
148-6	27943-27951	analysis	_
148-7	27952-27955	the	_
148-8	27956-27965	threshold	_
148-9	27966-27976	considered	_
148-10	27977-27982	would	_
148-11	27983-27989	appear	_
148-12	27990-27992	to	_
148-13	27993-27997	have	_
148-14	27998-28002	been	_
148-15	28003-28014	unimportant	_
148-16	28014-28015	:	_
148-17	28016-28023	broadly	_
148-18	28024-28027	the	_
148-19	28028-28032	same	_
148-20	28033-28042	cognitive	_
148-21	28043-28055	associations	_
148-22	28056-28060	were	_
148-23	28061-28069	observed	_
148-24	28070-28073	for	_
148-25	28074-28078	each	_
148-26	28079-28081	of	_
148-27	28082-28085	the	_
148-28	28086-28091	three	_
148-29	28092-28102	thresholds	_
148-30	28103-28113	considered	_
148-31	28113-28114	.	_

#Text=This would suggest that in fact a study of only one threshold would have been sufficient to characterize the cognitive consequences of this gene set.
149-1	28115-28119	This	_
149-2	28120-28125	would	_
149-3	28126-28133	suggest	_
149-4	28134-28138	that	_
149-5	28139-28141	in	_
149-6	28142-28146	fact	_
149-7	28147-28148	a	_
149-8	28149-28154	study	_
149-9	28155-28157	of	_
149-10	28158-28162	only	_
149-11	28163-28166	one	_
149-12	28167-28176	threshold	_
149-13	28177-28182	would	_
149-14	28183-28187	have	_
149-15	28188-28192	been	_
149-16	28193-28203	sufficient	_
149-17	28204-28206	to	_
149-18	28207-28219	characterize	_
149-19	28220-28223	the	_
149-20	28224-28233	cognitive	_
149-21	28234-28246	consequences	_
149-22	28247-28249	of	_
149-23	28250-28254	this	_
149-24	28255-28259	gene	_
149-25	28260-28263	set	_
149-26	28263-28264	.	_

#Text=For the neuroimaging study, an association between MIR137 polygenic risk and cortical activation during a working memory task was only significant at the most conservative threshold of P=10−5; why this might have been case is uncertain.
150-1	28265-28268	For	_
150-2	28269-28272	the	_
150-3	28273-28285	neuroimaging	_
150-4	28286-28291	study	_
150-5	28291-28292	,	_
150-6	28293-28295	an	_
150-7	28296-28307	association	_
150-8	28308-28315	between	_
150-9	28316-28322	MIR137	_
150-10	28323-28332	polygenic	_
150-11	28333-28337	risk	_
150-12	28338-28341	and	_
150-13	28342-28350	cortical	_
150-14	28351-28361	activation	_
150-15	28362-28368	during	_
150-16	28369-28370	a	_
150-17	28371-28378	working	_
150-18	28379-28385	memory	_
150-19	28386-28390	task	_
150-20	28391-28394	was	_
150-21	28395-28399	only	_
150-22	28400-28411	significant	_
150-23	28412-28414	at	_
150-24	28415-28418	the	_
150-25	28419-28423	most	_
150-26	28424-28436	conservative	_
150-27	28437-28446	threshold	_
150-28	28447-28449	of	_
150-29	28450-28451	P	_
150-30	28451-28452	=	_
150-31	28452-28454	10	_
150-32	28454-28455	−	_
150-33	28455-28456	5	_
150-34	28456-28457	;	_
150-35	28458-28461	why	_
150-36	28462-28466	this	_
150-37	28467-28472	might	_
150-38	28473-28477	have	_
150-39	28478-28482	been	_
150-40	28483-28487	case	_
150-41	28488-28490	is	_
150-42	28491-28500	uncertain	_
150-43	28500-28501	.	_

#Text=One possibility is that this was simply a false-positive finding; the fact that only a subsample of participants were included in this analysis, albeit relatively large for fMRI studies (n=108) might support this conclusion.
151-1	28502-28505	One	_
151-2	28506-28517	possibility	_
151-3	28518-28520	is	_
151-4	28521-28525	that	_
151-5	28526-28530	this	_
151-6	28531-28534	was	_
151-7	28535-28541	simply	_
151-8	28542-28543	a	_
151-9	28544-28558	false-positive	_
151-10	28559-28566	finding	_
151-11	28566-28567	;	_
151-12	28568-28571	the	_
151-13	28572-28576	fact	_
151-14	28577-28581	that	_
151-15	28582-28586	only	_
151-16	28587-28588	a	_
151-17	28589-28598	subsample	_
151-18	28599-28601	of	_
151-19	28602-28614	participants	_
151-20	28615-28619	were	_
151-21	28620-28628	included	_
151-22	28629-28631	in	_
151-23	28632-28636	this	_
151-24	28637-28645	analysis	_
151-25	28645-28646	,	_
151-26	28647-28653	albeit	_
151-27	28654-28664	relatively	_
151-28	28665-28670	large	_
151-29	28671-28674	for	_
151-30	28675-28679	fMRI	_
151-31	28680-28687	studies	_
151-32	28688-28689	(	_
151-33	28689-28690	n	_
151-34	28690-28691	=	_
151-35	28691-28694	108	_
151-36	28694-28695	)	_
151-37	28696-28701	might	_
151-38	28702-28709	support	_
151-39	28710-28714	this	_
151-40	28715-28725	conclusion	_
151-41	28725-28726	.	_

#Text=Other explanations include that imaging findings may be more sensitive to the signal to noise ratio inherent in high polygenic risk thresholds (that is, that more lenient thresholds harbor a greater percentage of variants not robustly associated with risk, hence making them less informative).
152-1	28727-28732	Other	_
152-2	28733-28745	explanations	_
152-3	28746-28753	include	_
152-4	28754-28758	that	_
152-5	28759-28766	imaging	_
152-6	28767-28775	findings	_
152-7	28776-28779	may	_
152-8	28780-28782	be	_
152-9	28783-28787	more	_
152-10	28788-28797	sensitive	_
152-11	28798-28800	to	_
152-12	28801-28804	the	_
152-13	28805-28811	signal	_
152-14	28812-28814	to	_
152-15	28815-28820	noise	_
152-16	28821-28826	ratio	_
152-17	28827-28835	inherent	_
152-18	28836-28838	in	_
152-19	28839-28843	high	_
152-20	28844-28853	polygenic	_
152-21	28854-28858	risk	_
152-22	28859-28869	thresholds	_
152-23	28870-28871	(	_
152-24	28871-28875	that	_
152-25	28876-28878	is	_
152-26	28878-28879	,	_
152-27	28880-28884	that	_
152-28	28885-28889	more	_
152-29	28890-28897	lenient	_
152-30	28898-28908	thresholds	_
152-31	28909-28915	harbor	_
152-32	28916-28917	a	_
152-33	28918-28925	greater	_
152-34	28926-28936	percentage	_
152-35	28937-28939	of	_
152-36	28940-28948	variants	_
152-37	28949-28952	not	_
152-38	28953-28961	robustly	_
152-39	28962-28972	associated	_
152-40	28973-28977	with	_
152-41	28978-28982	risk	_
152-42	28982-28983	,	_
152-43	28984-28989	hence	_
152-44	28990-28996	making	_
152-45	28997-29001	them	_
152-46	29002-29006	less	_
152-47	29007-29018	informative	_
152-48	29018-29019	)	_
152-49	29019-29020	.	_

#Text=To our knowledge, only one other polygenic fMRI study has been carried out to date, and as noted included only one threshold.
153-1	29021-29023	To	_
153-2	29024-29027	our	_
153-3	29028-29037	knowledge	_
153-4	29037-29038	,	_
153-5	29039-29043	only	_
153-6	29044-29047	one	_
153-7	29048-29053	other	_
153-8	29054-29063	polygenic	_
153-9	29064-29068	fMRI	_
153-10	29069-29074	study	_
153-11	29075-29078	has	_
153-12	29079-29083	been	_
153-13	29084-29091	carried	_
153-14	29092-29095	out	_
153-15	29096-29098	to	_
153-16	29099-29103	date	_
153-17	29103-29104	,	_
153-18	29105-29108	and	_
153-19	29109-29111	as	_
153-20	29112-29117	noted	_
153-21	29118-29126	included	_
153-22	29127-29131	only	_
153-23	29132-29135	one	_
153-24	29136-29145	threshold	_
153-25	29145-29146	.	_

#Text=As a consequence this relatively novel approach requires the accumulation of further studies to determine the best thresholding approach to take, as evidence for an optimum threshold (in terms of signal to noise ratio) has yet to emerge.
154-1	29147-29149	As	_
154-2	29150-29151	a	_
154-3	29152-29163	consequence	_
154-4	29164-29168	this	_
154-5	29169-29179	relatively	_
154-6	29180-29185	novel	_
154-7	29186-29194	approach	_
154-8	29195-29203	requires	_
154-9	29204-29207	the	_
154-10	29208-29220	accumulation	_
154-11	29221-29223	of	_
154-12	29224-29231	further	_
154-13	29232-29239	studies	_
154-14	29240-29242	to	_
154-15	29243-29252	determine	_
154-16	29253-29256	the	_
154-17	29257-29261	best	_
154-18	29262-29274	thresholding	_
154-19	29275-29283	approach	_
154-20	29284-29286	to	_
154-21	29287-29291	take	_
154-22	29291-29292	,	_
154-23	29293-29295	as	_
154-24	29296-29304	evidence	_
154-25	29305-29308	for	_
154-26	29309-29311	an	_
154-27	29312-29319	optimum	_
154-28	29320-29329	threshold	_
154-29	29330-29331	(	_
154-30	29331-29333	in	_
154-31	29334-29339	terms	_
154-32	29340-29342	of	_
154-33	29343-29349	signal	_
154-34	29350-29352	to	_
154-35	29353-29358	noise	_
154-36	29359-29364	ratio	_
154-37	29364-29365	)	_
154-38	29366-29369	has	_
154-39	29370-29373	yet	_
154-40	29374-29376	to	_
154-41	29377-29383	emerge	_
154-42	29383-29384	.	_

#Text=When examining brain regions showing increased blood oxygenation level dependent (BOLD) response with increasing spatial working memory load (contrast: 3 dots condition>1 dot condition), two clusters showed significantly increased BOLD response in individuals with higher MIR137 pathway risk score (MIR137 pathway risk score P=10−5 level).
155-1	29385-29389	When	_
155-2	29390-29399	examining	_
155-3	29400-29405	brain	_
155-4	29406-29413	regions	_
155-5	29414-29421	showing	_
155-6	29422-29431	increased	_
155-7	29432-29437	blood	_
155-8	29438-29449	oxygenation	_
155-9	29450-29455	level	_
155-10	29456-29465	dependent	_
155-11	29466-29467	(	_
155-12	29467-29471	BOLD	_
155-13	29471-29472	)	_
155-14	29473-29481	response	_
155-15	29482-29486	with	_
155-16	29487-29497	increasing	_
155-17	29498-29505	spatial	_
155-18	29506-29513	working	_
155-19	29514-29520	memory	_
155-20	29521-29525	load	_
155-21	29526-29527	(	_
155-22	29527-29535	contrast	_
155-23	29535-29536	:	_
155-24	29537-29538	3	_
155-25	29539-29543	dots	_
155-26	29544-29553	condition	_
155-27	29553-29554	>	_
155-28	29554-29555	1	_
155-29	29556-29559	dot	_
155-30	29560-29569	condition	_
155-31	29569-29570	)	_
155-32	29570-29571	,	_
155-33	29572-29575	two	_
155-34	29576-29584	clusters	_
155-35	29585-29591	showed	_
155-36	29592-29605	significantly	_
155-37	29606-29615	increased	_
155-38	29616-29620	BOLD	_
155-39	29621-29629	response	_
155-40	29630-29632	in	_
155-41	29633-29644	individuals	_
155-42	29645-29649	with	_
155-43	29650-29656	higher	_
155-44	29657-29663	MIR137	_
155-45	29664-29671	pathway	_
155-46	29672-29676	risk	_
155-47	29677-29682	score	_
155-48	29683-29684	(	_
155-49	29684-29690	MIR137	_
155-50	29691-29698	pathway	_
155-51	29699-29703	risk	_
155-52	29704-29709	score	_
155-53	29710-29711	P	_
155-54	29711-29712	=	_
155-55	29712-29714	10	_
155-56	29714-29715	−	_
155-57	29715-29716	5	_
155-58	29717-29722	level	_
155-59	29722-29723	)	_
155-60	29723-29724	.	_

#Text=The first cluster incorporated the right inferior occipital gyrus and right middle temporal gyrus.
156-1	29725-29728	The	_
156-2	29729-29734	first	_
156-3	29735-29742	cluster	_
156-4	29743-29755	incorporated	_
156-5	29756-29759	the	_
156-6	29760-29765	right	_
156-7	29766-29774	inferior	_
156-8	29775-29784	occipital	_
156-9	29785-29790	gyrus	_
156-10	29791-29794	and	_
156-11	29795-29800	right	_
156-12	29801-29807	middle	_
156-13	29808-29816	temporal	_
156-14	29817-29822	gyrus	_
156-15	29822-29823	.	_

#Text=Given that this cluster overlaps with cortical regions activated by our task (Figure 1), hyperactivation in this cluster may represent relative inefficiency in processing task stimuli in individuals with higher risk scores, although this suggestion remains speculative.
157-1	29824-29829	Given	_
157-2	29830-29834	that	_
157-3	29835-29839	this	_
157-4	29840-29847	cluster	_
157-5	29848-29856	overlaps	_
157-6	29857-29861	with	_
157-7	29862-29870	cortical	_
157-8	29871-29878	regions	_
157-9	29879-29888	activated	_
157-10	29889-29891	by	_
157-11	29892-29895	our	_
157-12	29896-29900	task	_
157-13	29901-29902	(	_
157-14	29902-29908	Figure	_
157-15	29909-29910	1	_
157-16	29910-29911	)	_
157-17	29911-29912	,	_
157-18	29913-29928	hyperactivation	_
157-19	29929-29931	in	_
157-20	29932-29936	this	_
157-21	29937-29944	cluster	_
157-22	29945-29948	may	_
157-23	29949-29958	represent	_
157-24	29959-29967	relative	_
157-25	29968-29980	inefficiency	_
157-26	29981-29983	in	_
157-27	29984-29994	processing	_
157-28	29995-29999	task	_
157-29	30000-30007	stimuli	_
157-30	30008-30010	in	_
157-31	30011-30022	individuals	_
157-32	30023-30027	with	_
157-33	30028-30034	higher	_
157-34	30035-30039	risk	_
157-35	30040-30046	scores	_
157-36	30046-30047	,	_
157-37	30048-30056	although	_
157-38	30057-30061	this	_
157-39	30062-30072	suggestion	_
157-40	30073-30080	remains	_
157-41	30081-30092	speculative	_
157-42	30092-30093	.	_

#Text=Although a second cluster, in the medial parietal region, showed significantly increased BOLD response with increasing MIR137 pathway risk score (P=10−5 level) also, no individual peak coordinates in MNI space were not found on any probability map (Figure 1).
158-1	30094-30102	Although	_
158-2	30103-30104	a	_
158-3	30105-30111	second	_
158-4	30112-30119	cluster	_
158-5	30119-30120	,	_
158-6	30121-30123	in	_
158-7	30124-30127	the	_
158-8	30128-30134	medial	_
158-9	30135-30143	parietal	_
158-10	30144-30150	region	_
158-11	30150-30151	,	_
158-12	30152-30158	showed	_
158-13	30159-30172	significantly	_
158-14	30173-30182	increased	_
158-15	30183-30187	BOLD	_
158-16	30188-30196	response	_
158-17	30197-30201	with	_
158-18	30202-30212	increasing	_
158-19	30213-30219	MIR137	_
158-20	30220-30227	pathway	_
158-21	30228-30232	risk	_
158-22	30233-30238	score	_
158-23	30239-30240	(	_
158-24	30240-30241	P	_
158-25	30241-30242	=	_
158-26	30242-30244	10	_
158-27	30244-30245	−	_
158-28	30245-30246	5	_
158-29	30247-30252	level	_
158-30	30252-30253	)	_
158-31	30254-30258	also	_
158-32	30258-30259	,	_
158-33	30260-30262	no	_
158-34	30263-30273	individual	_
158-35	30274-30278	peak	_
158-36	30279-30290	coordinates	_
158-37	30291-30293	in	_
158-38	30294-30297	MNI	_
158-39	30298-30303	space	_
158-40	30304-30308	were	_
158-41	30309-30312	not	_
158-42	30313-30318	found	_
158-43	30319-30321	on	_
158-44	30322-30325	any	_
158-45	30326-30337	probability	_
158-46	30338-30341	map	_
158-47	30342-30343	(	_
158-48	30343-30349	Figure	_
158-49	30350-30351	1	_
158-50	30351-30352	)	_
158-51	30352-30353	.	_

#Text=Given that visual inspection of this cluster reveals that a large proportion resides in white matter, this may be an artefactual finding and should be interpreted with caution.
159-1	30354-30359	Given	_
159-2	30360-30364	that	_
159-3	30365-30371	visual	_
159-4	30372-30382	inspection	_
159-5	30383-30385	of	_
159-6	30386-30390	this	_
159-7	30391-30398	cluster	_
159-8	30399-30406	reveals	_
159-9	30407-30411	that	_
159-10	30412-30413	a	_
159-11	30414-30419	large	_
159-12	30420-30430	proportion	_
159-13	30431-30438	resides	_
159-14	30439-30441	in	_
159-15	30442-30447	white	_
159-16	30448-30454	matter	_
159-17	30454-30455	,	_
159-18	30456-30460	this	_
159-19	30461-30464	may	_
159-20	30465-30467	be	_
159-21	30468-30470	an	_
159-22	30471-30482	artefactual	_
159-23	30483-30490	finding	_
159-24	30491-30494	and	_
159-25	30495-30501	should	_
159-26	30502-30504	be	_
159-27	30505-30516	interpreted	_
159-28	30517-30521	with	_
159-29	30522-30529	caution	_
159-30	30529-30530	.	_

#Text=It is possible that as regions of the medial parietal cortex typically show task-induced decreases in BOLD response, the present finding of increased BOLD response in this region may relate to a relative failure to deactivate this region during the working memory task in individuals with higher risk scores.
160-1	30531-30533	It	_
160-2	30534-30536	is	_
160-3	30537-30545	possible	_
160-4	30546-30550	that	_
160-5	30551-30553	as	_
160-6	30554-30561	regions	_
160-7	30562-30564	of	_
160-8	30565-30568	the	_
160-9	30569-30575	medial	_
160-10	30576-30584	parietal	_
160-11	30585-30591	cortex	_
160-12	30592-30601	typically	_
160-13	30602-30606	show	_
160-14	30607-30619	task-induced	_
160-15	30620-30629	decreases	_
160-16	30630-30632	in	_
160-17	30633-30637	BOLD	_
160-18	30638-30646	response	_
160-19	30646-30647	,	_
160-20	30648-30651	the	_
160-21	30652-30659	present	_
160-22	30660-30667	finding	_
160-23	30668-30670	of	_
160-24	30671-30680	increased	_
160-25	30681-30685	BOLD	_
160-26	30686-30694	response	_
160-27	30695-30697	in	_
160-28	30698-30702	this	_
160-29	30703-30709	region	_
160-30	30710-30713	may	_
160-31	30714-30720	relate	_
160-32	30721-30723	to	_
160-33	30724-30725	a	_
160-34	30726-30734	relative	_
160-35	30735-30742	failure	_
160-36	30743-30745	to	_
160-37	30746-30756	deactivate	_
160-38	30757-30761	this	_
160-39	30762-30768	region	_
160-40	30769-30775	during	_
160-41	30776-30779	the	_
160-42	30780-30787	working	_
160-43	30788-30794	memory	_
160-44	30795-30799	task	_
160-45	30800-30802	in	_
160-46	30803-30814	individuals	_
160-47	30815-30819	with	_
160-48	30820-30826	higher	_
160-49	30827-30831	risk	_
160-50	30832-30838	scores	_
160-51	30838-30839	.	_

#Text=However, as noted above, the fact that these results are obtained in a sample that, although large for imaging studies, is quite modest for genetics studies, requires caution in interpretation of these results.
161-1	30840-30847	However	_
161-2	30847-30848	,	_
161-3	30849-30851	as	_
161-4	30852-30857	noted	_
161-5	30858-30863	above	_
161-6	30863-30864	,	_
161-7	30865-30868	the	_
161-8	30869-30873	fact	_
161-9	30874-30878	that	_
161-10	30879-30884	these	_
161-11	30885-30892	results	_
161-12	30893-30896	are	_
161-13	30897-30905	obtained	_
161-14	30906-30908	in	_
161-15	30909-30910	a	_
161-16	30911-30917	sample	_
161-17	30918-30922	that	_
161-18	30922-30923	,	_
161-19	30924-30932	although	_
161-20	30933-30938	large	_
161-21	30939-30942	for	_
161-22	30943-30950	imaging	_
161-23	30951-30958	studies	_
161-24	30958-30959	,	_
161-25	30960-30962	is	_
161-26	30963-30968	quite	_
161-27	30969-30975	modest	_
161-28	30976-30979	for	_
161-29	30980-30988	genetics	_
161-30	30989-30996	studies	_
161-31	30996-30997	,	_
161-32	30998-31006	requires	_
161-33	31007-31014	caution	_
161-34	31015-31017	in	_
161-35	31018-31032	interpretation	_
161-36	31033-31035	of	_
161-37	31036-31041	these	_
161-38	31042-31049	results	_
161-39	31049-31050	.	_

#Text=In addition to the issue of sample size, further study limitations include that only healthy participants were used for studying the association of polygenic risk on patterns of brain activation.
162-1	31051-31053	In	_
162-2	31054-31062	addition	_
162-3	31063-31065	to	_
162-4	31066-31069	the	_
162-5	31070-31075	issue	_
162-6	31076-31078	of	_
162-7	31079-31085	sample	_
162-8	31086-31090	size	_
162-9	31090-31091	,	_
162-10	31092-31099	further	_
162-11	31100-31105	study	_
162-12	31106-31117	limitations	_
162-13	31118-31125	include	_
162-14	31126-31130	that	_
162-15	31131-31135	only	_
162-16	31136-31143	healthy	_
162-17	31144-31156	participants	_
162-18	31157-31161	were	_
162-19	31162-31166	used	_
162-20	31167-31170	for	_
162-21	31171-31179	studying	_
162-22	31180-31183	the	_
162-23	31184-31195	association	_
162-24	31196-31198	of	_
162-25	31199-31208	polygenic	_
162-26	31209-31213	risk	_
162-27	31214-31216	on	_
162-28	31217-31225	patterns	_
162-29	31226-31228	of	_
162-30	31229-31234	brain	_
162-31	31235-31245	activation	_
162-32	31245-31246	.	_

#Text=Ideally the analysis will be repeated in a patient sample to confirm findings in this group.
163-1	31247-31254	Ideally	_
163-2	31255-31258	the	_
163-3	31259-31267	analysis	_
163-4	31268-31272	will	_
163-5	31273-31275	be	_
163-6	31276-31284	repeated	_
163-7	31285-31287	in	_
163-8	31288-31289	a	_
163-9	31290-31297	patient	_
163-10	31298-31304	sample	_
163-11	31305-31307	to	_
163-12	31308-31315	confirm	_
163-13	31316-31324	findings	_
163-14	31325-31327	in	_
163-15	31328-31332	this	_
163-16	31333-31338	group	_
163-17	31338-31339	.	_

#Text=However, symptoms in SZ and cognitive deficits occur along a spectrum, so despite the lack of patient fMRI data, our current analysis does allow for investigation of the association between this polygene score and functional alterations in healthy participant endophenotypes.
164-1	31340-31347	However	_
164-2	31347-31348	,	_
164-3	31349-31357	symptoms	_
164-4	31358-31360	in	_
164-5	31361-31363	SZ	_
164-6	31364-31367	and	_
164-7	31368-31377	cognitive	_
164-8	31378-31386	deficits	_
164-9	31387-31392	occur	_
164-10	31393-31398	along	_
164-11	31399-31400	a	_
164-12	31401-31409	spectrum	_
164-13	31409-31410	,	_
164-14	31411-31413	so	_
164-15	31414-31421	despite	_
164-16	31422-31425	the	_
164-17	31426-31430	lack	_
164-18	31431-31433	of	_
164-19	31434-31441	patient	_
164-20	31442-31446	fMRI	_
164-21	31447-31451	data	_
164-22	31451-31452	,	_
164-23	31453-31456	our	_
164-24	31457-31464	current	_
164-25	31465-31473	analysis	_
164-26	31474-31478	does	_
164-27	31479-31484	allow	_
164-28	31485-31488	for	_
164-29	31489-31502	investigation	_
164-30	31503-31505	of	_
164-31	31506-31509	the	_
164-32	31510-31521	association	_
164-33	31522-31529	between	_
164-34	31530-31534	this	_
164-35	31535-31543	polygene	_
164-36	31544-31549	score	_
164-37	31550-31553	and	_
164-38	31554-31564	functional	_
164-39	31565-31576	alterations	_
164-40	31577-31579	in	_
164-41	31580-31587	healthy	_
164-42	31588-31599	participant	_
164-43	31600-31614	endophenotypes	_
164-44	31614-31615	.	_

#Text=In addition, a recent paper evaluating the effect of MIR137 on gray matter concentration found that the effects of SNPs in MIR137 and associated pathways have greater impact on brain structure and function in SZ patients than healthy participants.
165-1	31616-31618	In	_
165-2	31619-31627	addition	_
165-3	31627-31628	,	_
165-4	31629-31630	a	_
165-5	31631-31637	recent	_
165-6	31638-31643	paper	_
165-7	31644-31654	evaluating	_
165-8	31655-31658	the	_
165-9	31659-31665	effect	_
165-10	31666-31668	of	_
165-11	31669-31675	MIR137	_
165-12	31676-31678	on	_
165-13	31679-31683	gray	_
165-14	31684-31690	matter	_
165-15	31691-31704	concentration	_
165-16	31705-31710	found	_
165-17	31711-31715	that	_
165-18	31716-31719	the	_
165-19	31720-31727	effects	_
165-20	31728-31730	of	_
165-21	31731-31735	SNPs	_
165-22	31736-31738	in	_
165-23	31739-31745	MIR137	_
165-24	31746-31749	and	_
165-25	31750-31760	associated	_
165-26	31761-31769	pathways	_
165-27	31770-31774	have	_
165-28	31775-31782	greater	_
165-29	31783-31789	impact	_
165-30	31790-31792	on	_
165-31	31793-31798	brain	_
165-32	31799-31808	structure	_
165-33	31809-31812	and	_
165-34	31813-31821	function	_
165-35	31822-31824	in	_
165-36	31825-31827	SZ	_
165-37	31828-31836	patients	_
165-38	31837-31841	than	_
165-39	31842-31849	healthy	_
165-40	31850-31862	participants	_
165-41	31862-31863	.	_

#Text=The results of the present analysis of healthy participants may be indicative of a greater impact in a patient population.
166-1	31864-31867	The	_
166-2	31868-31875	results	_
166-3	31876-31878	of	_
166-4	31879-31882	the	_
166-5	31883-31890	present	_
166-6	31891-31899	analysis	_
166-7	31900-31902	of	_
166-8	31903-31910	healthy	_
166-9	31911-31923	participants	_
166-10	31924-31927	may	_
166-11	31928-31930	be	_
166-12	31931-31941	indicative	_
166-13	31942-31944	of	_
166-14	31945-31946	a	_
166-15	31947-31954	greater	_
166-16	31955-31961	impact	_
166-17	31962-31964	in	_
166-18	31965-31966	a	_
166-19	31967-31974	patient	_
166-20	31975-31985	population	_
166-21	31985-31986	.	_

#Text=Another potential limitation here is using a gene list derived from human progenitor neural cells, in which the stability of transcriptional regulation can change over time.
167-1	31987-31994	Another	_
167-2	31995-32004	potential	_
167-3	32005-32015	limitation	_
167-4	32016-32020	here	_
167-5	32021-32023	is	_
167-6	32024-32029	using	_
167-7	32030-32031	a	_
167-8	32032-32036	gene	_
167-9	32037-32041	list	_
167-10	32042-32049	derived	_
167-11	32050-32054	from	_
167-12	32055-32060	human	_
167-13	32061-32071	progenitor	_
167-14	32072-32078	neural	_
167-15	32079-32084	cells	_
167-16	32084-32085	,	_
167-17	32086-32088	in	_
167-18	32089-32094	which	_
167-19	32095-32098	the	_
167-20	32099-32108	stability	_
167-21	32109-32111	of	_
167-22	32112-32127	transcriptional	_
167-23	32128-32138	regulation	_
167-24	32139-32142	can	_
167-25	32143-32149	change	_
167-26	32150-32154	over	_
167-27	32155-32159	time	_
167-28	32159-32160	.	_

#Text=Nonetheless, at least some of the genetic variants identified to generate the polygenic score are present in both adult and embryonic stages, so the effect of the variant may have already had its substantial influence in neurodevelopmental stages.
168-1	32161-32172	Nonetheless	_
168-2	32172-32173	,	_
168-3	32174-32176	at	_
168-4	32177-32182	least	_
168-5	32183-32187	some	_
168-6	32188-32190	of	_
168-7	32191-32194	the	_
168-8	32195-32202	genetic	_
168-9	32203-32211	variants	_
168-10	32212-32222	identified	_
168-11	32223-32225	to	_
168-12	32226-32234	generate	_
168-13	32235-32238	the	_
168-14	32239-32248	polygenic	_
168-15	32249-32254	score	_
168-16	32255-32258	are	_
168-17	32259-32266	present	_
168-18	32267-32269	in	_
168-19	32270-32274	both	_
168-20	32275-32280	adult	_
168-21	32281-32284	and	_
168-22	32285-32294	embryonic	_
168-23	32295-32301	stages	_
168-24	32301-32302	,	_
168-25	32303-32305	so	_
168-26	32306-32309	the	_
168-27	32310-32316	effect	_
168-28	32317-32319	of	_
168-29	32320-32323	the	_
168-30	32324-32331	variant	_
168-31	32332-32335	may	_
168-32	32336-32340	have	_
168-33	32341-32348	already	_
168-34	32349-32352	had	_
168-35	32353-32356	its	_
168-36	32357-32368	substantial	_
168-37	32369-32378	influence	_
168-38	32379-32381	in	_
168-39	32382-32400	neurodevelopmental	_
168-40	32401-32407	stages	_
168-41	32407-32408	.	_

#Text=With regard to the effect of medication on cognition, medication dosage was not used as a covariate in our whole sample analysis, which included controls, as doing so would have limited our sample size in the analysis (n=1000) to patients with this information (n=585).
169-1	32409-32413	With	_
169-2	32414-32420	regard	_
169-3	32421-32423	to	_
169-4	32424-32427	the	_
169-5	32428-32434	effect	_
169-6	32435-32437	of	_
169-7	32438-32448	medication	_
169-8	32449-32451	on	_
169-9	32452-32461	cognition	_
169-10	32461-32462	,	_
169-11	32463-32473	medication	_
169-12	32474-32480	dosage	_
169-13	32481-32484	was	_
169-14	32485-32488	not	_
169-15	32489-32493	used	_
169-16	32494-32496	as	_
169-17	32497-32498	a	_
169-18	32499-32508	covariate	_
169-19	32509-32511	in	_
169-20	32512-32515	our	_
169-21	32516-32521	whole	_
169-22	32522-32528	sample	_
169-23	32529-32537	analysis	_
169-24	32537-32538	,	_
169-25	32539-32544	which	_
169-26	32545-32553	included	_
169-27	32554-32562	controls	_
169-28	32562-32563	,	_
169-29	32564-32566	as	_
169-30	32567-32572	doing	_
169-31	32573-32575	so	_
169-32	32576-32581	would	_
169-33	32582-32586	have	_
169-34	32587-32594	limited	_
169-35	32595-32598	our	_
169-36	32599-32605	sample	_
169-37	32606-32610	size	_
169-38	32611-32613	in	_
169-39	32614-32617	the	_
169-40	32618-32626	analysis	_
169-41	32627-32628	(	_
169-42	32628-32629	n	_
169-43	32629-32630	=	_
169-44	32630-32634	1000	_
169-45	32634-32635	)	_
169-46	32636-32638	to	_
169-47	32639-32647	patients	_
169-48	32648-32652	with	_
169-49	32653-32657	this	_
169-50	32658-32669	information	_
169-51	32670-32671	(	_
169-52	32671-32672	n	_
169-53	32672-32673	=	_
169-54	32673-32676	585	_
169-55	32676-32677	)	_
169-56	32677-32678	.	_

#Text=In the patient groups considered separately, results from the neuropsychological results were non-significant following Bonferroni correction; including medication dosage as a covariate in this analysis did not change these results.
170-1	32679-32681	In	_
170-2	32682-32685	the	_
170-3	32686-32693	patient	_
170-4	32694-32700	groups	_
170-5	32701-32711	considered	_
170-6	32712-32722	separately	_
170-7	32722-32723	,	_
170-8	32724-32731	results	_
170-9	32732-32736	from	_
170-10	32737-32740	the	_
170-11	32741-32759	neuropsychological	_
170-12	32760-32767	results	_
170-13	32768-32772	were	_
170-14	32773-32788	non-significant	_
170-15	32789-32798	following	_
170-16	32799-32809	Bonferroni	_
170-17	32810-32820	correction	_
170-18	32820-32821	;	_
170-19	32822-32831	including	_
170-20	32832-32842	medication	_
170-21	32843-32849	dosage	_
170-22	32850-32852	as	_
170-23	32853-32854	a	_
170-24	32855-32864	covariate	_
170-25	32865-32867	in	_
170-26	32868-32872	this	_
170-27	32873-32881	analysis	_
170-28	32882-32885	did	_
170-29	32886-32889	not	_
170-30	32890-32896	change	_
170-31	32897-32902	these	_
170-32	32903-32910	results	_
170-33	32910-32911	.	_

#Text=Taking a polygene approach to characterize genetic effects has particular significance for the MIR137 polygene score.
171-1	32912-32918	Taking	_
171-2	32919-32920	a	_
171-3	32921-32929	polygene	_
171-4	32930-32938	approach	_
171-5	32939-32941	to	_
171-6	32942-32954	characterize	_
171-7	32955-32962	genetic	_
171-8	32963-32970	effects	_
171-9	32971-32974	has	_
171-10	32975-32985	particular	_
171-11	32986-32998	significance	_
171-12	32999-33002	for	_
171-13	33003-33006	the	_
171-14	33007-33013	MIR137	_
171-15	33014-33022	polygene	_
171-16	33023-33028	score	_
171-17	33028-33029	.	_

#Text=As with other gene sets and putative biological pathways, discrepancies exist between genes that are bioinformatically predicted to be related, and those that have been empirically identified.
172-1	33030-33032	As	_
172-2	33033-33037	with	_
172-3	33038-33043	other	_
172-4	33044-33048	gene	_
172-5	33049-33053	sets	_
172-6	33054-33057	and	_
172-7	33058-33066	putative	_
172-8	33067-33077	biological	_
172-9	33078-33086	pathways	_
172-10	33086-33087	,	_
172-11	33088-33101	discrepancies	_
172-12	33102-33107	exist	_
172-13	33108-33115	between	_
172-14	33116-33121	genes	_
172-15	33122-33126	that	_
172-16	33127-33130	are	_
172-17	33131-33148	bioinformatically	_
172-18	33149-33158	predicted	_
172-19	33159-33161	to	_
172-20	33162-33164	be	_
172-21	33165-33172	related	_
172-22	33172-33173	,	_
172-23	33174-33177	and	_
172-24	33178-33183	those	_
172-25	33184-33188	that	_
172-26	33189-33193	have	_
172-27	33194-33198	been	_
172-28	33199-33210	empirically	_
172-29	33211-33221	identified	_
172-30	33221-33222	.	_

#Text=For the MIR137 polygene scores generated here, we included only empirically derived genes.
173-1	33223-33226	For	_
173-2	33227-33230	the	_
173-3	33231-33237	MIR137	_
173-4	33238-33246	polygene	_
173-5	33247-33253	scores	_
173-6	33254-33263	generated	_
173-7	33264-33268	here	_
173-8	33268-33269	,	_
173-9	33270-33272	we	_
173-10	33273-33281	included	_
173-11	33282-33286	only	_
173-12	33287-33298	empirically	_
173-13	33299-33306	derived	_
173-14	33307-33312	genes	_
173-15	33312-33313	.	_

#Text=Gene expression changes in this study were found to significantly correlate with those following miR-137 manipulation in another human neural progenitor cell line in the subsequent study.
174-1	33314-33318	Gene	_
174-2	33319-33329	expression	_
174-3	33330-33337	changes	_
174-4	33338-33340	in	_
174-5	33341-33345	this	_
174-6	33346-33351	study	_
174-7	33352-33356	were	_
174-8	33357-33362	found	_
174-9	33363-33365	to	_
174-10	33366-33379	significantly	_
174-11	33380-33389	correlate	_
174-12	33390-33394	with	_
174-13	33395-33400	those	_
174-14	33401-33410	following	_
174-15	33411-33414	miR	_
174-16	33414-33415	-	_
174-17	33415-33418	137	_
174-18	33419-33431	manipulation	_
174-19	33432-33434	in	_
174-20	33435-33442	another	_
174-21	33443-33448	human	_
174-22	33449-33455	neural	_
174-23	33456-33466	progenitor	_
174-24	33467-33471	cell	_
174-25	33472-33476	line	_
174-26	33477-33479	in	_
174-27	33480-33483	the	_
174-28	33484-33494	subsequent	_
174-29	33495-33500	study	_
174-30	33500-33501	.	_

#Text=Several lines of evidence suggest that at least part of the risk for SZ conferred by genetic variation at the MIR137 locus is via effects of miR-137 perturbation on the expression of other SZ susceptibility genes.
175-1	33502-33509	Several	_
175-2	33510-33515	lines	_
175-3	33516-33518	of	_
175-4	33519-33527	evidence	_
175-5	33528-33535	suggest	_
175-6	33536-33540	that	_
175-7	33541-33543	at	_
175-8	33544-33549	least	_
175-9	33550-33554	part	_
175-10	33555-33557	of	_
175-11	33558-33561	the	_
175-12	33562-33566	risk	_
175-13	33567-33570	for	_
175-14	33571-33573	SZ	_
175-15	33574-33583	conferred	_
175-16	33584-33586	by	_
175-17	33587-33594	genetic	_
175-18	33595-33604	variation	_
175-19	33605-33607	at	_
175-20	33608-33611	the	_
175-21	33612-33618	MIR137	_
175-22	33619-33624	locus	_
175-23	33625-33627	is	_
175-24	33628-33631	via	_
175-25	33632-33639	effects	_
175-26	33640-33642	of	_
175-27	33643-33646	miR	_
175-28	33646-33647	-	_
175-29	33647-33650	137	_
175-30	33651-33663	perturbation	_
175-31	33664-33666	on	_
175-32	33667-33670	the	_
175-33	33671-33681	expression	_
175-34	33682-33684	of	_
175-35	33685-33690	other	_
175-36	33691-33693	SZ	_
175-37	33694-33708	susceptibility	_
175-38	33709-33714	genes	_
175-39	33714-33715	.	_

#Text=Thus, variants within this empirically derived miR-137 regulated gene score that contribute to SZ polygenic risk may be hypothesized to impact upon cognitive function that is a central feature of the disorder.
176-1	33716-33720	Thus	_
176-2	33720-33721	,	_
176-3	33722-33730	variants	_
176-4	33731-33737	within	_
176-5	33738-33742	this	_
176-6	33743-33754	empirically	_
176-7	33755-33762	derived	_
176-8	33763-33766	miR	_
176-9	33766-33767	-	_
176-10	33767-33770	137	_
176-11	33771-33780	regulated	_
176-12	33781-33785	gene	_
176-13	33786-33791	score	_
176-14	33792-33796	that	_
176-15	33797-33807	contribute	_
176-16	33808-33810	to	_
176-17	33811-33813	SZ	_
176-18	33814-33823	polygenic	_
176-19	33824-33828	risk	_
176-20	33829-33832	may	_
176-21	33833-33835	be	_
176-22	33836-33848	hypothesized	_
176-23	33849-33851	to	_
176-24	33852-33858	impact	_
176-25	33859-33863	upon	_
176-26	33864-33873	cognitive	_
176-27	33874-33882	function	_
176-28	33883-33887	that	_
176-29	33888-33890	is	_
176-30	33891-33892	a	_
176-31	33893-33900	central	_
176-32	33901-33908	feature	_
176-33	33909-33911	of	_
176-34	33912-33915	the	_
176-35	33916-33924	disorder	_
176-36	33924-33925	.	_

#Text=This study, by charactering the cumulative polygenic effects of these downstream risk variants while excluding the effects of risk variants with the miR-137 gene itself supports this hypothesis, both at a cognitive and at a cortical level.
177-1	33926-33930	This	_
177-2	33931-33936	study	_
177-3	33936-33937	,	_
177-4	33938-33940	by	_
177-5	33941-33953	charactering	_
177-6	33954-33957	the	_
177-7	33958-33968	cumulative	_
177-8	33969-33978	polygenic	_
177-9	33979-33986	effects	_
177-10	33987-33989	of	_
177-11	33990-33995	these	_
177-12	33996-34006	downstream	_
177-13	34007-34011	risk	_
177-14	34012-34020	variants	_
177-15	34021-34026	while	_
177-16	34027-34036	excluding	_
177-17	34037-34040	the	_
177-18	34041-34048	effects	_
177-19	34049-34051	of	_
177-20	34052-34056	risk	_
177-21	34057-34065	variants	_
177-22	34066-34070	with	_
177-23	34071-34074	the	_
177-24	34075-34078	miR	_
177-25	34078-34079	-	_
177-26	34079-34082	137	_
177-27	34083-34087	gene	_
177-28	34088-34094	itself	_
177-29	34095-34103	supports	_
177-30	34104-34108	this	_
177-31	34109-34119	hypothesis	_
177-32	34119-34120	,	_
177-33	34121-34125	both	_
177-34	34126-34128	at	_
177-35	34129-34130	a	_
177-36	34131-34140	cognitive	_
177-37	34141-34144	and	_
177-38	34145-34147	at	_
177-39	34148-34149	a	_
177-40	34150-34158	cortical	_
177-41	34159-34164	level	_
177-42	34164-34165	.	_

#Text=Functional studies indicate that miR-137 is involved in proliferation, migration and maturation of neural cells, likely to be the mechanisms behind this involvement with the cognitive process.
178-1	34166-34176	Functional	_
178-2	34177-34184	studies	_
178-3	34185-34193	indicate	_
178-4	34194-34198	that	_
178-5	34199-34202	miR	_
178-6	34202-34203	-	_
178-7	34203-34206	137	_
178-8	34207-34209	is	_
178-9	34210-34218	involved	_
178-10	34219-34221	in	_
178-11	34222-34235	proliferation	_
178-12	34235-34236	,	_
178-13	34237-34246	migration	_
178-14	34247-34250	and	_
178-15	34251-34261	maturation	_
178-16	34262-34264	of	_
178-17	34265-34271	neural	_
178-18	34272-34277	cells	_
178-19	34277-34278	,	_
178-20	34279-34285	likely	_
178-21	34286-34288	to	_
178-22	34289-34291	be	_
178-23	34292-34295	the	_
178-24	34296-34306	mechanisms	_
178-25	34307-34313	behind	_
178-26	34314-34318	this	_
178-27	34319-34330	involvement	_
178-28	34331-34335	with	_
178-29	34336-34339	the	_
178-30	34340-34349	cognitive	_
178-31	34350-34357	process	_
178-32	34357-34358	.	_

#Text=Further studies of the effects of MIR137 polygene scores may benefit from adopting a more fine-grained approach to the selection of SNPs.
179-1	34359-34366	Further	_
179-2	34367-34374	studies	_
179-3	34375-34377	of	_
179-4	34378-34381	the	_
179-5	34382-34389	effects	_
179-6	34390-34392	of	_
179-7	34393-34399	MIR137	_
179-8	34400-34408	polygene	_
179-9	34409-34415	scores	_
179-10	34416-34419	may	_
179-11	34420-34427	benefit	_
179-12	34428-34432	from	_
179-13	34433-34441	adopting	_
179-14	34442-34443	a	_
179-15	34444-34448	more	_
179-16	34449-34461	fine-grained	_
179-17	34462-34470	approach	_
179-18	34471-34473	to	_
179-19	34474-34477	the	_
179-20	34478-34487	selection	_
179-21	34488-34490	of	_
179-22	34491-34495	SNPs	_
179-23	34495-34496	.	_

#Text=This could include parsing the effects on cognition of those variants in this network that are directly versus indirectly influenced by MIR137, given that both are likely to have been included in the gene set.
180-1	34497-34501	This	_
180-2	34502-34507	could	_
180-3	34508-34515	include	_
180-4	34516-34523	parsing	_
180-5	34524-34527	the	_
180-6	34528-34535	effects	_
180-7	34536-34538	on	_
180-8	34539-34548	cognition	_
180-9	34549-34551	of	_
180-10	34552-34557	those	_
180-11	34558-34566	variants	_
180-12	34567-34569	in	_
180-13	34570-34574	this	_
180-14	34575-34582	network	_
180-15	34583-34587	that	_
180-16	34588-34591	are	_
180-17	34592-34600	directly	_
180-18	34601-34607	versus	_
180-19	34608-34618	indirectly	_
180-20	34619-34629	influenced	_
180-21	34630-34632	by	_
180-22	34633-34639	MIR137	_
180-23	34639-34640	,	_
180-24	34641-34646	given	_
180-25	34647-34651	that	_
180-26	34652-34656	both	_
180-27	34657-34660	are	_
180-28	34661-34667	likely	_
180-29	34668-34670	to	_
180-30	34671-34675	have	_
180-31	34676-34680	been	_
180-32	34681-34689	included	_
180-33	34690-34692	in	_
180-34	34693-34696	the	_
180-35	34697-34701	gene	_
180-36	34702-34705	set	_
180-37	34705-34706	.	_

#Text=This was not possible in this study as the method of gene selection could not differentiate between direct and indirect interactors of MIR137.
181-1	34707-34711	This	_
181-2	34712-34715	was	_
181-3	34716-34719	not	_
181-4	34720-34728	possible	_
181-5	34729-34731	in	_
181-6	34732-34736	this	_
181-7	34737-34742	study	_
181-8	34743-34745	as	_
181-9	34746-34749	the	_
181-10	34750-34756	method	_
181-11	34757-34759	of	_
181-12	34760-34764	gene	_
181-13	34765-34774	selection	_
181-14	34775-34780	could	_
181-15	34781-34784	not	_
181-16	34785-34798	differentiate	_
181-17	34799-34806	between	_
181-18	34807-34813	direct	_
181-19	34814-34817	and	_
181-20	34818-34826	indirect	_
181-21	34827-34838	interactors	_
181-22	34839-34841	of	_
181-23	34842-34848	MIR137	_
181-24	34848-34849	.	_

#Text=In conclusion, these data suggest that increased polygenic risk in a gene set consisting of downstream targets of miR-137 was associated with decreased cognitive performance, both in terms of memory function, and for general cognitive ability.
182-1	34850-34852	In	_
182-2	34853-34863	conclusion	_
182-3	34863-34864	,	_
182-4	34865-34870	these	_
182-5	34871-34875	data	_
182-6	34876-34883	suggest	_
182-7	34884-34888	that	_
182-8	34889-34898	increased	_
182-9	34899-34908	polygenic	_
182-10	34909-34913	risk	_
182-11	34914-34916	in	_
182-12	34917-34918	a	_
182-13	34919-34923	gene	_
182-14	34924-34927	set	_
182-15	34928-34938	consisting	_
182-16	34939-34941	of	_
182-17	34942-34952	downstream	_
182-18	34953-34960	targets	_
182-19	34961-34963	of	_
182-20	34964-34967	miR	_
182-21	34967-34968	-	_
182-22	34968-34971	137	_
182-23	34972-34975	was	_
182-24	34976-34986	associated	_
182-25	34987-34991	with	_
182-26	34992-35001	decreased	_
182-27	35002-35011	cognitive	_
182-28	35012-35023	performance	_
182-29	35023-35024	,	_
182-30	35025-35029	both	_
182-31	35030-35032	in	_
182-32	35033-35038	terms	_
182-33	35039-35041	of	_
182-34	35042-35048	memory	_
182-35	35049-35057	function	_
182-36	35057-35058	,	_
182-37	35059-35062	and	_
182-38	35063-35066	for	_
182-39	35067-35074	general	_
182-40	35075-35084	cognitive	_
182-41	35085-35092	ability	_
182-42	35092-35093	.	_

#Text=Notably, the strength of association was stronger for the gene set as a whole than for the most strongly associated MIR137 SNP.
183-1	35094-35101	Notably	_
183-2	35101-35102	,	_
183-3	35103-35106	the	_
183-4	35107-35115	strength	_
183-5	35116-35118	of	_
183-6	35119-35130	association	_
183-7	35131-35134	was	_
183-8	35135-35143	stronger	_
183-9	35144-35147	for	_
183-10	35148-35151	the	_
183-11	35152-35156	gene	_
183-12	35157-35160	set	_
183-13	35161-35163	as	_
183-14	35164-35165	a	_
183-15	35166-35171	whole	_
183-16	35172-35176	than	_
183-17	35177-35180	for	_
183-18	35181-35184	the	_
183-19	35185-35189	most	_
183-20	35190-35198	strongly	_
183-21	35199-35209	associated	_
183-22	35210-35216	MIR137	_
183-23	35217-35220	SNP	_
183-24	35220-35221	.	_

#Text=These data are consistent with emerging evidence that at least some of the genetic risk for SZ conferred by MIR137 variation relates to its downstream effects on gene expression.
184-1	35222-35227	These	_
184-2	35228-35232	data	_
184-3	35233-35236	are	_
184-4	35237-35247	consistent	_
184-5	35248-35252	with	_
184-6	35253-35261	emerging	_
184-7	35262-35270	evidence	_
184-8	35271-35275	that	_
184-9	35276-35278	at	_
184-10	35279-35284	least	_
184-11	35285-35289	some	_
184-12	35290-35292	of	_
184-13	35293-35296	the	_
184-14	35297-35304	genetic	_
184-15	35305-35309	risk	_
184-16	35310-35313	for	_
184-17	35314-35316	SZ	_
184-18	35317-35326	conferred	_
184-19	35327-35329	by	_
184-20	35330-35336	MIR137	_
184-21	35337-35346	variation	_
184-22	35347-35354	relates	_
184-23	35355-35357	to	_
184-24	35358-35361	its	_
184-25	35362-35372	downstream	_
184-26	35373-35380	effects	_
184-27	35381-35383	on	_
184-28	35384-35388	gene	_
184-29	35389-35399	expression	_
184-30	35399-35400	.	_

#Text=Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)
#Text=The authors declare no conflict of interest.
185-1	35401-35414	Supplementary	_
185-2	35415-35426	Information	_
185-3	35427-35438	accompanies	_
185-4	35439-35442	the	_
185-5	35443-35448	paper	_
185-6	35449-35451	on	_
185-7	35452-35455	the	_
185-8	35456-35469	Translational	_
185-9	35470-35480	Psychiatry	_
185-10	35481-35488	website	_
185-11	35489-35490	(	_
185-12	35490-35494	http	_
185-13	35494-35495	:	_
185-14	35495-35496	/	_
185-15	35496-35497	/	_
185-16	35497-35511	www.nature.com	_
185-17	35511-35512	/	_
185-18	35512-35514	tp	_
185-19	35514-35515	)	_
185-20	35516-35519	The	_
185-21	35520-35527	authors	_
185-22	35528-35535	declare	_
185-23	35536-35538	no	_
185-24	35539-35547	conflict	_
185-25	35548-35550	of	_
185-26	35551-35559	interest	_
185-27	35559-35560	.	_

#Text=Biological insights from 108 schizophrenia-associated genetic loci
#Text=Ensembl 2015
#Text=Genome-wide association study identifies five new schizophrenia loci
#Text=HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants
#Text=Genome-wide association analysis identifies 13 new risk loci for schizophrenia
#Text=MicroRNA miR-137 regulates neuronal maturation by targeting ubiquitin ligase mind bomb-1
#Text=MicroRNA loss enhances learning and memory in mice
#Text=Chromosome 1p21.3 microdeletions comprising DPYD and MIR137 are associated with intellectual disability
#Text=Mood congruent psychotic symptoms and specific cognitive deficits in carriers of the novel schizophrenia risk variant at MIR-137
#Text=Effects of MIR137 on fronto-amygdala functional connectivity
#Text=The impact of genome wide supported microRNA‐137 (MIR137) risk variants on frontal and striatal white matter integrity, neurocognitive functioning, and negative symptoms in schizophrenia
#Text=The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia
#Text=No effect of schizophrenia risk genes MIR137, TCF4, and ZNF804A on macroscopic brain structure
#Text=Genome-wide schizophrenia variant at MIR137 does not impact white matter microstructure in healthy participants
#Text=Transcriptional consequences of schizophrenia candidate miR-137 manipulation in human neural progenitor cells
#Text=miR-137: a new player in schizophrenia
#Text=Experimental validation of candidate schizophrenia gene ZNF804A as target for hsa-miR-137
#Text=Potential impact of miR-137 and its targets in schizophrenia
#Text=MIR137 gene and target gene CACNA1C of miR-137 contribute to schizophrenia susceptibility in Han Chinese
#Text=Validation of schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 as miR-137 targets
#Text=Transcriptional targets of the schizophrenia risk gene MIR137
#Text=Variability in working memory performance explained by epistasis vs polygenic scores in the ZNF804A pathway
#Text=Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia
#Text=Variance in facial recognition performance associated with BDNF in schizophrenia
#Text=The effects of CACNA1C gene polymorphism on spatial working memory in both healthy controls and patients with schizophrenia or bipolar disorder
#Text=The miR-137 schizophrenia susceptibility variant rs1625579 does not predict variability in brain volume in a sample of schizophrenic patients and healthy individuals
#Text=
#Text=
#Text=
#Text=Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers
#Text=The Continuous Performance Test, identical pairs version (CPT-IP): I.
186-1	35561-35571	Biological	_
186-2	35572-35580	insights	_
186-3	35581-35585	from	_
186-4	35586-35589	108	_
186-5	35590-35614	schizophrenia-associated	_
186-6	35615-35622	genetic	_
186-7	35623-35627	loci	_
186-8	35628-35635	Ensembl	_
186-9	35636-35640	2015	_
186-10	35641-35652	Genome-wide	_
186-11	35653-35664	association	_
186-12	35665-35670	study	_
186-13	35671-35681	identifies	_
186-14	35682-35686	five	_
186-15	35687-35690	new	_
186-16	35691-35704	schizophrenia	_
186-17	35705-35709	loci	_
186-18	35710-35718	HaploReg	_
186-19	35718-35719	:	_
186-20	35720-35721	a	_
186-21	35722-35730	resource	_
186-22	35731-35734	for	_
186-23	35735-35744	exploring	_
186-24	35745-35754	chromatin	_
186-25	35755-35761	states	_
186-26	35761-35762	,	_
186-27	35763-35775	conservation	_
186-28	35775-35776	,	_
186-29	35777-35780	and	_
186-30	35781-35791	regulatory	_
186-31	35792-35797	motif	_
186-32	35798-35809	alterations	_
186-33	35810-35816	within	_
186-34	35817-35821	sets	_
186-35	35822-35824	of	_
186-36	35825-35836	genetically	_
186-37	35837-35843	linked	_
186-38	35844-35852	variants	_
186-39	35853-35864	Genome-wide	_
186-40	35865-35876	association	_
186-41	35877-35885	analysis	_
186-42	35886-35896	identifies	_
186-43	35897-35899	13	_
186-44	35900-35903	new	_
186-45	35904-35908	risk	_
186-46	35909-35913	loci	_
186-47	35914-35917	for	_
186-48	35918-35931	schizophrenia	_
186-49	35932-35940	MicroRNA	_
186-50	35941-35944	miR	_
186-51	35944-35945	-	_
186-52	35945-35948	137	_
186-53	35949-35958	regulates	_
186-54	35959-35967	neuronal	_
186-55	35968-35978	maturation	_
186-56	35979-35981	by	_
186-57	35982-35991	targeting	_
186-58	35992-36001	ubiquitin	_
186-59	36002-36008	ligase	_
186-60	36009-36013	mind	_
186-61	36014-36018	bomb	_
186-62	36018-36019	-	_
186-63	36019-36020	1	_
186-64	36021-36029	MicroRNA	_
186-65	36030-36034	loss	_
186-66	36035-36043	enhances	_
186-67	36044-36052	learning	_
186-68	36053-36056	and	_
186-69	36057-36063	memory	_
186-70	36064-36066	in	_
186-71	36067-36071	mice	_
186-72	36072-36082	Chromosome	_
186-73	36083-36089	1p21.3	_
186-74	36090-36104	microdeletions	_
186-75	36105-36115	comprising	_
186-76	36116-36120	DPYD	_
186-77	36121-36124	and	_
186-78	36125-36131	MIR137	_
186-79	36132-36135	are	_
186-80	36136-36146	associated	_
186-81	36147-36151	with	_
186-82	36152-36164	intellectual	_
186-83	36165-36175	disability	_
186-84	36176-36180	Mood	_
186-85	36181-36190	congruent	_
186-86	36191-36200	psychotic	_
186-87	36201-36209	symptoms	_
186-88	36210-36213	and	_
186-89	36214-36222	specific	_
186-90	36223-36232	cognitive	_
186-91	36233-36241	deficits	_
186-92	36242-36244	in	_
186-93	36245-36253	carriers	_
186-94	36254-36256	of	_
186-95	36257-36260	the	_
186-96	36261-36266	novel	_
186-97	36267-36280	schizophrenia	_
186-98	36281-36285	risk	_
186-99	36286-36293	variant	_
186-100	36294-36296	at	_
186-101	36297-36300	MIR	_
186-102	36300-36301	-	_
186-103	36301-36304	137	_
186-104	36305-36312	Effects	_
186-105	36313-36315	of	_
186-106	36316-36322	MIR137	_
186-107	36323-36325	on	_
186-108	36326-36341	fronto-amygdala	_
186-109	36342-36352	functional	_
186-110	36353-36365	connectivity	_
186-111	36366-36369	The	_
186-112	36370-36376	impact	_
186-113	36377-36379	of	_
186-114	36380-36386	genome	_
186-115	36387-36391	wide	_
186-116	36392-36401	supported	_
186-117	36402-36410	microRNA	_
186-118	36410-36411	‐	_
186-119	36411-36414	137	_
186-120	36415-36416	(	_
186-121	36416-36422	MIR137	_
186-122	36422-36423	)	_
186-123	36424-36428	risk	_
186-124	36429-36437	variants	_
186-125	36438-36440	on	_
186-126	36441-36448	frontal	_
186-127	36449-36452	and	_
186-128	36453-36461	striatal	_
186-129	36462-36467	white	_
186-130	36468-36474	matter	_
186-131	36475-36484	integrity	_
186-132	36484-36485	,	_
186-133	36486-36500	neurocognitive	_
186-134	36501-36512	functioning	_
186-135	36512-36513	,	_
186-136	36514-36517	and	_
186-137	36518-36526	negative	_
186-138	36527-36535	symptoms	_
186-139	36536-36538	in	_
186-140	36539-36552	schizophrenia	_
186-141	36553-36556	The	_
186-142	36557-36568	genome-wide	_
186-143	36569-36578	supported	_
186-144	36579-36587	microRNA	_
186-145	36587-36588	-	_
186-146	36588-36591	137	_
186-147	36592-36599	variant	_
186-148	36600-36608	predicts	_
186-149	36609-36619	phenotypic	_
186-150	36620-36633	heterogeneity	_
186-151	36634-36640	within	_
186-152	36641-36654	schizophrenia	_
186-153	36655-36657	No	_
186-154	36658-36664	effect	_
186-155	36665-36667	of	_
186-156	36668-36681	schizophrenia	_
186-157	36682-36686	risk	_
186-158	36687-36692	genes	_
186-159	36693-36699	MIR137	_
186-160	36699-36700	,	_
186-161	36701-36705	TCF4	_
186-162	36705-36706	,	_
186-163	36707-36710	and	_
186-164	36711-36718	ZNF804A	_
186-165	36719-36721	on	_
186-166	36722-36733	macroscopic	_
186-167	36734-36739	brain	_
186-168	36740-36749	structure	_
186-169	36750-36761	Genome-wide	_
186-170	36762-36775	schizophrenia	_
186-171	36776-36783	variant	_
186-172	36784-36786	at	_
186-173	36787-36793	MIR137	_
186-174	36794-36798	does	_
186-175	36799-36802	not	_
186-176	36803-36809	impact	_
186-177	36810-36815	white	_
186-178	36816-36822	matter	_
186-179	36823-36837	microstructure	_
186-180	36838-36840	in	_
186-181	36841-36848	healthy	_
186-182	36849-36861	participants	_
186-183	36862-36877	Transcriptional	_
186-184	36878-36890	consequences	_
186-185	36891-36893	of	_
186-186	36894-36907	schizophrenia	_
186-187	36908-36917	candidate	_
186-188	36918-36921	miR	_
186-189	36921-36922	-	_
186-190	36922-36925	137	_
186-191	36926-36938	manipulation	_
186-192	36939-36941	in	_
186-193	36942-36947	human	_
186-194	36948-36954	neural	_
186-195	36955-36965	progenitor	_
186-196	36966-36971	cells	_
186-197	36972-36975	miR	_
186-198	36975-36976	-	_
186-199	36976-36979	137	_
186-200	36979-36980	:	_
186-201	36981-36982	a	_
186-202	36983-36986	new	_
186-203	36987-36993	player	_
186-204	36994-36996	in	_
186-205	36997-37010	schizophrenia	_
186-206	37011-37023	Experimental	_
186-207	37024-37034	validation	_
186-208	37035-37037	of	_
186-209	37038-37047	candidate	_
186-210	37048-37061	schizophrenia	_
186-211	37062-37066	gene	_
186-212	37067-37074	ZNF804A	_
186-213	37075-37077	as	_
186-214	37078-37084	target	_
186-215	37085-37088	for	_
186-216	37089-37096	hsa-miR	_
186-217	37096-37097	-	_
186-218	37097-37100	137	_
186-219	37101-37110	Potential	_
186-220	37111-37117	impact	_
186-221	37118-37120	of	_
186-222	37121-37124	miR	_
186-223	37124-37125	-	_
186-224	37125-37128	137	_
186-225	37129-37132	and	_
186-226	37133-37136	its	_
186-227	37137-37144	targets	_
186-228	37145-37147	in	_
186-229	37148-37161	schizophrenia	_
186-230	37162-37168	MIR137	_
186-231	37169-37173	gene	_
186-232	37174-37177	and	_
186-233	37178-37184	target	_
186-234	37185-37189	gene	_
186-235	37190-37197	CACNA1C	_
186-236	37198-37200	of	_
186-237	37201-37204	miR	_
186-238	37204-37205	-	_
186-239	37205-37208	137	_
186-240	37209-37219	contribute	_
186-241	37220-37222	to	_
186-242	37223-37236	schizophrenia	_
186-243	37237-37251	susceptibility	_
186-244	37252-37254	in	_
186-245	37255-37258	Han	_
186-246	37259-37266	Chinese	_
186-247	37267-37277	Validation	_
186-248	37278-37280	of	_
186-249	37281-37305	schizophrenia-associated	_
186-250	37306-37311	genes	_
186-251	37312-37317	CSMD1	_
186-252	37317-37318	,	_
186-253	37319-37327	C10orf26	_
186-254	37327-37328	,	_
186-255	37329-37336	CACNA1C	_
186-256	37337-37340	and	_
186-257	37341-37345	TCF4	_
186-258	37346-37348	as	_
186-259	37349-37352	miR	_
186-260	37352-37353	-	_
186-261	37353-37356	137	_
186-262	37357-37364	targets	_
186-263	37365-37380	Transcriptional	_
186-264	37381-37388	targets	_
186-265	37389-37391	of	_
186-266	37392-37395	the	_
186-267	37396-37409	schizophrenia	_
186-268	37410-37414	risk	_
186-269	37415-37419	gene	_
186-270	37420-37426	MIR137	_
186-271	37427-37438	Variability	_
186-272	37439-37441	in	_
186-273	37442-37449	working	_
186-274	37450-37456	memory	_
186-275	37457-37468	performance	_
186-276	37469-37478	explained	_
186-277	37479-37481	by	_
186-278	37482-37491	epistasis	_
186-279	37492-37494	vs	_
186-280	37495-37504	polygenic	_
186-281	37505-37511	scores	_
186-282	37512-37514	in	_
186-283	37515-37518	the	_
186-284	37519-37526	ZNF804A	_
186-285	37527-37534	pathway	_
186-286	37535-37544	Psychosis	_
186-287	37545-37559	susceptibility	_
186-288	37560-37564	gene	_
186-289	37565-37572	ZNF804A	_
186-290	37573-37576	and	_
186-291	37577-37586	cognitive	_
186-292	37587-37598	performance	_
186-293	37599-37601	in	_
186-294	37602-37615	schizophrenia	_
186-295	37616-37624	Variance	_
186-296	37625-37627	in	_
186-297	37628-37634	facial	_
186-298	37635-37646	recognition	_
186-299	37647-37658	performance	_
186-300	37659-37669	associated	_
186-301	37670-37674	with	_
186-302	37675-37679	BDNF	_
186-303	37680-37682	in	_
186-304	37683-37696	schizophrenia	_
186-305	37697-37700	The	_
186-306	37701-37708	effects	_
186-307	37709-37711	of	_
186-308	37712-37719	CACNA1C	_
186-309	37720-37724	gene	_
186-310	37725-37737	polymorphism	_
186-311	37738-37740	on	_
186-312	37741-37748	spatial	_
186-313	37749-37756	working	_
186-314	37757-37763	memory	_
186-315	37764-37766	in	_
186-316	37767-37771	both	_
186-317	37772-37779	healthy	_
186-318	37780-37788	controls	_
186-319	37789-37792	and	_
186-320	37793-37801	patients	_
186-321	37802-37806	with	_
186-322	37807-37820	schizophrenia	_
186-323	37821-37823	or	_
186-324	37824-37831	bipolar	_
186-325	37832-37840	disorder	_
186-326	37841-37844	The	_
186-327	37845-37848	miR	_
186-328	37848-37849	-	_
186-329	37849-37852	137	_
186-330	37853-37866	schizophrenia	_
186-331	37867-37881	susceptibility	_
186-332	37882-37889	variant	_
186-333	37890-37899	rs1625579	_
186-334	37900-37904	does	_
186-335	37905-37908	not	_
186-336	37909-37916	predict	_
186-337	37917-37928	variability	_
186-338	37929-37931	in	_
186-339	37932-37937	brain	_
186-340	37938-37944	volume	_
186-341	37945-37947	in	_
186-342	37948-37949	a	_
186-343	37950-37956	sample	_
186-344	37957-37959	of	_
186-345	37960-37973	schizophrenic	_
186-346	37974-37982	patients	_
186-347	37983-37986	and	_
186-348	37987-37994	healthy	_
186-349	37995-38006	individuals	_
186-350	38010-38019	Cambridge	_
186-351	38020-38038	Neuropsychological	_
186-352	38039-38043	Test	_
186-353	38044-38053	Automated	_
186-354	38054-38061	Battery	_
186-355	38062-38063	(	_
186-356	38063-38069	CANTAB	_
186-357	38069-38070	)	_
186-358	38070-38071	:	_
186-359	38072-38073	a	_
186-360	38074-38080	factor	_
186-361	38081-38089	analytic	_
186-362	38090-38095	study	_
186-363	38096-38098	of	_
186-364	38099-38100	a	_
186-365	38101-38106	large	_
186-366	38107-38113	sample	_
186-367	38114-38116	of	_
186-368	38117-38123	normal	_
186-369	38124-38131	elderly	_
186-370	38132-38142	volunteers	_
186-371	38143-38146	The	_
186-372	38147-38157	Continuous	_
186-373	38158-38169	Performance	_
186-374	38170-38174	Test	_
186-375	38174-38175	,	_
186-376	38176-38185	identical	_
186-377	38186-38191	pairs	_
186-378	38192-38199	version	_
186-379	38200-38201	(	_
186-380	38201-38207	CPT-IP	_
186-381	38207-38208	)	_
186-382	38208-38209	:	_
186-383	38210-38211	I	_
186-384	38211-38212	.	_

#Text=New findings about sustained attention in normal families
#Text=Oops!'
187-1	38213-38216	New	_
187-2	38217-38225	findings	_
187-3	38226-38231	about	_
187-4	38232-38241	sustained	_
187-5	38242-38251	attention	_
187-6	38252-38254	in	_
187-7	38255-38261	normal	_
187-8	38262-38270	families	_
187-9	38271-38275	Oops	_
187-10	38275-38276	!	_
187-11	38276-38277	'	_

#Text=: performance correlates of everyday attentional failures in traumatic brain injured and normal subjects
#Text=Altered medial prefrontal activity during dynamic face processing in schizophrenia spectrum patients
#Text=The “Reading the Mind in the Eyes” test revised version: A study with normal adults, and adults with Asperger syndrome or high‐functioning autism
#Text=Schizophrenia, symptomatology and social inference: investigating "theory of mind" in people with schizophrenia
#Text=A new measure of causal locus: the internal, personal and situational attributions questionnaire
#Text=Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia
#Text=Fine-tuning some resistant rules for outlier labeling
#Text=
#Text=
#Text=Statistical power analyses using G* Power 3.1: Tests for correlation and regression analyses
#Text=The abuse of power
#Text=The NOS1 variant rs6490121 is associated with variation in prefrontal function and grey matter density in healthy individuals
#Text=The effect of the neurogranin schizophrenia risk variant rs12807809 on brain structure and function
#Text=Neural effects of the CSMD1 genome-wide associated schizophrenia risk variant rs10503253
#Text=Brain networks involved in viewing angry hands or faces
#Text=Assignment of functional activations to probabilistic cytoarchitectonic areas revisited
#Text=Testing anatomically specified hypotheses in functional imaging using cytoarchitectonic maps
#Text=A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data
#Text=The influence of polygenic risk for bipolar disorder on neural activation assessed using fMRI
#Text=The brain's default network: anatomy, function, and relevance to disease
#Text=Polymorphisms in MIR137HG and microRNA-137-regulated genes influence gray matter structure in schizophrenia
#Text=Meta gene set enrichment analyses link miR-137-regulated pathways with schizophrenia risk
#Text=Supplementary Material
#Text=Effect of increasing MIR137 pathway risk score (P=10−5 level) on neural activity during increasing spatial working memory load (3 dots versus 1 dot), 3 outliers removed (N=83; shown in red), shown alongside overall activation for this contrast in the same group (shown in blue).
188-1	38277-38278	:	_
188-2	38279-38290	performance	_
188-3	38291-38301	correlates	_
188-4	38302-38304	of	_
188-5	38305-38313	everyday	_
188-6	38314-38325	attentional	_
188-7	38326-38334	failures	_
188-8	38335-38337	in	_
188-9	38338-38347	traumatic	_
188-10	38348-38353	brain	_
188-11	38354-38361	injured	_
188-12	38362-38365	and	_
188-13	38366-38372	normal	_
188-14	38373-38381	subjects	_
188-15	38382-38389	Altered	_
188-16	38390-38396	medial	_
188-17	38397-38407	prefrontal	_
188-18	38408-38416	activity	_
188-19	38417-38423	during	_
188-20	38424-38431	dynamic	_
188-21	38432-38436	face	_
188-22	38437-38447	processing	_
188-23	38448-38450	in	_
188-24	38451-38464	schizophrenia	_
188-25	38465-38473	spectrum	_
188-26	38474-38482	patients	_
188-27	38483-38486	The	_
188-28	38487-38488	“	_
188-29	38488-38495	Reading	_
188-30	38496-38499	the	_
188-31	38500-38504	Mind	_
188-32	38505-38507	in	_
188-33	38508-38511	the	_
188-34	38512-38516	Eyes	_
188-35	38516-38517	”	_
188-36	38518-38522	test	_
188-37	38523-38530	revised	_
188-38	38531-38538	version	_
188-39	38538-38539	:	_
188-40	38540-38541	A	_
188-41	38542-38547	study	_
188-42	38548-38552	with	_
188-43	38553-38559	normal	_
188-44	38560-38566	adults	_
188-45	38566-38567	,	_
188-46	38568-38571	and	_
188-47	38572-38578	adults	_
188-48	38579-38583	with	_
188-49	38584-38592	Asperger	_
188-50	38593-38601	syndrome	_
188-51	38602-38604	or	_
188-52	38605-38621	high‐functioning	_
188-53	38622-38628	autism	_
188-54	38629-38642	Schizophrenia	_
188-55	38642-38643	,	_
188-56	38644-38658	symptomatology	_
188-57	38659-38662	and	_
188-58	38663-38669	social	_
188-59	38670-38679	inference	_
188-60	38679-38680	:	_
188-61	38681-38694	investigating	_
188-62	38695-38696	"	_
188-63	38696-38702	theory	_
188-64	38703-38705	of	_
188-65	38706-38710	mind	_
188-66	38710-38711	"	_
188-67	38712-38714	in	_
188-68	38715-38721	people	_
188-69	38722-38726	with	_
188-70	38727-38740	schizophrenia	_
188-71	38741-38742	A	_
188-72	38743-38746	new	_
188-73	38747-38754	measure	_
188-74	38755-38757	of	_
188-75	38758-38764	causal	_
188-76	38765-38770	locus	_
188-77	38770-38771	:	_
188-78	38772-38775	the	_
188-79	38776-38784	internal	_
188-80	38784-38785	,	_
188-81	38786-38794	personal	_
188-82	38795-38798	and	_
188-83	38799-38810	situational	_
188-84	38811-38823	attributions	_
188-85	38824-38837	questionnaire	_
188-86	38838-38849	Genome-wide	_
188-87	38850-38861	association	_
188-88	38862-38867	study	_
188-89	38868-38878	implicates	_
188-90	38879-38884	HLA-C	_
188-91	38884-38885	*	_
188-92	38885-38887	01	_
188-93	38887-38888	:	_
188-94	38888-38890	02	_
188-95	38891-38893	as	_
188-96	38894-38895	a	_
188-97	38896-38900	risk	_
188-98	38901-38907	factor	_
188-99	38908-38910	at	_
188-100	38911-38914	the	_
188-101	38915-38920	major	_
188-102	38921-38939	histocompatibility	_
188-103	38940-38947	complex	_
188-104	38948-38953	locus	_
188-105	38954-38956	in	_
188-106	38957-38970	schizophrenia	_
188-107	38971-38982	Fine-tuning	_
188-108	38983-38987	some	_
188-109	38988-38997	resistant	_
188-110	38998-39003	rules	_
188-111	39004-39007	for	_
188-112	39008-39015	outlier	_
188-113	39016-39024	labeling	_
188-114	39027-39038	Statistical	_
188-115	39039-39044	power	_
188-116	39045-39053	analyses	_
188-117	39054-39059	using	_
188-118	39060-39061	G	_
188-119	39061-39062	*	_
188-120	39063-39068	Power	_
188-121	39069-39072	3.1	_
188-122	39072-39073	:	_
188-123	39074-39079	Tests	_
188-124	39080-39083	for	_
188-125	39084-39095	correlation	_
188-126	39096-39099	and	_
188-127	39100-39110	regression	_
188-128	39111-39119	analyses	_
188-129	39120-39123	The	_
188-130	39124-39129	abuse	_
188-131	39130-39132	of	_
188-132	39133-39138	power	_
188-133	39139-39142	The	_
188-134	39143-39147	NOS1	_
188-135	39148-39155	variant	_
188-136	39156-39165	rs6490121	_
188-137	39166-39168	is	_
188-138	39169-39179	associated	_
188-139	39180-39184	with	_
188-140	39185-39194	variation	_
188-141	39195-39197	in	_
188-142	39198-39208	prefrontal	_
188-143	39209-39217	function	_
188-144	39218-39221	and	_
188-145	39222-39226	grey	_
188-146	39227-39233	matter	_
188-147	39234-39241	density	_
188-148	39242-39244	in	_
188-149	39245-39252	healthy	_
188-150	39253-39264	individuals	_
188-151	39265-39268	The	_
188-152	39269-39275	effect	_
188-153	39276-39278	of	_
188-154	39279-39282	the	_
188-155	39283-39294	neurogranin	_
188-156	39295-39308	schizophrenia	_
188-157	39309-39313	risk	_
188-158	39314-39321	variant	_
188-159	39322-39332	rs12807809	_
188-160	39333-39335	on	_
188-161	39336-39341	brain	_
188-162	39342-39351	structure	_
188-163	39352-39355	and	_
188-164	39356-39364	function	_
188-165	39365-39371	Neural	_
188-166	39372-39379	effects	_
188-167	39380-39382	of	_
188-168	39383-39386	the	_
188-169	39387-39392	CSMD1	_
188-170	39393-39404	genome-wide	_
188-171	39405-39415	associated	_
188-172	39416-39429	schizophrenia	_
188-173	39430-39434	risk	_
188-174	39435-39442	variant	_
188-175	39443-39453	rs10503253	_
188-176	39454-39459	Brain	_
188-177	39460-39468	networks	_
188-178	39469-39477	involved	_
188-179	39478-39480	in	_
188-180	39481-39488	viewing	_
188-181	39489-39494	angry	_
188-182	39495-39500	hands	_
188-183	39501-39503	or	_
188-184	39504-39509	faces	_
188-185	39510-39520	Assignment	_
188-186	39521-39523	of	_
188-187	39524-39534	functional	_
188-188	39535-39546	activations	_
188-189	39547-39549	to	_
188-190	39550-39563	probabilistic	_
188-191	39564-39581	cytoarchitectonic	_
188-192	39582-39587	areas	_
188-193	39588-39597	revisited	_
188-194	39598-39605	Testing	_
188-195	39606-39618	anatomically	_
188-196	39619-39628	specified	_
188-197	39629-39639	hypotheses	_
188-198	39640-39642	in	_
188-199	39643-39653	functional	_
188-200	39654-39661	imaging	_
188-201	39662-39667	using	_
188-202	39668-39685	cytoarchitectonic	_
188-203	39686-39690	maps	_
188-204	39691-39692	A	_
188-205	39693-39696	new	_
188-206	39697-39700	SPM	_
188-207	39701-39708	toolbox	_
188-208	39709-39712	for	_
188-209	39713-39722	combining	_
188-210	39723-39736	probabilistic	_
188-211	39737-39754	cytoarchitectonic	_
188-212	39755-39759	maps	_
188-213	39760-39763	and	_
188-214	39764-39774	functional	_
188-215	39775-39782	imaging	_
188-216	39783-39787	data	_
188-217	39788-39791	The	_
188-218	39792-39801	influence	_
188-219	39802-39804	of	_
188-220	39805-39814	polygenic	_
188-221	39815-39819	risk	_
188-222	39820-39823	for	_
188-223	39824-39831	bipolar	_
188-224	39832-39840	disorder	_
188-225	39841-39843	on	_
188-226	39844-39850	neural	_
188-227	39851-39861	activation	_
188-228	39862-39870	assessed	_
188-229	39871-39876	using	_
188-230	39877-39881	fMRI	_
188-231	39882-39885	The	_
188-232	39886-39893	brain's	_
188-233	39894-39901	default	_
188-234	39902-39909	network	_
188-235	39909-39910	:	_
188-236	39911-39918	anatomy	_
188-237	39918-39919	,	_
188-238	39920-39928	function	_
188-239	39928-39929	,	_
188-240	39930-39933	and	_
188-241	39934-39943	relevance	_
188-242	39944-39946	to	_
188-243	39947-39954	disease	_
188-244	39955-39968	Polymorphisms	_
188-245	39969-39971	in	_
188-246	39972-39980	MIR137HG	_
188-247	39981-39984	and	_
188-248	39985-39993	microRNA	_
188-249	39993-39994	-	_
188-250	39994-39997	137	_
188-251	39997-39998	-	_
188-252	39998-40007	regulated	_
188-253	40008-40013	genes	_
188-254	40014-40023	influence	_
188-255	40024-40028	gray	_
188-256	40029-40035	matter	_
188-257	40036-40045	structure	_
188-258	40046-40048	in	_
188-259	40049-40062	schizophrenia	_
188-260	40063-40067	Meta	_
188-261	40068-40072	gene	_
188-262	40073-40076	set	_
188-263	40077-40087	enrichment	_
188-264	40088-40096	analyses	_
188-265	40097-40101	link	_
188-266	40102-40105	miR	_
188-267	40105-40106	-	_
188-268	40106-40109	137	_
188-269	40109-40110	-	_
188-270	40110-40119	regulated	_
188-271	40120-40128	pathways	_
188-272	40129-40133	with	_
188-273	40134-40147	schizophrenia	_
188-274	40148-40152	risk	_
188-275	40153-40166	Supplementary	_
188-276	40167-40175	Material	_
188-277	40176-40182	Effect	_
188-278	40183-40185	of	_
188-279	40186-40196	increasing	_
188-280	40197-40203	MIR137	_
188-281	40204-40211	pathway	_
188-282	40212-40216	risk	_
188-283	40217-40222	score	_
188-284	40223-40224	(	_
188-285	40224-40225	P	_
188-286	40225-40226	=	_
188-287	40226-40228	10	_
188-288	40228-40229	−	_
188-289	40229-40230	5	_
188-290	40231-40236	level	_
188-291	40236-40237	)	_
188-292	40238-40240	on	_
188-293	40241-40247	neural	_
188-294	40248-40256	activity	_
188-295	40257-40263	during	_
188-296	40264-40274	increasing	_
188-297	40275-40282	spatial	_
188-298	40283-40290	working	_
188-299	40291-40297	memory	_
188-300	40298-40302	load	_
188-301	40303-40304	(	_
188-302	40304-40305	3	_
188-303	40306-40310	dots	_
188-304	40311-40317	versus	_
188-305	40318-40319	1	_
188-306	40320-40323	dot	_
188-307	40323-40324	)	_
188-308	40324-40325	,	_
188-309	40326-40327	3	_
188-310	40328-40336	outliers	_
188-311	40337-40344	removed	_
188-312	40345-40346	(	_
188-313	40346-40347	N	_
188-314	40347-40348	=	_
188-315	40348-40350	83	_
188-316	40350-40351	;	_
188-317	40352-40357	shown	_
188-318	40358-40360	in	_
188-319	40361-40364	red	_
188-320	40364-40365	)	_
188-321	40365-40366	,	_
188-322	40367-40372	shown	_
188-323	40373-40382	alongside	_
188-324	40383-40390	overall	_
188-325	40391-40401	activation	_
188-326	40402-40405	for	_
188-327	40406-40410	this	_
188-328	40411-40419	contrast	_
188-329	40420-40422	in	_
188-330	40423-40426	the	_
188-331	40427-40431	same	_
188-332	40432-40437	group	_
188-333	40438-40439	(	_
188-334	40439-40444	shown	_
188-335	40445-40447	in	_
188-336	40448-40452	blue	_
188-337	40452-40453	)	_
188-338	40453-40454	.	_

#Text=Cluster 1 (right inferior occipital gyrus and right middle temporal gyrus), top panels; Cluster 2 (medial parietal region) bottom panels.
189-1	40455-40462	Cluster	_
189-2	40463-40464	1	_
189-3	40465-40466	(	_
189-4	40466-40471	right	_
189-5	40472-40480	inferior	_
189-6	40481-40490	occipital	_
189-7	40491-40496	gyrus	_
189-8	40497-40500	and	_
189-9	40501-40506	right	_
189-10	40507-40513	middle	_
189-11	40514-40522	temporal	_
189-12	40523-40528	gyrus	_
189-13	40528-40529	)	_
189-14	40529-40530	,	_
189-15	40531-40534	top	_
189-16	40535-40541	panels	_
189-17	40541-40542	;	_
189-18	40543-40550	Cluster	_
189-19	40551-40552	2	_
189-20	40553-40554	(	_
189-21	40554-40560	medial	_
189-22	40561-40569	parietal	_
189-23	40570-40576	region	_
189-24	40576-40577	)	_
189-25	40578-40584	bottom	_
189-26	40585-40591	panels	_
189-27	40591-40592	.	_

#Text=Clusters are significant at P<0.05, FWE-corrected at the cluster level and represent regions where neural activity was greater with increasing risk score.
190-1	40593-40601	Clusters	_
190-2	40602-40605	are	_
190-3	40606-40617	significant	_
190-4	40618-40620	at	_
190-5	40621-40622	P	_
190-6	40622-40623	<	_
190-7	40623-40627	0.05	_
190-8	40627-40628	,	_
190-9	40629-40642	FWE-corrected	_
190-10	40643-40645	at	_
190-11	40646-40649	the	_
190-12	40650-40657	cluster	_
190-13	40658-40663	level	_
190-14	40664-40667	and	_
190-15	40668-40677	represent	_
190-16	40678-40685	regions	_
190-17	40686-40691	where	_
190-18	40692-40698	neural	_
190-19	40699-40707	activity	_
190-20	40708-40711	was	_
190-21	40712-40719	greater	_
190-22	40720-40724	with	_
190-23	40725-40735	increasing	_
190-24	40736-40740	risk	_
190-25	40741-40746	score	_
190-26	40746-40747	.	_

#Text=Each 2D axial slice is labeled with an x-coordinate (MNI space).
191-1	40748-40752	Each	_
191-2	40753-40755	2D	_
191-3	40756-40761	axial	_
191-4	40762-40767	slice	_
191-5	40768-40770	is	_
191-6	40771-40778	labeled	_
191-7	40779-40783	with	_
191-8	40784-40786	an	_
191-9	40787-40799	x-coordinate	_
191-10	40800-40801	(	_
191-11	40801-40804	MNI	_
191-12	40805-40810	space	_
191-13	40810-40811	)	_
191-14	40811-40812	.	_

#Text=Clusters are rendered on the ‘ch256’ brain template using MRIcroGL (http://www.mccauslandcenter.sc.edu/mricrogl/).
192-1	40813-40821	Clusters	_
192-2	40822-40825	are	_
192-3	40826-40834	rendered	_
192-4	40835-40837	on	_
192-5	40838-40841	the	_
192-6	40842-40843	‘	_
192-7	40843-40848	ch256	_
192-8	40848-40849	’	_
192-9	40850-40855	brain	_
192-10	40856-40864	template	_
192-11	40865-40870	using	_
192-12	40871-40879	MRIcroGL	_
192-13	40880-40881	(	_
192-14	40881-40885	http	_
192-15	40885-40886	:	_
192-16	40886-40887	/	_
192-17	40887-40888	/	_
192-18	40888-40915	www.mccauslandcenter.sc.edu	_
192-19	40915-40916	/	_
192-20	40916-40924	mricrogl	_
192-21	40924-40925	/	_
192-22	40925-40926	)	_
192-23	40926-40927	.	_

#Text=Additional editing of figure (for example, changing the size/resolution) performed using MS Paint and/or Paint.NET v3.5.10.
193-1	40928-40938	Additional	_
193-2	40939-40946	editing	_
193-3	40947-40949	of	_
193-4	40950-40956	figure	_
193-5	40957-40958	(	_
193-6	40958-40961	for	_
193-7	40962-40969	example	_
193-8	40969-40970	,	_
193-9	40971-40979	changing	_
193-10	40980-40983	the	_
193-11	40984-40988	size	_
193-12	40988-40989	/	_
193-13	40989-40999	resolution	_
193-14	40999-41000	)	_
193-15	41001-41010	performed	_
193-16	41011-41016	using	_
193-17	41017-41019	MS	_
193-18	41020-41025	Paint	_
193-19	41026-41029	and	_
193-20	41029-41030	/	_
193-21	41030-41032	or	_
193-22	41033-41042	Paint.NET	_
193-23	41043-41050	v3.5.10	_
193-24	41050-41051	.	_

#Text=FWE, family-wise error; MIR137, microRNA-137; MNI, Montreal Neurological Institute.
194-1	41052-41055	FWE	_
194-2	41055-41056	,	_
194-3	41057-41068	family-wise	_
194-4	41069-41074	error	_
194-5	41074-41075	;	_
194-6	41076-41082	MIR137	_
194-7	41082-41083	,	_
194-8	41084-41092	microRNA	_
194-9	41092-41093	-	_
194-10	41093-41096	137	_
194-11	41096-41097	;	_
194-12	41098-41101	MNI	_
194-13	41101-41102	,	_
194-14	41103-41111	Montreal	_
194-15	41112-41124	Neurological	_
194-16	41125-41134	Institute	_
194-17	41134-41135	.	_

#Text=Participant demographic and genotype information – neuropsychological test sample
#Text=Variable\tWhole sample\tBroad psychosis\tNarrow psychosis (SZ/SZA)\tHealthy participants\t \tN\t1000\t808\t585\t192\t \tAge, mean (s.d.)\t41.40±12.74\t42.88±12.46\t42.07±12.54\t35.20±12.04\t \tFemale sex, %\t37.7\t34.4\t29.9\t51.6\t \tWAIS FSIQ, mean (s.d.)\t99.03±22.21\t92.17±19.49\t90.34±18.38\t121.20±14.68\t \tCPZE, mean (s.d.)\t—\t445.81±467.35\t512.35±496.69\t—\t \trs1702294 genotype %, TT/TC/CC\t2.8/29.0/65.7\t2.5/29.9/67.5\t2.8/30.3/66.9\t4.2/28.9/66.8\t \t
#Text=Abbreviations: CPZE, chlorpromazine equivalent; FSIQ, full-scale IQ; IQ, intelligence quotient; SZ, schizophrenia; SZA, schizoaffective disorder; WAIS, Wechsler Adult Intelligence Scale.
195-1	41136-41147	Participant	_
195-2	41148-41159	demographic	_
195-3	41160-41163	and	_
195-4	41164-41172	genotype	_
195-5	41173-41184	information	_
195-6	41185-41186	–	_
195-7	41187-41205	neuropsychological	_
195-8	41206-41210	test	_
195-9	41211-41217	sample	_
195-10	41218-41226	Variable	_
195-11	41227-41232	Whole	_
195-12	41233-41239	sample	_
195-13	41240-41245	Broad	_
195-14	41246-41255	psychosis	_
195-15	41256-41262	Narrow	_
195-16	41263-41272	psychosis	_
195-17	41273-41274	(	_
195-18	41274-41276	SZ	_
195-19	41276-41277	/	_
195-20	41277-41280	SZA	_
195-21	41280-41281	)	_
195-22	41282-41289	Healthy	_
195-23	41290-41302	participants	_
195-24	41305-41306	N	_
195-25	41307-41311	1000	_
195-26	41312-41315	808	_
195-27	41316-41319	585	_
195-28	41320-41323	192	_
195-29	41326-41329	Age	_
195-30	41329-41330	,	_
195-31	41331-41335	mean	_
195-32	41336-41337	(	_
195-33	41337-41340	s.d	_
195-34	41340-41341	.	_
195-35	41341-41342	)	_
195-36	41343-41348	41.40	_
195-37	41348-41349	±	_
195-38	41349-41354	12.74	_
195-39	41355-41360	42.88	_
195-40	41360-41361	±	_
195-41	41361-41366	12.46	_
195-42	41367-41372	42.07	_
195-43	41372-41373	±	_
195-44	41373-41378	12.54	_
195-45	41379-41384	35.20	_
195-46	41384-41385	±	_
195-47	41385-41390	12.04	_
195-48	41393-41399	Female	_
195-49	41400-41403	sex	_
195-50	41403-41404	,	_
195-51	41405-41406	%	_
195-52	41407-41411	37.7	_
195-53	41412-41416	34.4	_
195-54	41417-41421	29.9	_
195-55	41422-41426	51.6	_
195-56	41429-41433	WAIS	_
195-57	41434-41438	FSIQ	_
195-58	41438-41439	,	_
195-59	41440-41444	mean	_
195-60	41445-41446	(	_
195-61	41446-41449	s.d	_
195-62	41449-41450	.	_
195-63	41450-41451	)	_
195-64	41452-41457	99.03	_
195-65	41457-41458	±	_
195-66	41458-41463	22.21	_
195-67	41464-41469	92.17	_
195-68	41469-41470	±	_
195-69	41470-41475	19.49	_
195-70	41476-41481	90.34	_
195-71	41481-41482	±	_
195-72	41482-41487	18.38	_
195-73	41488-41494	121.20	_
195-74	41494-41495	±	_
195-75	41495-41500	14.68	_
195-76	41503-41507	CPZE	_
195-77	41507-41508	,	_
195-78	41509-41513	mean	_
195-79	41514-41515	(	_
195-80	41515-41518	s.d	_
195-81	41518-41519	.	_
195-82	41519-41520	)	_
195-83	41521-41522	—	_
195-84	41523-41529	445.81	_
195-85	41529-41530	±	_
195-86	41530-41536	467.35	_
195-87	41537-41543	512.35	_
195-88	41543-41544	±	_
195-89	41544-41550	496.69	_
195-90	41551-41552	—	_
195-91	41555-41564	rs1702294	_
195-92	41565-41573	genotype	_
195-93	41574-41575	%	_
195-94	41575-41576	,	_
195-95	41577-41579	TT	_
195-96	41579-41580	/	_
195-97	41580-41582	TC	_
195-98	41582-41583	/	_
195-99	41583-41585	CC	_
195-100	41586-41589	2.8	_
195-101	41589-41590	/	_
195-102	41590-41594	29.0	_
195-103	41594-41595	/	_
195-104	41595-41599	65.7	_
195-105	41600-41603	2.5	_
195-106	41603-41604	/	_
195-107	41604-41608	29.9	_
195-108	41608-41609	/	_
195-109	41609-41613	67.5	_
195-110	41614-41617	2.8	_
195-111	41617-41618	/	_
195-112	41618-41622	30.3	_
195-113	41622-41623	/	_
195-114	41623-41627	66.9	_
195-115	41628-41631	4.2	_
195-116	41631-41632	/	_
195-117	41632-41636	28.9	_
195-118	41636-41637	/	_
195-119	41637-41641	66.8	_
195-120	41645-41658	Abbreviations	_
195-121	41658-41659	:	_
195-122	41660-41664	CPZE	_
195-123	41664-41665	,	_
195-124	41666-41680	chlorpromazine	_
195-125	41681-41691	equivalent	_
195-126	41691-41692	;	_
195-127	41693-41697	FSIQ	_
195-128	41697-41698	,	_
195-129	41699-41709	full-scale	_
195-130	41710-41712	IQ	_
195-131	41712-41713	;	_
195-132	41714-41716	IQ	_
195-133	41716-41717	,	_
195-134	41718-41730	intelligence	_
195-135	41731-41739	quotient	_
195-136	41739-41740	;	_
195-137	41741-41743	SZ	_
195-138	41743-41744	,	_
195-139	41745-41758	schizophrenia	_
195-140	41758-41759	;	_
195-141	41760-41763	SZA	_
195-142	41763-41764	,	_
195-143	41765-41780	schizoaffective	_
195-144	41781-41789	disorder	_
195-145	41789-41790	;	_
195-146	41791-41795	WAIS	_
195-147	41795-41796	,	_
195-148	41797-41805	Wechsler	_
195-149	41806-41811	Adult	_
195-150	41812-41824	Intelligence	_
195-151	41825-41830	Scale	_
195-152	41830-41831	.	_

#Text=Mean±s.d. reported.
196-1	41832-41836	Mean	_
196-2	41836-41837	±	_
196-3	41837-41840	s.d	_
196-4	41840-41841	.	_
196-5	41842-41850	reported	_
196-6	41850-41851	.	_

#Text=Inverse variance meta-analysis results at the three defined MIR137 polygene score thresholds for all participants
#Text=Neuropsychological variable\tP=10−5\tP=0.05\tP=0.5\t \t \tB\tCI\tB\tCI\tB\tCI\t \t \tCombined sample\tLower\tUpper\tP-value\tCombined sample\tLower\tUpper\tP-value\tCombined sample\tLower\tUpper\tP-value\t \tPre-morbid IQ (WTAR)\t−42.477\t−148.624\t63.671\t0.433\t−503.302\t−1165.205\t158.601\t0.136\t−1671.986\t−5226.713\t1882.740\t0.357\t \tVerbal IQ\t−303.427\t−584.882\t−21.972\t0.035*\t−4618.646\t−7987.354\t−1249.938\t0.035*\t−15034.193\t−30768.408\t700.022\t0.035*\t \tPerformance IQ\t−139.662\t−359.382\t80.059\t0.213\t−3515.312\t−5765.215\t−1265.410\t0.002**\t−9699.454\t−17083.868\t−2315.041\t0.010*\t \tFull-scale IQ\t−217.145\t−434.944\t0.653\t0.051\t−3959.537\t−6193.356\t−1725.718\t0.001**\t−11042.282\t−18376.914\t−3707.651\t0.003**\t \tLogical memory 1\t−308.570\t−474.475\t−142.666\t0.000***\t−3641.810\t−5037.080\t−2246.541\t0.000***\t−10669.811\t−11909.440\t−6125.766\t0.000***\t \tLogical memory 2\t−221.538\t−318.807\t−124.269\t0.000***\t−2747.838\t−3757.958\t−1737.718\t0.000***\t−8330.306\t−11909.440\t−4751.172\t0.000***\t \tFaces 1\t−94.815\t−153.364\t−36.267\t0.002**\t−1013.981\t−1626.683\t−401.278\t0.002**\t−2492.285\t−4493.001\t−491.569\t0.002**\t \tFaces 2\t−71.837\t−129.448\t−14.226\t0.015*\t−791.795\t−1394.458\t−189.133\t0.015*\t−1534.968\t−3504.421\t434.485\t0.015*\t \tSWM (errors)\t200.546\t−45.339\t446.430\t0.110\t3260.415\t−465.077\t6985.908\t0.086\t9254.991\t91.947\t18418.036\t0.048*\t \tSWM (strategy)\t39.889\t−45.908\t−45.908\t0.362\t710.783\t−186.172\t1607.738\t0.120\t994.328\t−1929.699\t3918.354\t0.505\t \tLetter-number sequencing\t−36.605\t−69.831\t−3.378\t0.031*\t−621.413\t−967.522\t−275.304\t0.031*\t−1732.880\t−2867.928\t−597.833\t0.031*\t \tSART reaction time\t2048.904\t−255.171\t4352.979\t0.081\t19926.956\t6182.706\t33671.206\t0.004**\t45561.862\t−1929.699\t3918.354\t0.505\t \tCPT d’Prime 2 digit\t−9.986\t−26.034\t6.061\t0.223\t−9.181\t−181.359\t162.997\t0.917\t128.901\t−430.676\t688.477\t0.652\t \tCPT d’Prime 3 digit\t−1.246\t−16.494\t14.002\t0.873\t19.569\t−142.902\t182.039\t0.813\t243.740\t−204.455\t691.934\t0.286\t \tCPT d’Prime 4 digit\t5.034\t−7.721\t17.790\t0.439\t46.054\t−89.501\t181.609\t0.505\t229.518\t−213.062\t672.099\t0.309\t \tEyes\t27.701\t−39.150\t94.553\t0.417\t−61.410\t−748.152\t625.332\t0.861\t−96.271\t−2371.226\t2178.684\t0.934\t \tHint\t−23.224\t−80.013\t33.566\t0.423\t−503.302\t−1165.205\t158.601\t0.136\t−1553.490\t−3541.015\t434.036\t0.126\t \tExternalizing bias\t18.604\t−30.143\t67.352\t0.454\t194.019\t−327.109\t715.147\t0.466\t211.583\t−1473.479\t1896.644\t0.806\t \tPersonalizing bias\t−0.546\t−7.551\t6.458\t0.878\t−23.491\t−97.795\t50.812\t0.535\t−59.643\t−263.523\t144.236\t0.566\t \t
#Text=Abbreviations: CI, confidence interval; CPT, Continuous Performance Task; IQ, intelligence quotient; MIR137, microRNA-137; SART, Sustained Attention to Response Task; SWM, Spatial Working Memory; WTAR, Wechsler Test of Adult Reading.
197-1	41852-41859	Inverse	_
197-2	41860-41868	variance	_
197-3	41869-41882	meta-analysis	_
197-4	41883-41890	results	_
197-5	41891-41893	at	_
197-6	41894-41897	the	_
197-7	41898-41903	three	_
197-8	41904-41911	defined	_
197-9	41912-41918	MIR137	_
197-10	41919-41927	polygene	_
197-11	41928-41933	score	_
197-12	41934-41944	thresholds	_
197-13	41945-41948	for	_
197-14	41949-41952	all	_
197-15	41953-41965	participants	_
197-16	41966-41984	Neuropsychological	_
197-17	41985-41993	variable	_
197-18	41994-41995	P	_
197-19	41995-41996	=	_
197-20	41996-41998	10	_
197-21	41998-41999	−	_
197-22	41999-42000	5	_
197-23	42001-42002	P	_
197-24	42002-42003	=	_
197-25	42003-42007	0.05	_
197-26	42008-42009	P	_
197-27	42009-42010	=	_
197-28	42010-42013	0.5	_
197-29	42016-42017	 	_
197-30	42018-42019	B	_
197-31	42020-42022	CI	_
197-32	42023-42024	B	_
197-33	42025-42027	CI	_
197-34	42028-42029	B	_
197-35	42030-42032	CI	_
197-36	42035-42036	 	_
197-37	42037-42045	Combined	_
197-38	42046-42052	sample	_
197-39	42053-42058	Lower	_
197-40	42059-42064	Upper	_
197-41	42065-42072	P-value	_
197-42	42073-42081	Combined	_
197-43	42082-42088	sample	_
197-44	42089-42094	Lower	_
197-45	42095-42100	Upper	_
197-46	42101-42108	P-value	_
197-47	42109-42117	Combined	_
197-48	42118-42124	sample	_
197-49	42125-42130	Lower	_
197-50	42131-42136	Upper	_
197-51	42137-42144	P-value	_
197-52	42147-42157	Pre-morbid	_
197-53	42158-42160	IQ	_
197-54	42161-42162	(	_
197-55	42162-42166	WTAR	_
197-56	42166-42167	)	_
197-57	42168-42169	−	_
197-58	42169-42175	42.477	_
197-59	42176-42177	−	_
197-60	42177-42184	148.624	_
197-61	42185-42191	63.671	_
197-62	42192-42197	0.433	_
197-63	42198-42199	−	_
197-64	42199-42206	503.302	_
197-65	42207-42208	−	_
197-66	42208-42216	1165.205	_
197-67	42217-42224	158.601	_
197-68	42225-42230	0.136	_
197-69	42231-42232	−	_
197-70	42232-42240	1671.986	_
197-71	42241-42242	−	_
197-72	42242-42250	5226.713	_
197-73	42251-42259	1882.740	_
197-74	42260-42265	0.357	_
197-75	42268-42274	Verbal	_
197-76	42275-42277	IQ	_
197-77	42278-42279	−	_
197-78	42279-42286	303.427	_
197-79	42287-42288	−	_
197-80	42288-42295	584.882	_
197-81	42296-42297	−	_
197-82	42297-42303	21.972	_
197-83	42304-42309	0.035	_
197-84	42309-42310	*	_
197-85	42311-42312	−	_
197-86	42312-42320	4618.646	_
197-87	42321-42322	−	_
197-88	42322-42330	7987.354	_
197-89	42331-42332	−	_
197-90	42332-42340	1249.938	_
197-91	42341-42346	0.035	_
197-92	42346-42347	*	_
197-93	42348-42349	−	_
197-94	42349-42358	15034.193	_
197-95	42359-42360	−	_
197-96	42360-42369	30768.408	_
197-97	42370-42377	700.022	_
197-98	42378-42383	0.035	_
197-99	42383-42384	*	_
197-100	42387-42398	Performance	_
197-101	42399-42401	IQ	_
197-102	42402-42403	−	_
197-103	42403-42410	139.662	_
197-104	42411-42412	−	_
197-105	42412-42419	359.382	_
197-106	42420-42426	80.059	_
197-107	42427-42432	0.213	_
197-108	42433-42434	−	_
197-109	42434-42442	3515.312	_
197-110	42443-42444	−	_
197-111	42444-42452	5765.215	_
197-112	42453-42454	−	_
197-113	42454-42462	1265.410	_
197-114	42463-42468	0.002	_
197-115	42468-42469	*	_
197-116	42469-42470	*	_
197-117	42471-42472	−	_
197-118	42472-42480	9699.454	_
197-119	42481-42482	−	_
197-120	42482-42491	17083.868	_
197-121	42492-42493	−	_
197-122	42493-42501	2315.041	_
197-123	42502-42507	0.010	_
197-124	42507-42508	*	_
197-125	42511-42521	Full-scale	_
197-126	42522-42524	IQ	_
197-127	42525-42526	−	_
197-128	42526-42533	217.145	_
197-129	42534-42535	−	_
197-130	42535-42542	434.944	_
197-131	42543-42548	0.653	_
197-132	42549-42554	0.051	_
197-133	42555-42556	−	_
197-134	42556-42564	3959.537	_
197-135	42565-42566	−	_
197-136	42566-42574	6193.356	_
197-137	42575-42576	−	_
197-138	42576-42584	1725.718	_
197-139	42585-42590	0.001	_
197-140	42590-42591	*	_
197-141	42591-42592	*	_
197-142	42593-42594	−	_
197-143	42594-42603	11042.282	_
197-144	42604-42605	−	_
197-145	42605-42614	18376.914	_
197-146	42615-42616	−	_
197-147	42616-42624	3707.651	_
197-148	42625-42630	0.003	_
197-149	42630-42631	*	_
197-150	42631-42632	*	_
197-151	42635-42642	Logical	_
197-152	42643-42649	memory	_
197-153	42650-42651	1	_
197-154	42652-42653	−	_
197-155	42653-42660	308.570	_
197-156	42661-42662	−	_
197-157	42662-42669	474.475	_
197-158	42670-42671	−	_
197-159	42671-42678	142.666	_
197-160	42679-42684	0.000	_
197-161	42684-42685	*	_
197-162	42685-42686	*	_
197-163	42686-42687	*	_
197-164	42688-42689	−	_
197-165	42689-42697	3641.810	_
197-166	42698-42699	−	_
197-167	42699-42707	5037.080	_
197-168	42708-42709	−	_
197-169	42709-42717	2246.541	_
197-170	42718-42723	0.000	_
197-171	42723-42724	*	_
197-172	42724-42725	*	_
197-173	42725-42726	*	_
197-174	42727-42728	−	_
197-175	42728-42737	10669.811	_
197-176	42738-42739	−	_
197-177	42739-42748	11909.440	_
197-178	42749-42750	−	_
197-179	42750-42758	6125.766	_
197-180	42759-42764	0.000	_
197-181	42764-42765	*	_
197-182	42765-42766	*	_
197-183	42766-42767	*	_
197-184	42770-42777	Logical	_
197-185	42778-42784	memory	_
197-186	42785-42786	2	_
197-187	42787-42788	−	_
197-188	42788-42795	221.538	_
197-189	42796-42797	−	_
197-190	42797-42804	318.807	_
197-191	42805-42806	−	_
197-192	42806-42813	124.269	_
197-193	42814-42819	0.000	_
197-194	42819-42820	*	_
197-195	42820-42821	*	_
197-196	42821-42822	*	_
197-197	42823-42824	−	_
197-198	42824-42832	2747.838	_
197-199	42833-42834	−	_
197-200	42834-42842	3757.958	_
197-201	42843-42844	−	_
197-202	42844-42852	1737.718	_
197-203	42853-42858	0.000	_
197-204	42858-42859	*	_
197-205	42859-42860	*	_
197-206	42860-42861	*	_
197-207	42862-42863	−	_
197-208	42863-42871	8330.306	_
197-209	42872-42873	−	_
197-210	42873-42882	11909.440	_
197-211	42883-42884	−	_
197-212	42884-42892	4751.172	_
197-213	42893-42898	0.000	_
197-214	42898-42899	*	_
197-215	42899-42900	*	_
197-216	42900-42901	*	_
197-217	42904-42909	Faces	_
197-218	42910-42911	1	_
197-219	42912-42913	−	_
197-220	42913-42919	94.815	_
197-221	42920-42921	−	_
197-222	42921-42928	153.364	_
197-223	42929-42930	−	_
197-224	42930-42936	36.267	_
197-225	42937-42942	0.002	_
197-226	42942-42943	*	_
197-227	42943-42944	*	_
197-228	42945-42946	−	_
197-229	42946-42954	1013.981	_
197-230	42955-42956	−	_
197-231	42956-42964	1626.683	_
197-232	42965-42966	−	_
197-233	42966-42973	401.278	_
197-234	42974-42979	0.002	_
197-235	42979-42980	*	_
197-236	42980-42981	*	_
197-237	42982-42983	−	_
197-238	42983-42991	2492.285	_
197-239	42992-42993	−	_
197-240	42993-43001	4493.001	_
197-241	43002-43003	−	_
197-242	43003-43010	491.569	_
197-243	43011-43016	0.002	_
197-244	43016-43017	*	_
197-245	43017-43018	*	_
197-246	43021-43026	Faces	_
197-247	43027-43028	2	_
197-248	43029-43030	−	_
197-249	43030-43036	71.837	_
197-250	43037-43038	−	_
197-251	43038-43045	129.448	_
197-252	43046-43047	−	_
197-253	43047-43053	14.226	_
197-254	43054-43059	0.015	_
197-255	43059-43060	*	_
197-256	43061-43062	−	_
197-257	43062-43069	791.795	_
197-258	43070-43071	−	_
197-259	43071-43079	1394.458	_
197-260	43080-43081	−	_
197-261	43081-43088	189.133	_
197-262	43089-43094	0.015	_
197-263	43094-43095	*	_
197-264	43096-43097	−	_
197-265	43097-43105	1534.968	_
197-266	43106-43107	−	_
197-267	43107-43115	3504.421	_
197-268	43116-43123	434.485	_
197-269	43124-43129	0.015	_
197-270	43129-43130	*	_
197-271	43133-43136	SWM	_
197-272	43137-43138	(	_
197-273	43138-43144	errors	_
197-274	43144-43145	)	_
197-275	43146-43153	200.546	_
197-276	43154-43155	−	_
197-277	43155-43161	45.339	_
197-278	43162-43169	446.430	_
197-279	43170-43175	0.110	_
197-280	43176-43184	3260.415	_
197-281	43185-43186	−	_
197-282	43186-43193	465.077	_
197-283	43194-43202	6985.908	_
197-284	43203-43208	0.086	_
197-285	43209-43217	9254.991	_
197-286	43218-43224	91.947	_
197-287	43225-43234	18418.036	_
197-288	43235-43240	0.048	_
197-289	43240-43241	*	_
197-290	43244-43247	SWM	_
197-291	43248-43249	(	_
197-292	43249-43257	strategy	_
197-293	43257-43258	)	_
197-294	43259-43265	39.889	_
197-295	43266-43267	−	_
197-296	43267-43273	45.908	_
197-297	43274-43275	−	_
197-298	43275-43281	45.908	_
197-299	43282-43287	0.362	_
197-300	43288-43295	710.783	_
197-301	43296-43297	−	_
197-302	43297-43304	186.172	_
197-303	43305-43313	1607.738	_
197-304	43314-43319	0.120	_
197-305	43320-43327	994.328	_
197-306	43328-43329	−	_
197-307	43329-43337	1929.699	_
197-308	43338-43346	3918.354	_
197-309	43347-43352	0.505	_
197-310	43355-43368	Letter-number	_
197-311	43369-43379	sequencing	_
197-312	43380-43381	−	_
197-313	43381-43387	36.605	_
197-314	43388-43389	−	_
197-315	43389-43395	69.831	_
197-316	43396-43397	−	_
197-317	43397-43402	3.378	_
197-318	43403-43408	0.031	_
197-319	43408-43409	*	_
197-320	43410-43411	−	_
197-321	43411-43418	621.413	_
197-322	43419-43420	−	_
197-323	43420-43427	967.522	_
197-324	43428-43429	−	_
197-325	43429-43436	275.304	_
197-326	43437-43442	0.031	_
197-327	43442-43443	*	_
197-328	43444-43445	−	_
197-329	43445-43453	1732.880	_
197-330	43454-43455	−	_
197-331	43455-43463	2867.928	_
197-332	43464-43465	−	_
197-333	43465-43472	597.833	_
197-334	43473-43478	0.031	_
197-335	43478-43479	*	_
197-336	43482-43486	SART	_
197-337	43487-43495	reaction	_
197-338	43496-43500	time	_
197-339	43501-43509	2048.904	_
197-340	43510-43511	−	_
197-341	43511-43518	255.171	_
197-342	43519-43527	4352.979	_
197-343	43528-43533	0.081	_
197-344	43534-43543	19926.956	_
197-345	43544-43552	6182.706	_
197-346	43553-43562	33671.206	_
197-347	43563-43568	0.004	_
197-348	43568-43569	*	_
197-349	43569-43570	*	_
197-350	43571-43580	45561.862	_
197-351	43581-43582	−	_
197-352	43582-43590	1929.699	_
197-353	43591-43599	3918.354	_
197-354	43600-43605	0.505	_
197-355	43608-43611	CPT	_
197-356	43612-43613	d	_
197-357	43613-43614	’	_
197-358	43614-43619	Prime	_
197-359	43620-43621	2	_
197-360	43622-43627	digit	_
197-361	43628-43629	−	_
197-362	43629-43634	9.986	_
197-363	43635-43636	−	_
197-364	43636-43642	26.034	_
197-365	43643-43648	6.061	_
197-366	43649-43654	0.223	_
197-367	43655-43656	−	_
197-368	43656-43661	9.181	_
197-369	43662-43663	−	_
197-370	43663-43670	181.359	_
197-371	43671-43678	162.997	_
197-372	43679-43684	0.917	_
197-373	43685-43692	128.901	_
197-374	43693-43694	−	_
197-375	43694-43701	430.676	_
197-376	43702-43709	688.477	_
197-377	43710-43715	0.652	_
197-378	43718-43721	CPT	_
197-379	43722-43723	d	_
197-380	43723-43724	’	_
197-381	43724-43729	Prime	_
197-382	43730-43731	3	_
197-383	43732-43737	digit	_
197-384	43738-43739	−	_
197-385	43739-43744	1.246	_
197-386	43745-43746	−	_
197-387	43746-43752	16.494	_
197-388	43753-43759	14.002	_
197-389	43760-43765	0.873	_
197-390	43766-43772	19.569	_
197-391	43773-43774	−	_
197-392	43774-43781	142.902	_
197-393	43782-43789	182.039	_
197-394	43790-43795	0.813	_
197-395	43796-43803	243.740	_
197-396	43804-43805	−	_
197-397	43805-43812	204.455	_
197-398	43813-43820	691.934	_
197-399	43821-43826	0.286	_
197-400	43829-43832	CPT	_
197-401	43833-43834	d	_
197-402	43834-43835	’	_
197-403	43835-43840	Prime	_
197-404	43841-43842	4	_
197-405	43843-43848	digit	_
197-406	43849-43854	5.034	_
197-407	43855-43856	−	_
197-408	43856-43861	7.721	_
197-409	43862-43868	17.790	_
197-410	43869-43874	0.439	_
197-411	43875-43881	46.054	_
197-412	43882-43883	−	_
197-413	43883-43889	89.501	_
197-414	43890-43897	181.609	_
197-415	43898-43903	0.505	_
197-416	43904-43911	229.518	_
197-417	43912-43913	−	_
197-418	43913-43920	213.062	_
197-419	43921-43928	672.099	_
197-420	43929-43934	0.309	_
197-421	43937-43941	Eyes	_
197-422	43942-43948	27.701	_
197-423	43949-43950	−	_
197-424	43950-43956	39.150	_
197-425	43957-43963	94.553	_
197-426	43964-43969	0.417	_
197-427	43970-43971	−	_
197-428	43971-43977	61.410	_
197-429	43978-43979	−	_
197-430	43979-43986	748.152	_
197-431	43987-43994	625.332	_
197-432	43995-44000	0.861	_
197-433	44001-44002	−	_
197-434	44002-44008	96.271	_
197-435	44009-44010	−	_
197-436	44010-44018	2371.226	_
197-437	44019-44027	2178.684	_
197-438	44028-44033	0.934	_
197-439	44036-44040	Hint	_
197-440	44041-44042	−	_
197-441	44042-44048	23.224	_
197-442	44049-44050	−	_
197-443	44050-44056	80.013	_
197-444	44057-44063	33.566	_
197-445	44064-44069	0.423	_
197-446	44070-44071	−	_
197-447	44071-44078	503.302	_
197-448	44079-44080	−	_
197-449	44080-44088	1165.205	_
197-450	44089-44096	158.601	_
197-451	44097-44102	0.136	_
197-452	44103-44104	−	_
197-453	44104-44112	1553.490	_
197-454	44113-44114	−	_
197-455	44114-44122	3541.015	_
197-456	44123-44130	434.036	_
197-457	44131-44136	0.126	_
197-458	44139-44152	Externalizing	_
197-459	44153-44157	bias	_
197-460	44158-44164	18.604	_
197-461	44165-44166	−	_
197-462	44166-44172	30.143	_
197-463	44173-44179	67.352	_
197-464	44180-44185	0.454	_
197-465	44186-44193	194.019	_
197-466	44194-44195	−	_
197-467	44195-44202	327.109	_
197-468	44203-44210	715.147	_
197-469	44211-44216	0.466	_
197-470	44217-44224	211.583	_
197-471	44225-44226	−	_
197-472	44226-44234	1473.479	_
197-473	44235-44243	1896.644	_
197-474	44244-44249	0.806	_
197-475	44252-44265	Personalizing	_
197-476	44266-44270	bias	_
197-477	44271-44272	−	_
197-478	44272-44277	0.546	_
197-479	44278-44279	−	_
197-480	44279-44284	7.551	_
197-481	44285-44290	6.458	_
197-482	44291-44296	0.878	_
197-483	44297-44298	−	_
197-484	44298-44304	23.491	_
197-485	44305-44306	−	_
197-486	44306-44312	97.795	_
197-487	44313-44319	50.812	_
197-488	44320-44325	0.535	_
197-489	44326-44327	−	_
197-490	44327-44333	59.643	_
197-491	44334-44335	−	_
197-492	44335-44342	263.523	_
197-493	44343-44350	144.236	_
197-494	44351-44356	0.566	_
197-495	44360-44373	Abbreviations	_
197-496	44373-44374	:	_
197-497	44375-44377	CI	_
197-498	44377-44378	,	_
197-499	44379-44389	confidence	_
197-500	44390-44398	interval	_
197-501	44398-44399	;	_
197-502	44400-44403	CPT	_
197-503	44403-44404	,	_
197-504	44405-44415	Continuous	_
197-505	44416-44427	Performance	_
197-506	44428-44432	Task	_
197-507	44432-44433	;	_
197-508	44434-44436	IQ	_
197-509	44436-44437	,	_
197-510	44438-44450	intelligence	_
197-511	44451-44459	quotient	_
197-512	44459-44460	;	_
197-513	44461-44467	MIR137	_
197-514	44467-44468	,	_
197-515	44469-44477	microRNA	_
197-516	44477-44478	-	_
197-517	44478-44481	137	_
197-518	44481-44482	;	_
197-519	44483-44487	SART	_
197-520	44487-44488	,	_
197-521	44489-44498	Sustained	_
197-522	44499-44508	Attention	_
197-523	44509-44511	to	_
197-524	44512-44520	Response	_
197-525	44521-44525	Task	_
197-526	44525-44526	;	_
197-527	44527-44530	SWM	_
197-528	44530-44531	,	_
197-529	44532-44539	Spatial	_
197-530	44540-44547	Working	_
197-531	44548-44554	Memory	_
197-532	44554-44555	;	_
197-533	44556-44560	WTAR	_
197-534	44560-44561	,	_
197-535	44562-44570	Wechsler	_
197-536	44571-44575	Test	_
197-537	44576-44578	of	_
197-538	44579-44584	Adult	_
197-539	44585-44592	Reading	_
197-540	44592-44593	.	_

#Text=Results in bold indicate significance after correction for multiple testing across 5 cognitive domains.
198-1	44594-44601	Results	_
198-2	44602-44604	in	_
198-3	44605-44609	bold	_
198-4	44610-44618	indicate	_
198-5	44619-44631	significance	_
198-6	44632-44637	after	_
198-7	44638-44648	correction	_
198-8	44649-44652	for	_
198-9	44653-44661	multiple	_
198-10	44662-44669	testing	_
198-11	44670-44676	across	_
198-12	44677-44678	5	_
198-13	44679-44688	cognitive	_
198-14	44689-44696	domains	_
198-15	44696-44697	.	_

#Text=*P<0.05; **P<0.01; ***P<0.0001.
199-1	44698-44699	*	_
199-2	44699-44700	P	_
199-3	44700-44701	<	_
199-4	44701-44705	0.05	_
199-5	44705-44706	;	_
199-6	44707-44708	*	_
199-7	44708-44709	*	_
199-8	44709-44710	P	_
199-9	44710-44711	<	_
199-10	44711-44715	0.01	_
199-11	44715-44716	;	_
199-12	44717-44718	*	_
199-13	44718-44719	*	_
199-14	44719-44720	*	_
199-15	44720-44721	P	_
199-16	44721-44722	<	_
199-17	44722-44728	0.0001	_
199-18	44728-44729	.	_

#Text=Linear regression analyses of rs1702294 risk allele (C) effects on cognitive test scores for all participants
#Text=Neuropsychological variable\tStandardized β\tCI\tP-value\tr2\t \t \t \tLower\tUpper\t \t \t \tIQ\t \t Pre-morbid IQ (WTAR)\t−0.044\t−2.215\t0.482\t0.207\t0.002\t \t Verbal IQ\t−0.046\t−4.514\t0.709\t0.153\t0.002\t \t Performance IQ\t−0.091\t−6.701\t−1.041\t0.007**\t0.008\t \t Full-scale IQ\t−0.080\t−6.157\t−0.563\t0.019*\t0.006\t \t \t \t \t \t \t \t \tDM\t \t Logical memory 1\t−0.050\t−3.077\t0.298\t0.106\t0.003\t \t Logical memory 2\t−0.025\t−1.740\t0.726\t0.420\t0.001\t \t Faces 1\t−0.059\t−1.322\t0.151\t0.119\t0.003\t \t Faces 2\t−0.008\t−0.815\t0.646\t0.820\t0.000\t \t \t \t \t \t \t \t \tWM\t \t SWM (errors)\t0.031\t−1.611\t4.415\t0.361\t0.001\t \t SWM (strategy)\t0.017\t−0.800\t1.316\t0.632\t0.000\t \t Letter-number sequencing\t−0.032\t−0.642\t0.202\t0.306\t0.001\t \t \t \t \t \t \t \t \tAttention\t \t SART reaction time\t0.059\t−3.873\t30.073\t0.013*\t0.003\t \t CPT d’Prime 2 digit\t−0.044\t−0.302\t0.103\t0.334\t0.002\t \t CPT d’Prime 3 digit\t−0.031\t−0.257\t0.126\t0.504\t0.000\t \t CPT d’Prime 4 digit\t−0.019\t−0.194\t0.127\t0.679\t0.000\t \t \t \t \t \t \t \t \tSocial cognition\t \t Eyes\t−0.040\t−1.308\t0.449\t0.337\t0.001\t \t Hint\t−0.083\t−0.972\t−0.018\t0.042*\t0.008\t \t Externalizing bias\t0.000\t−0.613\t−0.614\t0.998\t0.000\t \t Personalizing bias\t0.020\t−0.033\t0.053\t0.645\t0.000\t \t
#Text=Abbreviations: CI, confidence interval; CPT, Continuous Performance Task; DM, declarative memory; IQ, intelligence quotient; SART, Sustained Attention to Response Task; SWM, Spatial Working Memory; WM, working memory; WTAR, Wechsler Test of Adult Reading.
200-1	44730-44736	Linear	_
200-2	44737-44747	regression	_
200-3	44748-44756	analyses	_
200-4	44757-44759	of	_
200-5	44760-44769	rs1702294	_
200-6	44770-44774	risk	_
200-7	44775-44781	allele	_
200-8	44782-44783	(	_
200-9	44783-44784	C	_
200-10	44784-44785	)	_
200-11	44786-44793	effects	_
200-12	44794-44796	on	_
200-13	44797-44806	cognitive	_
200-14	44807-44811	test	_
200-15	44812-44818	scores	_
200-16	44819-44822	for	_
200-17	44823-44826	all	_
200-18	44827-44839	participants	_
200-19	44840-44858	Neuropsychological	_
200-20	44859-44867	variable	_
200-21	44868-44880	Standardized	_
200-22	44881-44882	β	_
200-23	44883-44885	CI	_
200-24	44886-44893	P-value	_
200-25	44894-44896	r2	_
200-26	44899-44902	 	 	_
200-27	44903-44908	Lower	_
200-28	44909-44914	Upper	_
200-29	44915-44918	 	 	_
200-30	44921-44923	IQ	_
200-31	44927-44937	Pre-morbid	_
200-32	44938-44940	IQ	_
200-33	44941-44942	(	_
200-34	44942-44946	WTAR	_
200-35	44946-44947	)	_
200-36	44948-44949	−	_
200-37	44949-44954	0.044	_
200-38	44955-44956	−	_
200-39	44956-44961	2.215	_
200-40	44962-44967	0.482	_
200-41	44968-44973	0.207	_
200-42	44974-44979	0.002	_
200-43	44983-44989	Verbal	_
200-44	44990-44992	IQ	_
200-45	44993-44994	−	_
200-46	44994-44999	0.046	_
200-47	45000-45001	−	_
200-48	45001-45006	4.514	_
200-49	45007-45012	0.709	_
200-50	45013-45018	0.153	_
200-51	45019-45024	0.002	_
200-52	45028-45039	Performance	_
200-53	45040-45042	IQ	_
200-54	45043-45044	−	_
200-55	45044-45049	0.091	_
200-56	45050-45051	−	_
200-57	45051-45056	6.701	_
200-58	45057-45058	−	_
200-59	45058-45063	1.041	_
200-60	45064-45069	0.007	_
200-61	45069-45070	*	_
200-62	45070-45071	*	_
200-63	45072-45077	0.008	_
200-64	45081-45091	Full-scale	_
200-65	45092-45094	IQ	_
200-66	45095-45096	−	_
200-67	45096-45101	0.080	_
200-68	45102-45103	−	_
200-69	45103-45108	6.157	_
200-70	45109-45110	−	_
200-71	45110-45115	0.563	_
200-72	45116-45121	0.019	_
200-73	45121-45122	*	_
200-74	45123-45128	0.006	_
200-75	45131-45142	 	 	 	 	 	 	_
200-76	45145-45147	DM	_
200-77	45151-45158	Logical	_
200-78	45159-45165	memory	_
200-79	45166-45167	1	_
200-80	45168-45169	−	_
200-81	45169-45174	0.050	_
200-82	45175-45176	−	_
200-83	45176-45181	3.077	_
200-84	45182-45187	0.298	_
200-85	45188-45193	0.106	_
200-86	45194-45199	0.003	_
200-87	45203-45210	Logical	_
200-88	45211-45217	memory	_
200-89	45218-45219	2	_
200-90	45220-45221	−	_
200-91	45221-45226	0.025	_
200-92	45227-45228	−	_
200-93	45228-45233	1.740	_
200-94	45234-45239	0.726	_
200-95	45240-45245	0.420	_
200-96	45246-45251	0.001	_
200-97	45255-45260	Faces	_
200-98	45261-45262	1	_
200-99	45263-45264	−	_
200-100	45264-45269	0.059	_
200-101	45270-45271	−	_
200-102	45271-45276	1.322	_
200-103	45277-45282	0.151	_
200-104	45283-45288	0.119	_
200-105	45289-45294	0.003	_
200-106	45298-45303	Faces	_
200-107	45304-45305	2	_
200-108	45306-45307	−	_
200-109	45307-45312	0.008	_
200-110	45313-45314	−	_
200-111	45314-45319	0.815	_
200-112	45320-45325	0.646	_
200-113	45326-45331	0.820	_
200-114	45332-45337	0.000	_
200-115	45340-45351	 	 	 	 	 	 	_
200-116	45354-45356	WM	_
200-117	45360-45363	SWM	_
200-118	45364-45365	(	_
200-119	45365-45371	errors	_
200-120	45371-45372	)	_
200-121	45373-45378	0.031	_
200-122	45379-45380	−	_
200-123	45380-45385	1.611	_
200-124	45386-45391	4.415	_
200-125	45392-45397	0.361	_
200-126	45398-45403	0.001	_
200-127	45407-45410	SWM	_
200-128	45411-45412	(	_
200-129	45412-45420	strategy	_
200-130	45420-45421	)	_
200-131	45422-45427	0.017	_
200-132	45428-45429	−	_
200-133	45429-45434	0.800	_
200-134	45435-45440	1.316	_
200-135	45441-45446	0.632	_
200-136	45447-45452	0.000	_
200-137	45456-45469	Letter-number	_
200-138	45470-45480	sequencing	_
200-139	45481-45482	−	_
200-140	45482-45487	0.032	_
200-141	45488-45489	−	_
200-142	45489-45494	0.642	_
200-143	45495-45500	0.202	_
200-144	45501-45506	0.306	_
200-145	45507-45512	0.001	_
200-146	45515-45526	 	 	 	 	 	 	_
200-147	45529-45538	Attention	_
200-148	45542-45546	SART	_
200-149	45547-45555	reaction	_
200-150	45556-45560	time	_
200-151	45561-45566	0.059	_
200-152	45567-45568	−	_
200-153	45568-45573	3.873	_
200-154	45574-45580	30.073	_
200-155	45581-45586	0.013	_
200-156	45586-45587	*	_
200-157	45588-45593	0.003	_
200-158	45597-45600	CPT	_
200-159	45601-45602	d	_
200-160	45602-45603	’	_
200-161	45603-45608	Prime	_
200-162	45609-45610	2	_
200-163	45611-45616	digit	_
200-164	45617-45618	−	_
200-165	45618-45623	0.044	_
200-166	45624-45625	−	_
200-167	45625-45630	0.302	_
200-168	45631-45636	0.103	_
200-169	45637-45642	0.334	_
200-170	45643-45648	0.002	_
200-171	45652-45655	CPT	_
200-172	45656-45657	d	_
200-173	45657-45658	’	_
200-174	45658-45663	Prime	_
200-175	45664-45665	3	_
200-176	45666-45671	digit	_
200-177	45672-45673	−	_
200-178	45673-45678	0.031	_
200-179	45679-45680	−	_
200-180	45680-45685	0.257	_
200-181	45686-45691	0.126	_
200-182	45692-45697	0.504	_
200-183	45698-45703	0.000	_
200-184	45707-45710	CPT	_
200-185	45711-45712	d	_
200-186	45712-45713	’	_
200-187	45713-45718	Prime	_
200-188	45719-45720	4	_
200-189	45721-45726	digit	_
200-190	45727-45728	−	_
200-191	45728-45733	0.019	_
200-192	45734-45735	−	_
200-193	45735-45740	0.194	_
200-194	45741-45746	0.127	_
200-195	45747-45752	0.679	_
200-196	45753-45758	0.000	_
200-197	45761-45772	 	 	 	 	 	 	_
200-198	45775-45781	Social	_
200-199	45782-45791	cognition	_
200-200	45795-45799	Eyes	_
200-201	45800-45801	−	_
200-202	45801-45806	0.040	_
200-203	45807-45808	−	_
200-204	45808-45813	1.308	_
200-205	45814-45819	0.449	_
200-206	45820-45825	0.337	_
200-207	45826-45831	0.001	_
200-208	45835-45839	Hint	_
200-209	45840-45841	−	_
200-210	45841-45846	0.083	_
200-211	45847-45848	−	_
200-212	45848-45853	0.972	_
200-213	45854-45855	−	_
200-214	45855-45860	0.018	_
200-215	45861-45866	0.042	_
200-216	45866-45867	*	_
200-217	45868-45873	0.008	_
200-218	45877-45890	Externalizing	_
200-219	45891-45895	bias	_
200-220	45896-45901	0.000	_
200-221	45902-45903	−	_
200-222	45903-45908	0.613	_
200-223	45909-45910	−	_
200-224	45910-45915	0.614	_
200-225	45916-45921	0.998	_
200-226	45922-45927	0.000	_
200-227	45931-45944	Personalizing	_
200-228	45945-45949	bias	_
200-229	45950-45955	0.020	_
200-230	45956-45957	−	_
200-231	45957-45962	0.033	_
200-232	45963-45968	0.053	_
200-233	45969-45974	0.645	_
200-234	45975-45980	0.000	_
200-235	45984-45997	Abbreviations	_
200-236	45997-45998	:	_
200-237	45999-46001	CI	_
200-238	46001-46002	,	_
200-239	46003-46013	confidence	_
200-240	46014-46022	interval	_
200-241	46022-46023	;	_
200-242	46024-46027	CPT	_
200-243	46027-46028	,	_
200-244	46029-46039	Continuous	_
200-245	46040-46051	Performance	_
200-246	46052-46056	Task	_
200-247	46056-46057	;	_
200-248	46058-46060	DM	_
200-249	46060-46061	,	_
200-250	46062-46073	declarative	_
200-251	46074-46080	memory	_
200-252	46080-46081	;	_
200-253	46082-46084	IQ	_
200-254	46084-46085	,	_
200-255	46086-46098	intelligence	_
200-256	46099-46107	quotient	_
200-257	46107-46108	;	_
200-258	46109-46113	SART	_
200-259	46113-46114	,	_
200-260	46115-46124	Sustained	_
200-261	46125-46134	Attention	_
200-262	46135-46137	to	_
200-263	46138-46146	Response	_
200-264	46147-46151	Task	_
200-265	46151-46152	;	_
200-266	46153-46156	SWM	_
200-267	46156-46157	,	_
200-268	46158-46165	Spatial	_
200-269	46166-46173	Working	_
200-270	46174-46180	Memory	_
200-271	46180-46181	;	_
200-272	46182-46184	WM	_
200-273	46184-46185	,	_
200-274	46186-46193	working	_
200-275	46194-46200	memory	_
200-276	46200-46201	;	_
200-277	46202-46206	WTAR	_
200-278	46206-46207	,	_
200-279	46208-46216	Wechsler	_
200-280	46217-46221	Test	_
200-281	46222-46224	of	_
200-282	46225-46230	Adult	_
200-283	46231-46238	Reading	_
200-284	46238-46239	.	_

#Text=Results in bold indicate significance after correction for multiple testing across 5 cognitive domains.
201-1	46240-46247	Results	_
201-2	46248-46250	in	_
201-3	46251-46255	bold	_
201-4	46256-46264	indicate	_
201-5	46265-46277	significance	_
201-6	46278-46283	after	_
201-7	46284-46294	correction	_
201-8	46295-46298	for	_
201-9	46299-46307	multiple	_
201-10	46308-46315	testing	_
201-11	46316-46322	across	_
201-12	46323-46324	5	_
201-13	46325-46334	cognitive	_
201-14	46335-46342	domains	_
201-15	46342-46343	.	_

#Text=*P<0.05; **P<0.01; ***P<0.0001.
202-1	46344-46345	*	_
202-2	46345-46346	P	_
202-3	46346-46347	<	_
202-4	46347-46351	0.05	_
202-5	46351-46352	;	_
202-6	46353-46354	*	_
202-7	46354-46355	*	_
202-8	46355-46356	P	_
202-9	46356-46357	<	_
202-10	46357-46361	0.01	_
202-11	46361-46362	;	_
202-12	46363-46364	*	_
202-13	46364-46365	*	_
202-14	46365-46366	*	_
202-15	46366-46367	P	_
202-16	46367-46368	<	_
202-17	46368-46374	0.0001	_
202-18	46374-46375	.	_

#Text=Participant demographics: fMRI sample
#Text=Age\t28.79±9.05a\t \tGender\t38 M/48 F\t \tYears of education\t17.48±3.32b\t \tSWM accuracy (correct trials/72)\t63.59±8.77\t \tSWM reaction time (ms)\t8737.15±2166.99\t \tMIR137 pathway risk score at P=10−5\t0.047755814±0.006577924\t \tMIR137 pathway risk score at P=0.05\t0.022951163±0.000631104\t \tMIR137 pathway risk score at P=0.5\t0.014223256±0.000195643\t \t
#Text=Abbreviations: MIR137, microRNA-137; SWM, Spatial Working Memory.
203-1	46376-46387	Participant	_
203-2	46388-46400	demographics	_
203-3	46400-46401	:	_
203-4	46402-46406	fMRI	_
203-5	46407-46413	sample	_
203-6	46414-46417	Age	_
203-7	46418-46423	28.79	_
203-8	46423-46424	±	_
203-9	46424-46429	9.05a	_
203-10	46432-46438	Gender	_
203-11	46439-46441	38	_
203-12	46442-46443	M	_
203-13	46443-46444	/	_
203-14	46444-46446	48	_
203-15	46447-46448	F	_
203-16	46451-46456	Years	_
203-17	46457-46459	of	_
203-18	46460-46469	education	_
203-19	46470-46475	17.48	_
203-20	46475-46476	±	_
203-21	46476-46481	3.32b	_
203-22	46484-46487	SWM	_
203-23	46488-46496	accuracy	_
203-24	46497-46498	(	_
203-25	46498-46505	correct	_
203-26	46506-46512	trials	_
203-27	46512-46513	/	_
203-28	46513-46515	72	_
203-29	46515-46516	)	_
203-30	46517-46522	63.59	_
203-31	46522-46523	±	_
203-32	46523-46527	8.77	_
203-33	46530-46533	SWM	_
203-34	46534-46542	reaction	_
203-35	46543-46547	time	_
203-36	46548-46549	(	_
203-37	46549-46551	ms	_
203-38	46551-46552	)	_
203-39	46553-46560	8737.15	_
203-40	46560-46561	±	_
203-41	46561-46568	2166.99	_
203-42	46571-46577	MIR137	_
203-43	46578-46585	pathway	_
203-44	46586-46590	risk	_
203-45	46591-46596	score	_
203-46	46597-46599	at	_
203-47	46600-46601	P	_
203-48	46601-46602	=	_
203-49	46602-46604	10	_
203-50	46604-46605	−	_
203-51	46605-46606	5	_
203-52	46607-46618	0.047755814	_
203-53	46618-46619	±	_
203-54	46619-46630	0.006577924	_
203-55	46633-46639	MIR137	_
203-56	46640-46647	pathway	_
203-57	46648-46652	risk	_
203-58	46653-46658	score	_
203-59	46659-46661	at	_
203-60	46662-46663	P	_
203-61	46663-46664	=	_
203-62	46664-46668	0.05	_
203-63	46669-46680	0.022951163	_
203-64	46680-46681	±	_
203-65	46681-46692	0.000631104	_
203-66	46695-46701	MIR137	_
203-67	46702-46709	pathway	_
203-68	46710-46714	risk	_
203-69	46715-46720	score	_
203-70	46721-46723	at	_
203-71	46724-46725	P	_
203-72	46725-46726	=	_
203-73	46726-46729	0.5	_
203-74	46730-46741	0.014223256	_
203-75	46741-46742	±	_
203-76	46742-46753	0.000195643	_
203-77	46757-46770	Abbreviations	_
203-78	46770-46771	:	_
203-79	46772-46778	MIR137	_
203-80	46778-46779	,	_
203-81	46780-46788	microRNA	_
203-82	46788-46789	-	_
203-83	46789-46792	137	_
203-84	46792-46793	;	_
203-85	46794-46797	SWM	_
203-86	46797-46798	,	_
203-87	46799-46806	Spatial	_
203-88	46807-46814	Working	_
203-89	46815-46821	Memory	_
203-90	46821-46822	.	_

#Text=Mean±s.d. reported.
204-1	46823-46827	Mean	_
204-2	46827-46828	±	_
204-3	46828-46831	s.d	_
204-4	46831-46832	.	_
204-5	46833-46841	reported	_
204-6	46841-46842	.	_

#Text=Education information available for 82 of 86 participants.
205-1	46843-46852	Education	_
205-2	46853-46864	information	_
205-3	46865-46874	available	_
205-4	46875-46878	for	_
205-5	46879-46881	82	_
205-6	46882-46884	of	_
205-7	46885-46887	86	_
205-8	46888-46900	participants	_
205-9	46900-46901	.	_
